

Saturday, August 30, 2025

*Paediatric Epileptology*

08:00 - 12:00

Pavilion 3A

**Half-day Teaching Course: Neonatal EEG boot camp**

Ronit Pressler (United Kingdom)

Monika Eisermann (France)

**Introduction**

08:00 - 08:05

**EEG in neonates: How do I record a better EEG?**

08:05 - 08:50

Rachel Thornton (United Kingdom)

**Normal EEG in Neonates**

08:50 - 09:35

Sushma Goyal (United Kingdom)

**Brain injury in preterm and term infants**

09:35 - 10:20

Geraldine Boylan (Ireland)

**Neonatal seizures**

10:20 - 11:05

Ronit Pressler (United Kingdom)

**Epilepsy with onset in the neonatal period**

11:05 - 11:50

Monika Eisermann (France)

**Conclusion and Q&A**

11:50 - 12:00

*Neuroimaging*

08:00 - 17:00

Pavilion 3C

**Full-day Teaching Course: Neuroimaging in epilepsy - what the clinician should know**

Anna Elisabetta Vaudano (Italy)

**Introduction**

08:00 - 08:15

**Introduction to neuroimaging in epilepsy**

08:15 - 08:45

Anna Elisabetta Vaudano (Italy)

**MRI physics, sequence names, and MRI epilepsy protocol**

08:45 - 09:15

Stefan Rampp (Germany)

**MRI protocol and hints for neonates and infants**

09:15 - 09:45

Felice D'Arco (United Kingdom)

**Common epileptic pathologies: temporal epilepsy**

09:45 - 10:15

Angelo Labate (Italy)

**Common epileptic pathologies: extratemporal lobe epilepsy**

10:15 - 10:45

Britta Wandschneider (United Kingdom)

**Hands-on session**

10:45 - 12:15

**MRI-negative epilepsy. What are the next steps?**

12:15 - 12:45

Boris Bernhardt (Canada)

**Other neuroimaging modalities: PET, SPECT, ASL**

12:45 - 13:15

Lorenzo Caciagli (Switzerland)

**fMRI (task-based) & EEG-fMRI**

13:15 - 13:45

Paolo Federico (Canada)

**Diffusion imaging, presurgical image fusion**

13:45 - 14:15

Fernando Cendes (Brazil)

**Hands-on session**

|   |  |                      |
|---|--|----------------------|
|   | <b>Group discussion/feedback</b>   | <b>14:45 - 16:45</b> |
|   | <b>Conclusion and Q&amp;A</b>  | 16:45 - 17:00        |
| <i>Social Issues</i><br>08:00 - 12:00   |  | Room 0.2             |
| <b>Half-day Teaching Course: Patient and public involvement in epilepsy research</b>                            |  |                      |
| Reetta Kalviainen (Finland)<br>Marie Ennis O'Connor (Ireland)   |  |                      |
|   | <b>Introduction</b>  | 08:00 - 08:05        |
|   | <b>Definitions, role and impact of PPI in epilepsy research</b><br>Reetta Kalviainen (Finland)                           | 08:05 - 08:55        |
|   | <b>Fostering PPI for clinical trials with case examples</b><br>Jacqueline French (United States)                         | 08:55 - 09:45        |
|   | <b>Fostering PPI through co-design in seizure detection and monitoring technologies with case examples</b>               | 09:45 - 10:35        |
|   | <b>IBE role in building the knowledge and skills for PPI in epilepsy</b><br>Eli Cripps (Ireland)                         | 10:35 - 11:25        |
|   | <b>Conclusion and Q&amp;A</b>  | 11:25 - 12:00        |
| <i>Award Symposia</i><br>13:00 - 14:00  |  | AUD II               |
| <b>Michael Prize Award Symposium</b>  |  |                      |
| Bettina Schmitz (Germany)<br>Ulrich Stephani (Germany)  |  |                      |
|   | <b>Introduction</b>  | 13:00 - 13:10        |
|   | <b>Seizure cycles</b><br>Maxime Baud (Switzerland)   | 13:10 - 13:25        |
|   | <b>Multicentre Epilepsy Lesion Detection project</b><br>Sophie Adler (United Kingdom)<br>Konrad Wagstyl (United Kingdom) | 13:25 - 13:40        |
|   | <b>Award presentations</b><br>Bettina Schmitz (Germany)<br>Ulrich Stephani (Germany)                                     | 13:40 - 13:50        |
|   | <b>Conclusion and Q&amp;A</b>  | 13:50 - 14:00        |
| <i>Basic science</i><br>13:00 - 14:30   |  | AUD III + IV         |
| <b>WONOEP Symposium</b>   |  |                      |
| <i>Drug Therapy</i><br>13:00 - 17:00  |  | Pavilion 3A          |
| <b>Half-day Teaching Course: Optimizing pharmacotherapy in epilepsy. Which ASM to start with? When to stop?</b> |  |                      |
| Torbjorn Tomson (Sweden)<br>Stéphane Auvin (France)   |  |                      |
|   | <b>Introduction</b>  | 13:00 - 13:04        |
|   | <b>First ASM for children</b>  | 13:04 - 13:31        |

|   |               |
|---|---------------|
| Stéphane Auvin (France)   |               |
| <b>First ASM for adults</b>   | 13:31 - 13:58 |
| Anthony Marson (United Kingdom)   |               |
| <b>Uptitration and dose optimization</b>  | 13:58 - 14:25 |
| Torbjorn Tomson (Sweden)  |               |
| <b>Strategy when 1st monotherapy fails: switch or add-on a debate</b>                       | 14:25 - 14:52 |
| Anthony Marson (United Kingdom)   |               |
| Jacqueline French (United States)   |               |
| <b>Which ASM to consider if 1st monotherapy fails</b>                                       | 14:52 - 15:19 |
| Jacqueline French (United States)   |               |
| <b>What is the role of the newest ASMs?</b>   | 15:19 - 15:46 |
| Michael Sperling (United States)  |               |
| <b>Stopping ASM treatment in seizure free adults</b>  | 15:46 - 16:13 |
| Torbjorn Tomson (Sweden)  |               |
| <b>Stopping ASM treatment in seizure free children</b>                                      | 16:13 - 16:40 |
| Stéphane Auvin (France)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:40 - 17:00 |
| <br>  |               |
| <i>Status Epilepticus</i>   |               |
| 13:00 - 17:00   | Pavilion 3B   |
| <b>Half-day Teaching Course: Status epilepticus</b>   |               |
| Eugen Trinka (Austria)  |               |
| Aidan Neligan (United Kingdom)  |               |
| <b>Introduction</b>   | 13:00 - 13:10 |
| <b>Definition, classification and causes</b>  | 13:10 - 13:55 |
| Eugen Trinka (Austria)  |               |
| <b>Diagnosis of SE - Neurophysiology and Neuroimaging</b>                                   | 13:55 - 14:40 |
| Giada Giovannini (Italy)  |               |
| <b>Management of early and established SE</b>   | 14:40 - 15:25 |
| Camilo Espinoza Jovel (Colombia)  |               |
| <b>Treatment of refractory and super-refractory SE</b>                                      | 15:25 - 16:10 |
| Aidan Neligan (United Kingdom)  |               |
| <b>Conclusion and Q&amp;A</b>   | 16:10 - 16:30 |
| <br>  |               |
| <i>Clinical Neurophysiology</i>   |               |
| 13:00 - 17:00   | Room 1.09     |
| <b>Half-day Teaching Course: Let's read EEGs together!</b>                                  |               |
| Sándor Beniczky (Denmark)   |               |
| <b>Introduction</b>   | 13:00 - 13:04 |
| <b>Systematic approach to EEG reading. Background activity and interictal abnormalities</b> | 13:04 - 14:01 |
| Sándor Beniczky (Denmark)   |               |
| <b>Normal variants and artefacts</b>  | 14:01 - 14:58 |
| Fabio Nascimento (United States)  |               |
| <b>Ictal patterns</b>   | 14:58 - 15:55 |

Margitta Seeck (Switzerland)

**Electroclinical correlations in epilepsy syndromes**

15:55 - 16:52

Dana Craiu (Romania)

**Conclusion and Q&A**

16:52 - 17:00

*Genetics*

13:00 - 17:00

Room 1.15

**Half-day Teaching Course: Clinical and genetic diagnostics of epilepsy syndromes**

Guido Rubboli (Denmark)

Ingrid Scheffer (Australia)

**Introduction**

13:00 - 13:05

**Clinical and genetic diagnosis of epilepsy syndromes - where to start?**

13:05 - 13:50

Ingrid Scheffer (Australia)

**Genetic testing in epilepsy - which patients, which tests, and which yields in the clinics?**

13:50 - 14:35

Guido Rubboli (Denmark)

**The interplay of rare and common variants in the genetic architecture of the epilepsies**

14:35 - 15:20

Karen L Oliver (Australia)

**Precision medicine" in genetic epilepsies: hype or hope?**

15:20 - 16:05

Amy McTague (United Kingdom)

**Gene therapy in Dravet syndrome: are we there yet?**

16:05 - 16:50

Andreas Brunklaus (United Kingdom)

**Conclusion and Q&A**

16:50 - 17:00

*Epilepsy Surgery*

13:00 - 17:00

Room 0.2

**Half-day Teaching Course: Epilepsy surgery: learn from cases!**

Birgit Frauscher (United States)

**Introduction**

13:00 - 13:04

**Video-EEG in Presurgical Evaluation: A Critical Tool for Surgical Planning**

13:04 - 13:41

Philippe Kahane (France)

**Unmasking Non-Lesional Epilepsy: Key Techniques and Tips for Detecting Lesions**

13:41 - 14:18

Jörg Wellmer (Germany)

**SEEG-Informed Epilepsy Surgery: Essential Do's and Don't's**

14:18 - 14:55

Birgit Frauscher (United States)

**Mastering Pediatric Epilepsy Surgery: Expert Pearls for Success**

14:55 - 15:32

Julia Jacobs-LeVan (Canada)

**Personalized Treatment: When to Choose Resection or Ablation?**

15:32 - 16:09

Jorge Gonzalez-Martinez (United States)

**Role of neuromodulation in epilepsy surgery**

16:09 - 16:46

Philippe Ryvlin (Switzerland)

**Conclusion and Q&A**

16:46 - 17:00

*Epilepsy in Emergencies*

14:45 - 16:15

Aud V (Pav 1)

**When the inevitable happens: Addressing the needs of people with epilepsy during disasters and emergencies**

Timothy Welty (United States)

Olha Tychkivska (Ukraine)

**Introduction**

14:45 - 14:50

**Epilepsy and Disasters: An overview on the scope of the problem**

14:50 - 15:03

Timothy Welty (United States)

**Planning and preparing through government and public health engagement.**

15:03 - 15:16

Jean Marie Ahorro (Philippines)

**Training first responders in seizures and epilepsy**

15:16 - 15:29

Archana Patel (United States)

**Effective responses to disasters and emergencies**

15:29 - 15:42

Timothy Welty (United States)

**Continuous improvement of emergency responses**

15:42 - 15:55

Manuel Tomas Mesa Latorre (Chile)

**Left Behind: Amplifying the Voices of People with Epilepsy in Disasters and Humanitarian Crises**

15:55 - 16:08

Action Amos (Malawi)

**Conclusion and Q&A**

16:08 - 16:15

*Social Issues*

14:45 - 16:15

Aud VI+VII

**Self-stigma and psychoeducation in epilepsy**

Daichi Sone (Japan)

Faith Mosha (Tanzania)

**Introduction**

14:45 - 14:50

**Epilepsy self-stigma scale and one-day psychoeducation "Epi-School" in Japan**

14:50 - 15:10

Izumi Kuramochi (Japan)

**Perceived and self-stigma in people with epilepsy in Africa**

15:10 - 15:30

Musa Mamman Wtila (United Kingdom)

**Self-stigma, psychiatric problems, and psychoeducation in people with epilepsy in Australia**

15:30 - 15:50

Honor Coleman (Australia)

**Self-stigma and psychoeducation in Germany and the role of MOSES**

15:50 - 16:10

Anne Hagemann (Germany)

**Conclusion and Q&A**

16:10 - 16:15

*Epilepsy in Resource-restricted Settings*

14:45 - 16:15

AUD VIII

**Identifying and addressing global gaps in access to genetic testing for the epilepsies**

Ischia Lopes-Cendes (Brazil)

Gaetan Lesca (France)

**Introduction & Lived experience testimonies from different ends of the globe**

14:45 - 15:05

|   |               |
|---|---------------|
| Iscia Lopes-Cendes (Brazil)   |               |
| <b>The 'diagnostic gap' - Global reality of genetic testing. Insights from the 2023-2024 worldwide ILAE survey on genetic testing</b> | 15:05 - 15:20 |
| Andreas Brunklaus (United Kingdom)  |               |
| <b>Challenges in providing genetic services among children and adults in low- and middle-income countries</b>                         | 15:20 - 15:35 |
| Olfa Jallouli (Tunisia)   |               |
| <b>Pragmatic testing pathways - Enabling genetic testing for the epilepsies in South Africa</b>                                       | 15:35 - 15:50 |
| Alina Esterhuizen (South Africa)  |               |
| <b>The power of collaboration - Building research and education alliances to empower local genetic testing opportunities in LMICs</b> | 15:50 - 16:05 |
| Chahnez Triki (Tunisia)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:05 - 16:15 |
| <i>Epilepsy Surgery</i>   |               |
| 14:45 - 16:15   | AUD II        |
| <b>New insights for non-invasive and invasive neuromodulation techniques</b>  |               |
| Antonio Valentin (United Kingdom)   |               |
| Guy McKhann (United States)   |               |
| <b>Introduction</b>   | 14:45 - 14:50 |
| <b>Cathodal Transcranial Direct-Current Stimulation in Epilepsy</b>   | 14:50 - 15:10 |
| Daniel San Juan (Mexico)  |               |
| <b>Subacute (SCS) and chronic cortical stimulation (CCS) for epilepsy treatment</b>   | 15:10 - 15:30 |
| Antonio Valentin (United Kingdom)   |               |
| <b>The clinical value of TMS-EEG in epilepsy</b>  | 15:30 - 15:50 |
| Vasilios K. Kimiskidis (Greece)   |               |
| <b>Cortical stimulation for epilepsy: target the focus or the network?</b>  | 15:50 - 16:10 |
| Dorien van Blooij (Netherlands)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:10 - 16:15 |
| <i>Drug Therapy</i>   |               |
| 14:45 - 16:15   | AUD III + IV  |
| <b>Plant-based medicines: Development from ethnopharmacology to evidence-based medicine</b>   |               |
| Siegward Elsas (Switzerland)  |               |
| Lieven Lagae (Belgium)  |               |
| <b>Introduction</b>   | 14:45 - 14:55 |
| <b>A Patient's Perspective on the Therapeutic Potential of Cannabidiol</b>  | 14:55 - 15:05 |
| Ariane Orosz (Switzerland)  |               |
| <b>Cannabinoids in epilepsy; the journey</b>  | 15:05 - 15:20 |
| Kate Riney (Australia)  |               |
| <b>Huperzine A: Back to the Future</b>  | 15:20 - 15:35 |
| Steven Schachter (United States)  |               |
| <b>Kasholoza: From traditional medicine to novel therapeutic entry point</b>  | 15:35 - 15:50 |
| Joëlle Nsimire Chabwine (Congo (Democratic Republic))   |               |

**Turmeric: From Ayurvedic and Tanzanian traditional medicine to modern botanical drug candidate**

15:50 - 16:05

Alexander Crawford (Norway)

**Conclusion and Q&A**

16:05 - 16:15

*Other*

18:30 - 19:30

Aud 1

**Welcome Ceremony**

J Helen Cross (United States)

Francesca Sofia (Italy)

Sunday, August 31, 2025

*Paediatric Epileptology*

08:00 - 09:30

Aud V (Pav 1)

**Developmental and epileptic encephalopathies**

Alexis Arzimanoglou (Spain)

**Introduction**

08:00 - 08:06

**What are developmental and epileptic encephalopathies?**

08:06 - 08:32

Ingrid Scheffer (Australia)

**Holistic care of patients with DEEs - far more than seizure disorders**

08:32 - 08:58

Federico Vigevano (Italy)

**The path to precision management of DEEs**

08:58 - 09:24

J Helen Cross (United States)

**Conclusion and Q&A**

09:24 - 09:30

*Adult Epileptology*

08:00 - 09:30

Aud VI+VII

**Video session - Challenges in diagnosis**

Guido Rubboli (Denmark)

**Introduction**

08:00 - 08:05

**Myoclonus and myoclonic seizures**

08:05 - 08:30

Guido Rubboli (Denmark)

**Nocturnal events**

08:30 - 08:55

Matthew Walker (United Kingdom)

**Posterior quadrant seizures**

08:55 - 09:20

Laura Tassi (Italy)

**Conclusion and Q&A**

09:20 - 09:30

*Clinical Neurophysiology*

08:00 - 09:30

AUD II

**VIREPA Basic and Advanced EEG**

**Introduction**

08:00 - 08:10

**Exploring the EEG fundamentals: an introduction to the VIREPA Basic EEG course**

08:10 - 08:45

Elena Gardella (Denmark)

**EEG in the diagnosis & management of epilepsy Advance Course**

08:45 - 09:20

Antonio Valentin (United Kingdom)

**Conclusion and Q&A**

09:20 - 09:30

*Genetics*

08:00 - 09:30

Pavilion 3A

**New challenges and progress in treatment of inherited metabolic epilepsies**

Phillip Pearl (United States)

**Introduction**

08:00 - 08:04



|  |               |
|--|---------------|
| <b>New Approaches to Inherited Metabolic Epilepsies</b><br>Phillip Pearl (United States)   | 08:04 - 08:18 |
| <b>Clinical Trials for Inherited Metabolic Epilepsies: Plans and Pitfalls</b><br>William Theodore (United States)  | 08:18 - 08:32 |
| <b>Biomarker Development in Inherited Metabolic Epilepsies</b><br>Alexander Rotenberg (United States)  | 08:32 - 08:46 |
| <b>Inducible Models for Gene Therapy in Inherited Metabolic Epilepsies</b><br>Hingcheong Lee (Hong Kong)   | 08:46 - 09:00 |
| <b>Conclusion and Q&amp;A</b>  | 09:00 - 09:30 |
| <i>Climate Change</i><br>08:00 - 09:30   | Pavilion 3B   |
| <b>Climate change and epilepsy from the perspective of carbon footprint</b><br>Medine Gulcebi Idriz Oglu (Turkey)  |               |
| <b>Introduction</b>  | 08:00 - 08:05 |
| <b>Carbon footprints of participants from different countries to join the special interest session</b><br>Priyanka Madaan (India)                                | 08:05 - 08:25 |
| <b>The latest research breakthroughs about the effects of extreme weather events on epilepsy</b><br>Francesco Fortunato (Italy)                                  | 08:25 - 08:35 |
| <b>Practical tips for patients and clinicians to mitigate adverse consequences of climate change and to reduce carbon footprint</b><br>Patrick Moloney (Ireland) | 08:35 - 08:45 |
| <b>Carbon footprint of health sector and research</b><br>James Mills (Netherlands)   | 08:45 - 08:55 |
| <b>Conclusion and Q&amp;A</b>  | 08:55 - 09:30 |
| <i>Terminology and Classification</i><br>08:00 - 09:30   | Pavilion 3C   |
| <b>Acute Symptomatic Seizures: time to reconsider definitions and management?</b><br>Marian Galovic (Switzerland)  |               |
| <b>Introduction</b>  | 08:00 - 08:05 |
| <b>Controversy 1: The current definition of acute symptomatic seizures is adequate</b><br>Marian Galovic (Switzerland)   | 08:05 - 08:16 |
| <b>Controversy 1: The current definition of acute symptomatic seizures needs revising</b><br>Eugen Trinko (Austria)  | 08:16 - 08:27 |
| <b>Controversy 2: Acute symptomatic seizures do not require treatment</b><br>Carla Bentes (Portugal)   | 08:27 - 08:38 |
| <b>Controversy 2: Acute symptomatic seizures should be treated</b><br>Vineet Punia (United States)   | 08:38 - 08:49 |
| <b>Summary and take home message</b><br>Ronit Pressler (United Kingdom)  | 08:49 - 09:00 |

|   |               |
|---|---------------|
| <b>Conclusion and Q&amp;A</b>   | 09:00 - 09:30 |
| <i>Other</i><br>09:45 - 11:45   | Aud 1         |
| <b>Presidential Symposium: Patient-centered healthcare: from challenge to change</b><br>J Helen Cross (United States)<br>Francesca Sofia (Italy)  |               |
| <b>Introduction</b>   | 09:45 - 09:50 |
| <b>Setting the scene: What are the actual gaps and challenges the healthcare sector and medicine at large, are facing and how the patient-centered paradigm can provide innovative solutions</b><br>Daniel H. Löwenstein (United States)<br>Laura Lubbers (United States) | 09:50 - 10:12 |
| <b>A significant success story by a patient/advocate about impactful actions driven by the patient community</b><br>Ana Suller Marti (Canada)   | 10:12 - 10:34 |
| <b>Setting research priorities - involving those who matter</b><br>Laura M'Rabet (Netherlands)  | 10:34 - 10:56 |
| <b>What are the benefits of PPI for people with epilepsy and what are the benefits of PPI for researchers?</b><br>Sophie Bennett (United Kingdom)<br>Emma Dalrymple (United Kingdom)  | 10:56 - 11:18 |
| <b>Can patient engagement reduce healthcare expenditure, improve effectiveness and ultimately increase value of healthcare and foster growth of the industry sector?</b><br>Samuel Wiebe (Canada)   | 11:18 - 11:40 |
| <b>Conclusion and Q&amp;A</b>   | 11:40 - 11:45 |
| <i>ILAE YES</i><br>12:00 - 13:00  |               |
| <b>ILAE YES Career Development Session - How is Centre for Global Epilepsy going to address the global challenges in epilepsy care?</b>   |               |
| <b>Introduction</b>   | 12:00 - 12:05 |
| <b>How is Centre for Global Epilepsy going to address the global challenges in epilepsy care?</b><br>Arjune Sen (United Kingdom)  | 12:05 - 12:50 |
| <b>Conclusion and Q&amp;A</b>   | 12:50 - 13:00 |
| <i>ILAE Pharmacy</i><br>12:00 - 13:00   |               |
| <b>ILAE Pharmacy Section Session - Pharmacist Involvement in Caring for People with Epilepsy</b>  |               |
| <b>Introduction</b>   | 12:00 - 12:05 |
| <b>Pharmacist Involvement in Caring for People with Epilepsy</b><br>Timothy Welty (United States)   | 12:05 - 12:55 |
| <b>Conclusion and Q&amp;A</b>   | 12:55 - 13:00 |

*Basic science*

12:15 - 13:45

Aud 1

**Neurobiology Symposium: The neurobiology of epilepsy comorbidities - opportunities for disease modifying therapies?**

David Henshall (Ireland)

Aristea Galanopoulou (United States)

**Introduction**

12:15 - 12:20

**Potential cellular and network mechanisms underlying epilepsy and associated cognitive deficits and depression**

12:20 - 12:40

Christophe Bernard (France)

**Memory dysfunction in epilepsy: from mechanisms to neuromodulation**

12:40 - 13:00

Jennifer Gelinas (United States)

**Sex Differences in Cognitive, Behavioural, and Neuromotor Comorbidities in Acquired Epilepsy**

13:00 - 13:20

Pablo Casillas-Espinosa (Australia)

**Insights into the genetics of spreading depression and its impact on cognition and seizures**

13:20 - 13:40

Jeffrey Noebels (United States)

**Conclusion and Q&A**

13:40 - 13:45

*IGAP Implementation*

12:15 - 13:45

Aud V (Pav 1)

**IGAP - Details TBC***Comorbidities*

12:15 - 13:45

Aud VI+VII

**Cardiac disease in epilepsy - getting to the heart of the 'Epileptic Heart'**

Colin Josephson (Canada)

John Dunne (Australia)

**Introduction**

12:15 - 12:20

**Causes and consequences of cardiac disease in epilepsy**

12:20 - 12:36

Elizabeth Donner (Canada)

**Treating epilepsy: unraveling the associations between antiseizure medications and cardiovascular disease**

12:36 - 12:52

Samuel Terman (United States)

Test Person (Germany)

**Monitoring for cardiac disease in epilepsy - conventional and emerging approaches**

12:52 - 13:08

Shobi Sivathamboo (Australia)

**Sudden cardiac death: a cause of SUDEP or etymological fallacy**

13:08 - 13:24

Colin Josephson (Canada)

Roland Thijs (Netherlands)

**Patient and provider perspective: when and how should the risk of cardiac disease and sudden cardiac death be conveyed**

13:24 - 13:40

Gardiner Lapham (United States)

Samuel Wiebe (Canada)

**Conclusion and Q&A**

13:40 - 13:45

*Neuroimaging*

12:15 - 13:45

AUD VIII

**Recent progress in molecular neuroimaging for epilepsy**

Daichi Sone (Japan)

Jaideep Kapur (United States)

**Introduction**

12:15 - 12:20

**Glutamate receptor imaging in epilepsy**

12:20 - 12:40

Marian Galovic (Switzerland)

**Molecular neuroimaging for comorbidities in epilepsy**

12:40 - 13:00

Matthias Koepp (United Kingdom)

**Neuroinflammation imaging for epilepsy: PET and MRS findings**

13:00 - 13:20

Jerzy Szaflarski (United States)

**Blood-brain barrier imaging for epilepsy**

13:20 - 13:40

Maria Ilyas-Feldmann (Germany)

**Conclusion and Q&A**

13:40 - 13:45

*Drug Therapy*

12:15 - 13:45

AUD II

**Clinical trials for rare and severe epilepsies: Progress and challenges**

Elaine C. Wirrell (United States)

Sindhu Viswanathan (Australia)

**Introduction**

12:15 - 12:20

**Alternative trial designs to ensure relevance to real world patients**

12:20 - 12:40

Stéphane Auvin (France)

**The challenges of including non-seizure outcomes as endpoints**

12:40 - 13:00

Joseph Sullivan (United States)

**Are such trials feasible outside of high-resource regions?**

13:00 - 13:20

Kette Valente (Brazil)

**Challenges and lessons learned in designing first in human trials of genetic therapies**

13:20 - 13:40

Sal Rico (United States)

**Conclusion and Q&A**

13:40 - 13:45

*Nursing*

12:15 - 16:15

AUD III + IV

**Half-day Nursing Symposium: Individualized Nursing Care for People with Epilepsy: Promoting Education and Self-Management**

Ludivine Rohrer (France)

Tolu Olaniyan (United Kingdom)

**Section 1: Promoting Epilepsy Self-Management - Regional Variations**

12:15 - 12:15

**Welcome and Introductions**

12:15 - 12:25

**Living with Epilepsy**

12:25 - 12:35

Torie Robinson (United Kingdom)

**Assessing Self-management Needs**

12:35 - 12:50

Wendy R. Trueblood Miller (United States)

**Tackling Health Disparities with Self-management Education**

12:50 - 13:10

Karen McLeod (United Kingdom)  
Faith Sila (Kenya)

**The “Invisible Patients” in Epilepsy: Needs of Caregivers and Partners**

13:10 - 13:30

Adel Bounif (France)  
Marion Danse (France)

**Engaging People with Epilepsy and Intellectual/Cognitive Comorbidities**

13:30 - 13:45

Ariane Bernier (Switzerland)

**Panel Q&A**

13:45 - 14:05

**30-Minute Lunch Break**

14:05 - 14:35

**Section 2: About Safety Management: Are we doing enough to keep people safe?**

14:35 - 14:35

**Introductions**

14:35 - 14:40

**Adherence with Care: Does it start with engagement?**

14:40 - 14:55

Katherinne Moreno Duran (Chile)

**Managing Risks for Early Death and SUDEP**

14:55 - 15:15

Alwina Koch (Germany)

**Safety and Children: Preventing Risks in Childhood Epilepsy**

15:15 - 15:25

Zahide İyi Altınışık (Turkey)

**Epilepsy and Physical Exercise: What Nurses Need to Know**

15:25 - 15:35

Glauber Lopim (Brazil)

**Panel Q&A**

15:35 - 16:05

**Closing Remarks**

16:05 - 16:15

*In-Person Posters*

13:45 - 15:15

In-Person Poster Presentations

**In-Person Poster Presentations**

**Temporal lobe epilepsy with amygdala enlargement: long-term outcome and memory**

13:45 - 13:45

Yuyu Yang (China)

**EEG demonstration of the efficacy of glasses with a selective filter for treating photosensitive epilepsy**

13:45 - 13:45

Alvaro Sanchez-Larsen (Spain)

**Neurologists' Perspectives and Challenges in Managing Uncontrolled Epilepsy in Spain**

13:45 - 13:45

Ángel Aledo-Serrano (Spain)

**Mesial Temporal Lobe Epilepsy in Association with Antibodies against Glutamic Acid Decarboxylase 65**

13:45 - 13:45

Feras Alanazi (Saudi Arabia)

**The Diagnostic Challenge of Epilepsy with Eyelid Myoclonia - A Case Series of 3 Patients in 112 Patients with Idiopathic Generalized Epilepsy**

13:45 - 13:45

Theodora Afrantou (Greece)

**A Rare Presentation in Epilepsy: Report of “Triple Pathology”**

13:45 - 13:45

Eithel Alejandro Valenzuela Mendivil (Mexico)

|   |               |
|---|---------------|
| <b>Management of Antiseizure Medication in Patients with Epileptic Encephalopathies in Adulthood</b>  | 13:45 - 13:45 |
| Eithel Alejandro Valenzuela Mendivil (Mexico)   |               |
| <b>Signal Quality of a Long-Term At-Home Protocol for Repeated Self-Applied Non-Invasive EEG (EEG@HOME) in people with epilepsy</b>               | 13:45 - 13:45 |
| Andrea Biondi (United Kingdom)  |               |
| <b>Highlights and differences between frontal lobe seizures and functional seizures from video-electroencephalography (VEEG) findings</b>         | 13:45 - 13:45 |
| Anilu Daza Restrepo (Argentina)   |               |
| <b>Characterization of ictal hand postures as a localizing and lateralizing sign in frontal and temporal lobe epilepsy</b>                        | 13:45 - 13:45 |
| Anilu Daza Restrepo (Argentina)   |               |
| <b>Seizure-Related Road Accidents and Injuries Among People with Epilepsy in Indonesia's National Referral Hospital: A Pilot Study</b>            | 13:45 - 13:45 |
| Astri Budikayanti (Indonesia)   |               |
| <b>Sex differences in efficacy of antiseizure medications in adults with epilepsy: A systematic review</b>  | 13:45 - 13:45 |
| Barbara Mostacci (Italy)  |               |
| <b>Atypical Course of Adult-onset Rasmussen Encephalitis</b>  | 13:45 - 13:45 |
| Evgeniia Golovneva (Russian Federation)   |               |
| <b>Neuropsychological Assessment of Executive Functions in Temporal Lobe Epilepsy: A Cross-Sectional Study</b>                                    | 13:45 - 13:45 |
|   |               |
| <b>Stakeholder workshops to optimise design of a risk prediction webtool for seizure prediction in people with epilepsy - The PRISE study</b>     | 13:45 - 13:45 |
| Beth Morris (United Kingdom)  |               |
| <b>The challenge of Lennox-Gastaut Syndrome (LGS) diagnosis in adult patients according to ILAE criteria: A Retrospective Observational Study</b> | 13:45 - 13:45 |
| Giulia Bruschi (Italy)  |               |
| <b>Side-To-Side Head Shaking as an Ictal Feature in Epileptic Seizures: A Video-EEG Case Series</b>   | 13:45 - 13:45 |
| Christina Pourlou (United Kingdom)  |               |
| <b>Dravet syndrome in Norway - a population- based study</b>  | 13:45 - 13:45 |
| Caroline Lund (Norway)  |               |
| <b>Seizure Type at Relapse as a Predictor of Recurrence Etiology in New Onset Epilepsy</b>  | 13:45 - 13:45 |
| Cecilia Catania (Switzerland)   |               |
| <b>LEgEND: Learning hEalth systEm iN a Digital hospital</b>   | 13:45 - 13:45 |
| Colm Mc Carthy (Ireland)  |               |
| <b>Clinical characteristics of Juvenil Myoclonic Epilepsy and risk factors for drug-resistant patients</b>  | 13:45 - 13:45 |
| Maria Inês Silva (Portugal)   |               |
| <b>Characterising Patient and Caregiver Experiences Resulting from Prolonged Seizures</b>   | 13:45 - 13:45 |
| Danya Kaye (United States)  |               |
| <b>Improving quality of life in patients with intellectual disability and epilepsy through comprehensive inpatient treatment</b>                  | 13:45 - 13:45 |
| David Steinbart (Germany)   |               |

|   |               |
|---|---------------|
| <b>Enhancing Care for Women with Epilepsy in Kazakhstan: Implementation of the 2022 ILAE Classification in Primary Care</b><br>Dina Kasimova (Kazakhstan)                                     | 13:45 - 13:45 |
| <b>Epidemiology of catamenial epilepsy</b><br>Diana Komarova (Russian Federation)   | 13:45 - 13:45 |
| <b>Investigating skin volatiles for epileptic seizure prediction</b><br>Dinakaran Thirumalai (Ireland)  | 13:45 - 13:45 |
| <b>Ictal hypotension, but not hypertension, is associated with increased interictal sympathetic activity</b><br>Dmitry Zhuravlev (Russian Federation)   | 13:45 - 13:45 |
| <b>Assesment of cognitive function in patients with epilepsy</b><br>Ra'no Azizova (Uzbekistan)  | 13:45 - 13:45 |
| <b>Evaluating the Impact of Vagus Nerve Stimulation (VNS) on seizure frequency, intensity, quality of life and mood</b><br>Donald Adjorlolo (United Kingdom)                                  | 13:45 - 13:45 |
| <b>Efficacy of cannabis versus Everolimus in TSC complex :comparatives studies</b><br>Mashaël Alkhateeb (Saudi Arabia)  | 13:45 - 13:45 |
| <b>Valproic acid use and risk of intracranial hemorrhage in invasive EEG monitoring</b><br>Hassan Aldandan (Saudi Arabia)   | 13:45 - 13:45 |
| <b>Ictal spitting in patients with temporal lobe epilepsy: A case series</b><br>José Zambrano (Argentina)   | 13:45 - 13:45 |
| <b>Introducing needs-based epilepsy follow-up - patient satisfaction compared to traditional follow-up</b><br>Eline Dahl-Hansen (Norway)  | 13:45 - 13:45 |
| <b>Blood-brain-barrier evaluation of patients with highly refractory, highly active focal epilepsy before and after high-dose intravenous methylprednisolone</b><br>Elisabeth Doran (Ireland) | 13:45 - 13:45 |
| <b>Clinical and Paraclinical Characteristics of Post-Traumatic Epilepsy (PTE) patient : Predictive Factors and Management Considerations</b><br>Emna Ellouz (Tunisia)                         | 13:45 - 13:45 |
| <b>Neurodegeneration in Mesial Temporal Lobe Epilepsy (MTLE): Absence of Alpha-Synuclein and TDP-43 Pathology</b><br>Eva Zatloukalova (Czech Republic)  | 13:45 - 13:45 |
| <b>Beyond Psychogenic Non-Epileptic Seizures: Head No-No Movements as an Epileptic Phenomenon</b><br>Futoon Alotaibi (Saudi Arabia)   | 13:45 - 13:45 |
| <b>Anti-seizure medications: adherence and adverse effects in adults with epilepsy</b><br>Gloria Maria Tedrus (Brazil)  | 13:45 - 13:45 |
| <b>Epilepsia Partialis Continua: Insights from a 15-year cohort study</b><br>Pedro Guimarães (Portugal)   | 13:45 - 13:45 |
| <b>Real-World Efficacy and Tolerability of Cenobamate in Drug-Resistant Epilepsy: A Single-Centre Retrospective Study from the United Kingdom</b><br>Alex Huang (United Kingdom)              | 13:45 - 13:45 |
| <b>Prevalence of sleep disorders in people with epilepsy: A single-</b>   | 13:45 - 13:45 |

**center self-reported sleep assessment**

Ilaria Barbaro (Italy)

**Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): A Novel, Prospective, Large-scale, Observational Study Designed to Better Understand the Patient Journey**

13:45 - 13:45

Jacqueline French (United States)

**Healthcare Resource Utilization among Adult Patients with Focal-Onset Seizures using Cenobamate: a US Database Analysis**

13:45 - 13:45

John Paul Leach (Italy)

**Altered States of Consciousness: Does Treating the EEG Help?**

13:45 - 13:45

João Peres (Portugal)

**Routine EEG versus 24-hour EEG in the discontinuation of anti-seizure medications in patients with epilepsy and long-term seizure freedom**

13:45 - 13:45

João Peres (Portugal)

**Preventing Post-Stroke Epilepsy with Antihypertensive and Lipid-Lowering Medications**

13:45 - 13:45

Kai Michael Schubert (Switzerland)

**Screening for cognitive impairment in people with epilepsy: test Test your memory**

13:45 - 13:45

Karmen Vizjak Sterman (Slovenia)

**Possibility of stopping bilateral tonic-clonic seizures using the mobile application EpiTapp® in drug-resistant epilepsy caused by arteriovenous malformation in a young man**

13:45 - 13:45

Ekaterina Narodova (Russian Federation)

**Hippocampal calponin-3 is Involved in the comorbidity of AD and epilepsy**

13:45 - 13:45

Wenqian Yang (China)

**Developing a transition intervention for young people with epilepsy**

13:45 - 13:45

Anna Eklund (Sweden)

**A Targeted Literature Review of Comorbidity Burden in Focal Onset Seizures**

13:45 - 13:45

Alvin Ong (Canada)

**Evaluation of depressive-like effects in an animal model of epilepsy**

13:45 - 13:45

Nicolò Birtolo (Italy)

**Theta slowing accompanies the onset of the epileptic and cognitive phenotype in Dravet Syndrome**

13:45 - 13:45

Fabrizio Capitano (France)

**Predictive factors for developing epilepsy after autoimmune encephalitis in Neurological Institute of Thailand**

13:45 - 13:45

Chalee Veeratanaporn (Thailand)

**Prevalence and possible associations of brain-gut axis disorders in children aged 4 to 18 years with epilepsy**

13:45 - 13:45

Christian Andres Rojas Ceron (Colombia)

**Elevated suicide risk in individuals with epilepsy: A systematic review and meta-analysis**

13:45 - 13:45

Churl-Su Kwon (United States)

**Online CO-OP (Cognitive orientation to daily occupational performance) approach applied with parents for improving**

13:45 - 13:45



|  |               |
|--|---------------|
| <b>performance in daily activities of children with Dravet Syndrome</b><br>Domenica Immacolata Battaglia (Italy)   |               |
| <b>Management Of Epilepsy Related Cognitive Impairment: A Systematic review and Meta-analysis</b><br>Shady Georgy (Egypt)  | 13:45 - 13:45 |
| <b>A Qualitative Analysis of the Perceptions of Adults with Epilepsy Engaged in an Online Modular Stigma Self-Management Program</b><br>Elaine Kiriakopoulos (United States)                           | 13:45 - 13:45 |
| <b>Science to Service: Growing Capacity and Impact via an Epilepsy Self-Management Translational Network</b><br>Elaine Kiriakopoulos (United States)   | 13:45 - 13:45 |
| <b>Somniloquy: an “underdog” from sleep with important associations in epilepsy</b><br>Elza Balian (Armenia)   | 13:45 - 13:45 |
| <b>Motor impairment in people with epilepsy persists regardless of seizure control</b><br>Fernando Cendes (Brazil)   | 13:45 - 13:45 |
| <b>Epilepsy and vascular risk: evaluation of the influence of antiseizure medications on atherosclerotic disease</b><br>Francisco Millet Barros (Portugal)   | 13:45 - 13:45 |
| <b>CYP2C19 polymorphism and prevalence of depression in persons with epilepsy on antiseizure drug levetiracetam</b><br>Jatinder Katyal (India)   | 13:45 - 13:45 |
| <b>Eslicarbazepine Acetate Ameliorates Hyperactivity and Cognitive Deficits in a Murine Model of Focal Stroke</b><br>Lea Adenauer (Germany)  | 13:45 - 13:45 |
| <b>Somatic comorbidity impact on effectiveness of epilepsy treatment in children</b><br>Leanid Shalkevich (Belarus)  | 13:45 - 13:45 |
| <b>Why does epilepsy develop after predominantly subcortical strokes?</b><br>Maria Pagiantza MD (Switzerland)  | 13:45 - 13:45 |
| <b>Beyond Seizures: Mapping Cognitive Development in Genetic Absence Epilepsy</b><br>Mariana Neuparth-Sottomayor (Portugal)  | 13:45 - 13:45 |
| <b>Neurodegeneration in Epilepsy: Pilot Study of Risk Biomarkers for Cognitive Decline in Cerebrospinal Fluid of Patients with Temporal Lobe Epilepsy</b><br>Marta Marin Gracia (Spain)                | 13:45 - 13:45 |
| <b>Differing Perspectives of Caregivers and Physicians in France on Key Issues in the Management of Patients With Lennox-Gastaut Syndrome: Results From the REFLET Survey</b><br>Mathieu Milh (France) | 13:45 - 13:45 |
| <b>Seizure prevention in angioplasty for symptomatic extracranial carotid and vertebral artery stenosis</b><br>Mohamed Ibrahim (Egypt)   | 13:45 - 13:45 |
| <b>Comorbidities in adult patients with epilepsy: A population-based cross-sectional study</b><br>Jie Mu (China)   | 13:45 - 13:45 |
| <b>ISEM: Impact of Sleep referrals in Epilepsy Management</b><br>Olga Tanda (United Kingdom)   | 13:45 - 13:45 |

|  |               |
|--|---------------|
| <b>When a seizure isn't a seizure ... Or is it a seizure?: Finding functional seizures in an epilepsy monitoring unit</b>  | 13:45 - 13:45 |
| Paul Wilkerson (United States)   |               |
| <b>Visual aura and driving</b>   | 13:45 - 13:45 |
| Julius Simko (Czech Republic)  |               |
| <b>Cognitive impairment in children with epilepsy due to focal cortical dysplasia</b>  | 13:45 - 13:45 |
| Sviatlana Kulikova (Belarus)   |               |
| <b>Thyroid Under Siege: The Impact of Anti-Seizure Medications on Epileptic Patients</b>   | 13:45 - 13:45 |
| Rohith M G (India)   |               |
| <b>A case of linear sebaceous nevus syndrome treated with alpelisib</b>  | 13:45 - 13:45 |
| M.Asuncion Díaz-Gómez (Spain)  |               |
| <b>Post-hoc Analysis of Fenfluramine for Lennox-Gastaut Syndrome by Baseline Frequency Quartiles of Seizures Associated With a Fall</b>  | 13:45 - 13:45 |
| Sameer Zuberi (United Kingdom)   |               |
| <b>Ethnic Disparities in Pharmacogenetics of Antiseizure Medications: A Systematic Review Subanalysis</b>  | 13:45 - 13:45 |
| Ainara Barguilla (Spain)   |               |
| <b>An open-label, observational, prospective, multicenter study to evaluate the long-term efficacy and safety of perampanel as monotherapy in subjects age 4 years and older with focal onset seizures: PORTABLE Study</b> | 13:45 - 13:45 |
| Naoki Akamatsu (Japan)   |               |
| <b>A Phase 1 clinical study of BMB-101 shows linear PK and a reduced rate of somnolence and GI/Urinary side effects compared to other 5-HT<sub>2C</sub> agonists</b>   | 13:45 - 13:45 |
| Alex Vasilkevich (United States)   |               |
| <b>Prospective evaluation of non-seizure benefits related to treatment with fenfluramine in pediatric and adult patients with Dravet syndrome</b>  | 13:45 - 13:45 |
| Alexander Rosendahl (Sweden)   |               |
| <b>Real life experience with cenobamate as monotherapy or part of dual therapy: a Spanish cohort</b>   | 13:45 - 13:45 |
| Álvaro Sánchez-Guijo Benavente (Spain)   |               |
| <b>Antiseizure rescue medications use in Epilepsy clinic of a level 4 Epilepsy center</b>  | 13:45 - 13:45 |
| Amir Arain (United States)   |               |
| <b>Anti-seizure medication prescribing habits in Portugal in stroke patients - a national-wide survey</b>  | 13:45 - 13:45 |
| Ana Franco (Portugal)  |               |
| <b>Prescription patterns of antiseizure medications in Sweden 2007-2023</b>  | 13:45 - 13:45 |
| André Idegård (Sweden)   |               |
| <b>Tolerability and Safety of Fenfluramine and Global Functioning of Patients in a Combined Open-label Extension Study of Children and Adults With Dravet and Lennox-Gastaut Syndromes</b>                                 | 13:45 - 13:45 |
| An-Sofie Schoonjans (Belgium)  |               |
| <b>Repurposing approved drugs as a pathway to novel treatments for Lafora Disease</b>  | 13:45 - 13:45 |
| Antonella Liantonio (Italy)  |               |

|  |               |
|--|---------------|
| <b>Highly purified cannabidiol in patients with monogenic Rett and Rett-like developmental and epileptic encephalopathies</b>  | 13:45 - 13:45 |
| Alessandro Orsini (Italy)  |               |
| <b>ARGUS: A Phase 3 Study of EPX-100 (Clemizole Hydrochloride) in Patients with Dravet Syndrome</b>  | 13:45 - 13:45 |
| Amit Ray (United States)   |               |
| <b>A 20-Week Multicenter, Randomized, Double-Blind (DB), Placebo-Controlled, Phase 3 Trial (EPX 100-003) evaluating EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in patients with Lennox-Gastaut Syndrome (LGS)</b> | 13:45 - 13:45 |
| Juby Philip (United States)  |               |
| <b>Use of Phenoazanic acid in patients with epileptic seizures and ischemic stroke</b>   | 13:45 - 13:45 |
| Anna Lebedeva (Russian Federation)   |               |
| <b>Analysis of the final medication adjustment leading to seizure freedom in patients treated with cenobamate</b>  | 13:45 - 13:45 |
| Bassel Abou-Khalil (United States)   |               |
| <b>Relugirine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study</b>   | 13:45 - 13:45 |
| Antonio Gil-Nagel (Spain)  |               |
| <b>Emergency Use Case of Relugirine, a Functional State Sodium Channel Modulator, in an Infant with SCN2A-DEE and Refractory Status Epilepticus</b>  | 13:45 - 13:45 |
| Brian Spar (United States)   |               |
| <b>Non-seizure benefits of long-term fenfluramine treatment in pediatric patients with Dravet syndrome</b>   | 13:45 - 13:45 |
| Cathrine Elisabeth Gjerulfsen (Denmark)  |               |
| <b>How could cenobamate influence the plasma lipid levels in epilepsy patients</b>   | 13:45 - 13:45 |
| Catarina Fernandes (Portugal)  |               |
| <b>Clinically relevant pharmacokinetic interactions with cenobamate</b>  | 13:45 - 13:45 |
| Cecilie Johannessen-Landmark (Norway)  |               |
| <b>Characterizing Seizure Free Epochs based on Anti-seizure Medications Failed for Patients with Focal Treatment Resistant Epilepsy (FTRE)</b>   | 13:45 - 13:45 |
| Caitlin Grzeskowiak (United States)  |               |
| <b>Cannabidiol administration in patients with Lennox-Gastaut syndrome or other pharmacoresistant epilepsy: a single center's experience</b>   | 13:45 - 13:45 |
| Chrysanthi Tsimakidi (Greece)  |               |
| <b>Glutamate-dependent inhibition and desynchronization of early AMPAergic currents by the anticonvulsant perampanel</b>   | 13:45 - 13:45 |
| Chung-Chin Kuo (Taiwan, China)   |               |
| <b>Experience and opinions regarding therapeutic drug monitoring in Irish epilepsy care: a patient perspective survey</b>  | 13:45 - 13:45 |
| Investigating the effect of steady state cannabidiol on the single dose pharmacokinetics of CYP2B6, CYP2C9, UGT2B7, and UGT1A9 substrates  | 13:45 - 13:45 |
| Cuiping Chen (United States)   |               |
| <b>Neuropsychiatric symptoms in patients with epilepsy on levetiracetam monotherapy and its correlation with biomarkers</b>  | 13:45 - 13:45 |

**levels and neuroimaging findings**

Deeksha Sharma (India)

**Zonisamide in the practise of an epileptologist: Focus on safety**

13:45 - 13:45

Diana Komarova (Russian Federation)

**Association between Antiseizure Medication Therapy and Quality of Life in Patients with Temporal Lobe Epilepsy**

13:45 - 13:45

Dinda Larastika Riyanto (Indonesia)

**Highly purified cannabidiol (hpCBD) in CDKL5 deficiency disorder (CDD): open label prospective study**

13:45 - 13:45

Marco Perulli (Italy)

**Use of oral cannabis in a drug-resistant epilepsy: A five-year single center experience**

13:45 - 13:45

Young Ho Kim (Korea, Republic of)

**Two-year safety, efficacy, and retention of Cannabidiol (CBD) as add-on therapy in patients with refractory epilepsy**

13:45 - 13:45

Elena Kkolou (Cyprus)

**Highly purified cannabidiol in highly active genetic developmental and epileptic encephalopathies: a multicenter real-world study**

13:45 - 13:45

Emanuele Cerulli Irelli (Italy)

**A time based analysis for Cenobamate use in focal epilepsy**

13:45 - 13:45

Emilio Russo (Italy)

**Clinically Meaningful Reduction in Seizure Frequency in Patients with Tuberous Sclerosis Complex Treated with Cannabidiol**

13:45 - 13:45

Elizabeth A Thiele (United States)

**High-dose cenobamate in the treatment of drug-resistant epilepsy and the effect on the concomitant medication**

13:45 - 13:45

Eva Pakosova (Slovakia)

**Enhancing Executive Function in Dravet Syndrome: The Impact of Fenfluramine on Behavioral Performance and Quality of Life**

13:45 - 13:45

Federica Ascione (Italy)

**Is earlier better? One year cenobamate outcome in a large real world population**

13:45 - 13:45

Federica Ranzato (Italy)

**Association of metformin use with a reduction in epilepsy related hospital admissions in Wales, United Kingdom**

13:45 - 13:45

Gashirai K Mbizvo (United Kingdom)

**Cenobamate treatment for drug-resistant epilepsy: A quality of life and drug utilization study from an Italian pharmacy**

13:45 - 13:45

Giorgia Dinoi (Italy)

**TrkB activation as a novel target for drug resistant temporal lobe epilepsy: from animal models to the human epileptic brain**

13:45 - 13:45

Annunziata Guarino (Italy)

**Outcomes of Adjunctive Cenobamate Therapy in a Large Early Access Cohort of Adult Patients with Drug Refractory Epilepsy with Focal-Onset Seizures**

13:45 - 13:45

Hester Rose Garratt (United Kingdom)

**Identifying antiseizure medications specific association with systemic inflammatory biomarker**

13:45 - 13:45

Kyung-Il Park (Korea, Republic of)

|   |               |
|---|---------------|
| <b>Efficacy and tolerability of Brivaracetam: preliminary results of a National multicentre prospective audit on a mixed adult and paediatric population</b>  | 13:45 - 13:45 |
| Ioannis Stavropoulos  |               |
| <b>Levetiracetam to Brivaracetam : A Mood Swing in Epilepsy Management?</b>   | 13:45 - 13:45 |
| Ishreen Ahuja (India)   |               |
| <b>Loss of Function <i>ABCG2</i> c.421C&gt;A (rs2231142) Polymorphism Decreases Lamotrigine Trough Concentrations in Adults with Epilepsy</b>   | 13:45 - 13:45 |
| Ivana Šušak Sporiš (Croatia)  |               |
| <b>Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent K<sub>v</sub>7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-Year Open-Label Extension of X-TOLE</b> | 13:45 - 13:45 |
| Jacqueline French (United States)   |               |
| <b>Clinical Utility of Therapeutic Drug Monitoring of Anti-Seizure Medications Following Breakthrough Seizures</b>  | 13:45 - 13:45 |
| Janet Mifsud (Malta)  |               |
| <b>Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator</b>   | 13:45 - 13:45 |
| Jason Lerner (United States)  |               |
| <b>Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut Syndrome (LennoVig): A randomized double-blind placebo-controlled trial</b>   | 13:45 - 13:45 |
| Jayantee Kalita (India)   |               |
| <b>Bexicaserin Reduces Seizures and Modulates Interictal Spectral Power in the GAERS Absence Epilepsy Model</b>   | 13:45 - 13:45 |
| Jesper Frank Bastlund (Denmark)   |               |
| Sheryl Anne D. Vermudez (United States)   |               |
| <b>Treatment simplification is key to optimize and maintain long-term efficacy and tolerability of cenobamate: a retrospective study in Spain</b>   | 13:45 - 13:45 |
| Juan Maria Sanchez-Caro (Spain)   |               |
| <b>Histone deacetylase inhibitors in epilepsy: insights on blood-brain barrier integrity and excitation-inhibition balance</b>  | 13:45 - 13:45 |
| Joana Bicker (Portugal)   |               |
| <b>Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Outcomes Following Add-on Cannabidiol Treatment: 3-Month Analysis of the Open-Label Phase 3b/4 Trial EpiCom</b>                       | 13:45 - 13:45 |
| Joanne Stevens (United States)  |               |
| <b>Efficacy and safety of cenobamate in adults with uncontrolled focal seizures in the Spanish cohort of a Phase 3 open-label clinical trial: a multicenter retrospective study</b>                       | 13:45 - 13:45 |
| José M. Serratosa (Spain)   |               |
| <b>RADIANT - An Open Label Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Vormatrigine in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures</b>                 | 13:45 - 13:45 |
| Karl Hansen (United States)   |               |
| <b>Efficacy and Safety of Trofinetide for the Treatment of Rett Syndrome: Results From the Pivotal Phase 3 LAVENDER Study</b>   | 13:45 - 13:45 |
| Kasia Dobrzynska (Switzerland)  |               |

|  |               |
|--|---------------|
| <b>Point of care Lamotrigine monitoring in epilepsy: A Pilot Study Using a Carbon Screen-Printed Electrode</b>   | 13:45 - 13:45 |
| Albert Kelly (Ireland)   |               |
| <b>An integrated single-cell and spatial transcriptomic atlas of human hippocampus in patients with temporal lobe epilepsy and hippocampal sclerosis</b> | 13:45 - 13:45 |
| Jiayao Li (China)  |               |
| <b>Identification of the ABCB1 gene in pediatric epilepsy patients of Kazakhstan</b>   | 13:45 - 13:45 |
| Aidana Gabdulkayum (Kazakhstan)  |               |
| <b>Phenotypic spectrum in patients with chromosome15-long-arm-duplication-syndrome</b>   | 13:45 - 13:45 |
| Alessandra Rossi (Italy)   |               |
| <b>Genetic and Clinical Characterization of Adult Patients with GABAA-receptor related disorders</b>   | 13:45 - 13:45 |
| Anna Gretel Pinzon-Acevedo (Denmark)   |               |
| <b>Identification of potential microRNA biomarkers in pediatric patients with refractory epilepsy</b>  | 13:45 - 13:45 |
| Angie Paola Rueda Céspedes (Colombia)  |               |
| <b>PPP2R1A-Related Neurodevelopmental Disorder: The First Korean Case with a Novel Variant of PPP2R1A and Literature Review</b>                          | 13:45 - 13:45 |
| Eu Gene Park (Korea, Republic of)  |               |
| <b>Novel risk alleles for Familial Focal Epilepsy with Variable Foci (FFEVF) identified from whole exome sequencing of a small nuclear family</b>        | 13:45 - 13:45 |
| Russell J Buono (United States)  |               |
| <b>The phenotypic presentation of adult individuals with IQSEC2-related neurodevelopmental disorders</b>   | 13:45 - 13:45 |
| Chiara Ferrazzoli (Italy)  |               |
| <b>Genotype-phenotype correlation in GABRB3 loss-of-function</b>   | 13:45 - 13:45 |
| Cordelia Katharine Lindhard Smidth (United States)   |               |
| <b>Spatial distribution of brain somatic variants and affected cell types in focal epilepsy</b>  | 13:45 - 13:45 |
| Daria Merrikh (Canada)   |               |
| <b>Whole genome sequencing insights in child epilepsy in Kazakhstan</b>  | 13:45 - 13:45 |
| Dauren Yerezhepov (Kazakhstan)   |               |
| <b>Experience of Multidisciplinary Care for Tuber Sclerosis Complex patients; Quality of life and patient satisfaction on follow up</b>                  | 13:45 - 13:45 |
| Mashaal Alkhateeb (Saudi Arabia)   |               |
| <b>Differentiating MERRF Syndrome from Juvenile Myoclonic Epilepsy - case report</b>   | 13:45 - 13:45 |
| Marija Babunovska (North Macedonia)  |               |
| <b>Atypical Rett syndrome in a boy with MECP2 pathogenic variant: case report</b>  | 13:45 - 13:45 |
| Irina Ivanova (Russian Federation)   |               |
| <b>Mitochondrial dysfunction in monogenic epilepsies</b>   | 13:45 - 13:45 |
| Eva Brilstra (Netherlands)   |               |
| <b>Epileptic seizures and 2q23.1 microdeletion syndrome in pediatric patient - case report</b>   | 13:45 - 13:45 |
| Ecaterina Grigore (Romania)  |               |

|   |               |
|---|---------------|
| <b>Can non convulsive status epilepticus lead to the diagnosis of a genetic syndrome? Case report</b>                             | 13:45 - 13:45 |
| Busra Sezen Nacak (Turkey)  |               |
| <b>Delta Power Analysis in EEG of Patients with Mitochondrial DNA Depletion Disorders</b>   | 13:45 - 13:45 |
| Erica Minato (Canada)   |               |
| <b>Antiseizure Medication Management for Dravet Syndrome: A Retrospective Analysis</b>  | 13:45 - 13:45 |
| Gonca Bektas (United States)  |               |
| <b>Genetic Alterations in Pediatric Patients with Cerebral Palsy and Epilepsy</b>   | 13:45 - 13:45 |
| Ji Yoon Han (Korea, Republic of)  |               |
| <b>Dynamic analysis of diagnostics and management of monogenic epilepsies and developmental and epileptic encephalopathies</b>    | 13:45 - 13:45 |
| Olga Shestakova (Russian Federation)  |               |
| <b>It is a rare cause of West syndrome. SLC38A3 mutation</b>  | 13:45 - 13:45 |
| Hüseyin Per (Turkey)  |               |
| <b>ODLURO Syndrome: A Recently Identified Cause of Neurodevelopmental Delay and Epilepsy - expanding the phenotype</b>            | 13:45 - 13:45 |
| Inês Carmo e Pinto (Portugal)   |               |
| <b>A LAMC3 mutation linked with lissencephaly associated with pachygyria in different cortical lobes</b>                          | 13:45 - 13:45 |
| Ioanna Kousiappa (Cyprus)   |               |
| <b>In vitro electrophysiological study of hippocampal network activity in a mouse model of STXBP1 haploinsufficiency</b>          | 13:45 - 13:45 |
| Isabelle Niespodziany (Belgium)   |               |
| <b>Germline genetic signatures of epilepsy surgery response: an individual-case meta-analysis</b>                                 | 13:45 - 13:45 |
| Alina Ivaniuk (United States)   |               |
| <b>Characterising Epilepsy Phenotype Heterogeneity in Biobank-Derived Disease Cases</b>   | 13:45 - 13:45 |
| Janne Auning Hansen (Denmark)   |               |
| <b>4-phenylbutyrate use and efficacy in SLC6A1-related neurodevelopmental disorders</b>   | 13:45 - 13:45 |
| Katrine Johannesen (Denmark)  |               |
| <b>SEEG data in two patients with temporal epilepsy of genetic origin with NPRL2 and NPRL3 variants</b>                           | 13:45 - 13:45 |
| Karine Ostrowsky-Coste (France)   |               |
| <b>Novel variants and high diagnostic yield of Whole Exome Sequencing analysis in young epilepsy patients</b>                     | 13:45 - 13:45 |
| Sofia Markoula (Greece)   |               |
| <b>Epilepsy-Associated Chromatin Conformation and Structural Variants Revealed by Hi-C</b>  | 13:45 - 13:45 |
| Kristina Karandasheva (Germany)   |               |
| <b>Diagnostic yield and copy number variants findings in 220 adult patients with developmental and epileptic encephalopathies</b> | 13:45 - 13:45 |
| Laura Licchetta (Italy)   |               |
| <b>The Genetic and clinical phenotype of PCDH19-related epilepsy</b>  | 13:45 - 13:45 |
| Kyoung min Lee (Korea, Republic of)   |               |

|  |               |
|--|---------------|
| <b>Peri-ictal respiratory disfunction in focal epilepsy due to mTOR pathway disorders</b><br>Leonardo Affronte (Italy)   | 13:45 - 13:45 |
| <b>Variants in <i>FLNB</i> gene associated with epilepsy in the <i>Drosophila</i> model</b><br>Lixia Li (China)  | 13:45 - 13:45 |
| <b>Genetic Susceptibility for Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorders in Children Born to Women with Epilepsy</b><br>Mathilde Kinge-Rasmussen (Norway)                          | 13:45 - 13:45 |
| <b>Mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations (MCC-CH-CM) related to <i>MAST1</i> gene: an accurate electroclinical case description</b><br>Martina Malaspina (Italy) | 13:45 - 13:45 |
| <b>CADASIL and epilepsy: a rare yet significant association</b><br>Mariana Seco (Portugal)   | 13:45 - 13:45 |
| <b>Circulating microRNAs as Biomarkers of juvenile myoclonic epilepsy</b><br>Diana V. Dmitrenko (Russian Federation)   | 13:45 - 13:45 |
| <b>Association of <i>GSTM1</i> gene deletion with therapeutic response in epilepsy</b><br>Marija Milanovska (North Macedonia)  | 13:45 - 13:45 |
| <b>DDC c.1357C&gt;T Variant in a Patient from Uzbekistan with Aromatic L-Amino Acid Decarboxylase Deficiency and Seizures</b><br>Nodira M. Tychibaeva (Uzbekistan)   | 13:45 - 13:45 |
| <b>Evidence of causality of metabolic and lipid species in epilepsy disease risk, with strongest signals in genetic generalised epilepsies</b><br>Karen L Oliver (Australia)                                   | 13:45 - 13:45 |
| <b>Genotype-phenotype correlation of novel <i>SCN1A</i> variants selected from the Italian Registry of Dravet Syndrome Residras</b><br>Paola Imbrici (Italy)   | 13:45 - 13:45 |
| <b>Developing minimum reporting standards for research articles on the treatment of genetic epilepsies</b><br>Patrick Moloney (Ireland)  | 13:45 - 13:45 |
| <b>Focal refractory epilepsy associated to 15q13.3 microduplication</b><br>Daniel San Juan (Mexico)  | 13:45 - 13:45 |
| <b>The GABAA-Receptor Portal: A Comprehensive Online Database and Webtool of Homologous Variants</b><br>Rebekka Staal Dahl (Denmark)   | 13:45 - 13:45 |
| <b>Acetazolamide response in a UK cohort of adults and children with CHD2 associated epilepsy</b><br>Rhys Thomas (United Kingdom)  | 13:45 - 13:45 |
| <b>Low-level mosaic <i>SCN2A</i> variant causing early infantile onset epileptic encephalopathy: characterization using heterologous cell expression and neurons from iPSC cells</b><br>Antonella Riva (Italy) | 13:45 - 13:45 |
| <b>Clinical Heterogeneity in Genetic Sleep-Related Hypermotor Epilepsy - A Systematic Review of Published Cases</b><br>Valentina Rizzo (Italy)   | 13:45 - 13:45 |



|   |               |
|---|---------------|
| <b>Actionable genetic variants in a South Indian cohort of complex childhood-onset epilepsy- a whole-exome sequencing based analysis</b><br>Ramshekhar N Menon (India)                              | 13:45 - 13:45 |
| <b>Single-Nucleus RNA Sequencing Reveals Cell-specific Dysregulation in the Hippocampus of a Mouse Model of CDKL5 Deficiency Disorder</b><br>Samuel Egan (Ireland)                                  | 13:45 - 13:45 |
| <b>Lafora Disease: The First Clinically Diagnosed Case in Ecuador via Genetic Testing</b><br>Santiago Andrés Vintimilla Pesántez (Ecuador)  | 13:45 - 13:45 |
| <b>Genes and Epilepsy</b><br>Sara Lima (Portugal)   | 13:45 - 13:45 |
| <b>Systematic review of genome wide association studies (GWAS) of epilepsy identifies common risk variants and associated genes</b><br>Sarah Jacobs (South Africa)                                  | 13:45 - 13:45 |
| <b>SLC6A1-related neurodevelopmental disorders: prevalence and characterization of non-epileptic findings</b><br>Sebastian Silva Soto (Denmark)   | 13:45 - 13:45 |
| <b>Beyond Seizures: Deep Phenotyping of GABA<sub>A</sub> Receptor Variants Reveals Functional Segregation and Predicts Risk of Gross Motor Dysfunction</b><br>Sebatian Ortiz De la Rosa (Denmark)   | 13:45 - 13:45 |
| <b>Electro-clinical and molecular characterization of patients with SYNGAP1-associated encephalopathy in Argentina</b><br>Nicolás Schnitzler (Argentina)  | 13:45 - 13:45 |
| <b>Radiologic findings of patients with sodium channelopathies</b><br>SeHee Kim (Korea, Republic of)  | 13:45 - 13:45 |
| <b>Adult-Onset Drug Resistant Progressive Epilepsy in a Patient with MECP2 Mutation</b><br>Sophey Ho (United States)  | 13:45 - 13:45 |
| <b>Genetic causes of malformation of cortical development in children undergoing epilepsy surgery in Norway: Characterization of germline and somatic mutations</b><br>Fridny Heimisdottir (Norway) | 13:45 - 13:45 |
| <b>A Case Report of Lafora Disease Associated with NHLRC1 Gene Mutation</b><br>Fulya Eren (Turkey)  | 13:45 - 13:45 |
| <b>Establishing inclusive teaching in medical education: development of a new and innovative curriculum</b><br>Christian Brandt (Germany)   | 13:45 - 13:45 |
| <b>IGAP: Challenges for its implementation in Latin America</b><br>Keryma Acevedo (Chile)   | 13:45 - 13:45 |
| <b>Strengthening Epilepsy Care in Kazakhstan Through Telemedicine: Policy Challenges and IGAP Implementation</b><br>Leila Dairbayeva (Kazakhstan)   | 13:45 - 13:45 |
| <b>Access to diagnosis and treatment for epileptic people in Argentina: survey within the framework of the Intersectorial Global Action Plan (IGAP)</b>   | 13:45 - 13:45 |
| <b>Empowering Community Health Workers: A Multistate Evaluation of Epilepsy Training Outcomes in India's Primary Care System</b>  | 13:45 - 13:45 |

|   |               |
|---|---------------|
| Mayank Sharma (India)   |               |
| <b>Fostering Effective Community-Based Collaborative Research</b>   | 13:45 - 13:45 |
| Mary Secco (Canada)   |               |
| <b>Access and visibility of International League Against Epilepsy Young Epilepsy Section (ILAE-YES) members within ILAE chapters: Global survey 2023</b>  | 13:45 - 13:45 |
| Stuart Smith (United Kingdom)   |               |
| <b>Tuberous Sclerosis Complex: Exploring the Relationship Between Epilepsy, Cognitive Outcomes, and Tuber Burden</b>  | 13:45 - 13:45 |
| Rita Cagigal (Portugal)   |               |
| <b>Functional Connectivity Abnormalities Mediating Verbal Fluency Deficits in Newly Diagnosed Epilepsy Patients</b>   | 13:45 - 13:45 |
| Fangzhou Liu (China)  |               |
| <b>Alternations in morphometric similarity network in temporal lobe epilepsy correlated to neuroinflammation pathway gene transcriptions</b>  | 13:45 - 13:45 |
| Lu Lu (China)   |               |
| <b>Clinical and video-EEG topography predict diagnostic benefit of 7 Tesla MRI in epilepsy patients</b>   | 13:45 - 13:45 |
| Ahmed Haydar (Brazil)   |               |
| <b>Structural and functional connectome-based predictive models (CPM) for temporal lobe epilepsy with hippocampal sclerosis (TLE-HS)</b>  | 13:45 - 13:45 |
| Alejandro Hugo Nasimbera (Argentina)  |               |
| <b>Unveiling Variability in MRI-Negative Temporal Lobe Epilepsy: Distinct Phenotypes from a Multicentric Study</b>  | 13:45 - 13:45 |
| Alice Ballerini (Italy)   |               |
| <b>Evaluating PET Metabolic Activity in Hippocampal Sclerosis: Concordance Between Visual and Quantitative Analyses</b>   | 13:45 - 13:45 |
| Bengi Gul Turk (Turkey)   |               |
| <b>Association between gray matter volume changes and SEEG-defined epileptogenicity</b>   | 13:45 - 13:45 |
| Andrew Neal (Australia)   |               |
| <b>The Role Of Perfusion Head CT In Defining Non-Convulsive Status Epilepticus: A Review</b>  | 13:45 - 13:45 |
| António Martins-de-Campos (Portugal)  |               |
| <b>Brain perfusion imaging by arterial spin labelling predicts postsurgical seizure freedom in pediatric focal lesional epilepsy: a pilot study</b>   | 13:45 - 13:45 |
| Antonio Giulio Gennari (Switzerland)  |               |
| <b>Assessing the Consistency and Reliability of Hub Metrics Across Parcellations in Temporal Lobe Epilepsy</b>  | 13:45 - 13:45 |
| Arielle Dascal (Canada)   |               |
| <b>Atrophy network mapping of clinical symptoms in temporal lobe epilepsy</b>   | 13:45 - 13:45 |
| Zirong Chen (China)   |               |
| <b>Preoperative diffusion tensor imaging (DTI) and neurite dispersion and density imaging (NODDI) in IDH-mutant grade 2 and 3 gliomas: definition of tumor-related epilepsy and predictive factors of seizure outcomes based on a single-center retrospective case series</b> | 13:45 - 13:45 |

Beatrice Claudia Bono (Italy)

**Visual and verbal memory networks in temporal lobe epilepsy** 13:45 - 13:45

Marc Berger (Austria)

**Differences in Functional Connectivity Patterns in Temporal Lobe Epilepsy with Hippocampal Sclerosis: A Resting-State fMRI Study** 13:45 - 13:45

Brenda Giagante (Argentina)

**Neuroimaging Findings in Patients with Focal Cortical Dysplasia and Secondary Bilateral Synchrony on Interictal EEG** 13:45 - 13:45

Ana Carolina Piauilino Santos Falcão (Brazil)

**Determining the Computed Tomography Perfusion Changes in Patients Presenting with Acute Seizures of Different Etiologies - A Case-control Study** 13:45 - 13:45

Ching Soong Khoo (Malaysia)

**Integration of Diffusion Metrics for Enhanced Detection of Focal Cortical Dysplasia** 13:45 - 13:45

David Kala (Czech Republic)

**High-Resolution Imaging of Epilepsy: HARNESS MRI Compared to Conventional Protocols** 13:45 - 13:45

Ra'no Azizova (Uzbekistan)

**Connectivity-based activity flow mapping predicts altered declarative memory states in drug-resistant epilepsy** 13:45 - 13:45

Donna Gift Cabalo (Canada)

**Examining 'neural soma' compartments to support focal cortical dysplasia lesion detection in paediatric epilepsy** 13:45 - 13:45

Yi Jie Li (United Kingdom)

**Lesion phenotypes in different focal cortical dysplasia subtypes and locations** 13:45 - 13:45

Ella Sahlas (Canada)

**Distributed hypometabolism associated with focal cortical dysplasia reflects structural connectivity of the human brain** 13:45 - 13:45

Emma Macdonald-Laurs (Australia)

**Distinct Phases of Hub Reorganization and Their Association with Post-Surgical Outcomes in Temporal Lobe Epilepsy: A Multimodal Connectivity Analysis** 13:45 - 13:45

Ezequiel Gleichgerrcht (United States)

**Enhancing Seizure Onset Zone Detection Through Combined Neuroimaging Data Features and sEEG Signal Analysis in Pediatric Epilepsy** 13:45 - 13:45

Ferran Craven-Bartle Corominas (Spain)

**Are peri-ictal MRI abnormalities markers of seizure duration? Insights from a prospective study on status epilepticus and single seizures** 13:45 - 13:45

Giorgi Kuchukhidze (Austria)

**Are enlarged perivascular space a predictor of acute early post-traumatic seizures after traumatic brain injury?** 13:45 - 13:45

Gernot Hlauschek (Norway)

**Preoperative Seizures Correlate with Elevated  $^{11}\text{C}$ -Methionine PET Uptake in Oligodendroglioma Patients** 13:45 - 13:45

Ryosuke Hanaya (Japan)

**Neurodegenerative Biomarkers and Cognitive Impairment in** 13:45 - 13:45

**Temporal Lobe Epilepsy: Insights from PET Imaging**

Xianghe Liu (China)

**Quantitative brain T1 relaxometry in Mesial Temporal Lobe Epilepsy**

13:45 - 13:45

Ilaria Sammarra (Italy)

**Metabolic machine learning for temporal lobe epilepsy lateralisation**

13:45 - 13:45

Jack Lam (Canada)

**Automated whole-brain segmentation with MAPER in refractory temporal lobe epilepsy: a multicenter international validation study**

13:45 - 13:45

Jakob Rosén (Sweden)

**Estimation of patient head movement during FDG-PET scanning**

13:45 - 13:45

Radek Janca (Czech Republic)

**Altered Seizure Dynamics and Cortical Oscillations in a Mouse Model of Cyclin-Dependent Kinase-Like 5 Deficiency Disorder**

13:45 - 13:45

Jordan Higgins (Ireland)

**Multisite validation of a patient-specific MRI-based lesion mapping tool for clinical decision-making in drug-resistant temporal lobe epilepsy**

13:45 - 13:45

Judy Chen (Canada)

**Total gray matter in adults with epilepsy and associations with drug resistant epilepsy, ASM side effects, tonic-clonic seizures and valproic acid**

13:45 - 13:45

Klara Andersson (Sweden)

**Ictal SPECT success rate using a single SPECT session protocol**

13:45 - 13:45

Kheng Seang Lim (Malaysia)

**Antiseizure Medications Serial Levels and Quantitative MRI Analysis in Mesial Temporal Lobe Epilepsy**

13:45 - 13:45

Lilian Audi Goulart (Brazil)

**Metabolic heterogeneity of mesial Temporal Lobe Epilepsy and functional correlates. Preliminary data**

13:45 - 13:45

Pietro Mattioli (Italy)

**Value of 7T MRI versus 3T MRI with post-processing in patients with non-lesional focal epilepsy (NLFE)**

13:45 - 13:45

O. Kukhlenko (Germany)

**Seizure Laterality on EEG is Associated with Thalamic SPECT Lateralization**

13:45 - 13:45

Gloria Ortiz Guerrero (United States)

**Crossed Cerebellar Diaschisis in Status Epilepticus: a Systematic Review of the Literature**

13:45 - 13:45

Payam Tabaei Damavandi (Austria)

**Clinical Relevance of Interictal PET and SPECT in Localizing Epileptogenic Foci for Surgical Planning**

13:45 - 13:45

Daniel San Juan (Mexico)

**Increased hippocampal T2 relaxation is associated with differential functional pathways expression in temporal lobe epilepsy patients**

13:45 - 13:45

Jose Eduardo Peixoto-Santos (Brazil)

**Validation of the FlaT1 Analysis for Detecting Focal Cortical Dysplasia in Epilepsy Surgery**

13:45 - 13:45

Pietro Milano (Italy)

|  |               |
|--|---------------|
| <b>In-vivo evidence for increased tau deposition in temporal lobe epilepsy</b>   | 13:45 - 13:45 |
| Raul R. Cruces (Canada)  |               |
| <b>Evaluate Tau Distribution Using [<sup>18</sup>F] PI-2620 PET/CT to Predict Traumatic Brain Injury and Post-Traumatic Epilepsy Outcomes in Sprague Dawley Rat</b>    | 13:45 - 13:45 |
| Runxuan Lin (Australia)  |               |
| <b>Arterial Spin Labeling (ASL) perfusion imaging in Rasmussen Syndrome</b>  | 13:45 - 13:45 |
| Roberto Horacio Caraballo (Argentina)  |               |
| <b>Thalamic Nuclei Alterations in Paediatric Focal Epilepsy: A Quantitative MRI Study</b>  | 13:45 - 13:45 |
| Ryan Isaac Sia Zu Wern (United Kingdom)  |               |
| <b>Late-Onset Rasmussen Encephalitis</b>   | 13:45 - 13:45 |
| Silvia Gonzalez (Argentina)  |               |
| <b>Role of 18F-FDG-PET/CT in a non-surgical epilepsy center: enhancing diagnostic accuracy</b>   | 13:45 - 13:45 |
| Sofía Lallana (Spain)  |               |
| <b>Sex-related structural abnormalities across different epilepsies: a worldwide ENIGMA study</b>  | 13:45 - 13:45 |
| Huantao Wen (Germany)  |               |
| <b>Analysis of Resting-State Functional Brain MRI Connectivity and Clinical Outcomes on Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis</b>                   | 13:45 - 13:45 |
| William Souza Martins Ferreira (Brazil)  |               |
| <b>Bilateral precentral gyri and caudate nuclei atrophy in epilepsy patients with postictal generalized EEG suppression</b>  | 13:45 - 13:45 |
| Yingchun Xu (China)  |               |
| <b>Distinct Brain Connectivity Patterns in Autoimmune Limbic Encephalitis and Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis: Insights from Graph Theory</b> | 13:45 - 13:45 |
| Yao Ding (China)   |               |
| <b>Theta bursts and impaired inhibitory control in sleep-related hypermotor epilepsy</b>   | 13:45 - 13:45 |
| Jing Xiao (China)  |               |
| <b>The volume of particular brain regions and working memory performance in patients with left mesial temporal lobe epilepsy</b>                                       | 13:45 - 13:45 |
| Agnieszka Olejnik (Poland)   |               |
| <b>Cognitive and Emotional profiles in Children with new-onset Epilepsy: a longitudinal Cohort study 5 years follow-up (EpileTRE)</b>                                  | 13:45 - 13:45 |
| Andrea Palacio Navarro (Spain)   |               |
| <b>How much difference does depression make to the outcome of neuropsychological assessment of patients with epilepsy</b>  | 13:45 - 13:45 |
| Christoph Helmstaedter (Germany)   |               |
| <b>Neurocognitive Characterization and Clinical Aspects of Glioma-Related Epilepsy: Insights from a Surgical Cohort</b>  | 13:45 - 13:45 |
| Chiara Falamesca (Italy)   |               |
| <b>Understanding Caregiver Stress in Pediatric Epilepsy: The Mitigation of Cognitive Level, Education, and Treatment</b>   | 13:45 - 13:45 |
| Cinzia Correale (Italy)  |               |

|   |               |
|---|---------------|
| <b>Cognitive profile and family dynamics of patients with psychogenic non-epileptic, epileptic, and coexisting seizure: A comparative study in India</b><br>Ekamjeet Kaur (India)   | 13:45 - 13:45 |
| <b>Intellectual Functioning in Individuals with Developmental and Epileptic Encephalopathies: A Systematic Review</b><br>Esther Hiu Chung Chan (Australia)  | 13:45 - 13:45 |
| <b>Frontal lobe lesion and overeating/mockings seizures: a case-report</b><br>Gonçalo Diniz de Pinho (Portugal)   | 13:45 - 13:45 |
| <b>The impact of postoperative residual seizures on long-term intellectual outcomes after epilepsy surgery</b><br>Naoya Hasegawa (Japan)  | 13:45 - 13:45 |
| <b>Neuropsychological and linguistic evaluation of patients with Dravet syndrome: a systematic review</b><br>Jose Angel Aibar (Spain)   | 13:45 - 13:45 |
| <b>Emotion recognition across visual and auditory modalities in temporal lobe epilepsy</b><br>Maja Milovanović (Serbia)   | 13:45 - 13:45 |
| <b>Executive Functioning Improvement with Behavioral Psychotherapy, but not with Sertraline, in Persons with Mesial Temporal Lobe Epilepsy due to Hippocampal Sclerosis and Major Depressive Disorder: a pilot, randomized and controlled study</b><br>Kette Valente (Brazil) | 13:45 - 13:45 |
| <b>Comparing the Classification of Cognitive Function by The International Classification of Cognitive Disorders in Epilepsy, IC-CoDE and The Bonn Code</b><br>Kirsten Vinter (Denmark)   | 13:45 - 13:45 |
| <b>Cognitive phenotype of patients with juvenile myoclonic epilepsy</b><br>Anastasia I. Paramonova (Russian Federation)   | 13:45 - 13:45 |
| <b>The development and implementation of an evidence-based psychosocial intervention for children and young people with epilepsy</b><br>Liam Dorris (United Kingdom)  | 13:45 - 13:45 |
| <b>Postoperative cognitive outcomes in patients with left Temporal Lobe Epilepsy</b><br>Manuela Jiménez Cárdenas (Colombia)   | 13:45 - 13:45 |
| <b>Influence of epilepsy on neuropsychiatric symptoms and cognitive profile in patients with tuberous sclerosis complex</b><br>Victoria Ros Castelló (Spain)  | 13:45 - 13:45 |
| <b>Novel tasks to assess material-specific memory impairments in patients with focal epilepsy: preliminary data with pre-surgical patients</b><br>Olivier Boucher (Canada)  | 13:45 - 13:45 |
| <b>Theory of mind in patients with juvenile myoclonic epilepsy</b><br>Patricia Braga (Uruguay)  | 13:45 - 13:45 |
| <b>Correlation between subclinical seizures and cognitive impairment in adult epilepsy patients - a retrospective observational study</b><br>Pedro Viana (United Kingdom)   | 13:45 - 13:45 |
| <b>Meta-analysis of neurodevelopmental outcomes following prenatal exposure to monotherapy antiseizure medications</b><br>Rebecca L Bromley (United Kingdom)  | 13:45 - 13:45 |

|   |               |
|---|---------------|
| <b>Very long-term cognitive outcomes in generalized epilepsies: a 20-year follow-up study</b><br>Ruta Mameniskiė (Lithuania)  | 13:45 - 13:45 |
| <b>Epilepsy beyond seizures: Exploring psychosocial determinants of treatment adherence in patients with epilepsy</b><br>Saher Ayub (India)   | 13:45 - 13:45 |
| <b>Trackognize: A Smartphone-Based Tool for Monitoring Mental Fitness - Willingness of People with Epilepsy to Use It</b><br>Sarah Al-Haj Mustafa (Germany)   | 13:45 - 13:45 |
| <b>Pre-Surgical Neuropsychological Evaluations for Epilepsy Patients in Mongolia</b><br>Sophey Ho (United States)   | 13:45 - 13:45 |
| <b>Epilepsy Surgery During the Golden Years - Five Year Neuropsychological Outcomes of an Elderly Patient with Refractory Left Temporal Lobe Epilepsy</b><br>Timothy Ainger (United States)                               | 13:45 - 13:45 |
| <b>Social Cognition and Epilepsy: A Pilot Study on Happé Strange Stories and Baron-Cohen Reading The Mind in The Eyes Tests</b><br>Leny Frossard de Amorim Leite (Brazil)   | 13:45 - 13:45 |
| <b>Promoting health literacy in people with epilepsy: recent advances and future directions</b><br>David Loura (Portugal)   | 13:45 - 13:45 |
| <b>Try it, adopt it : Appreciative Inquiry in a French Pediatric Epileptology Departement</b><br>Karine Ostrowsky-Coste (France)  | 13:45 - 13:45 |
| <b>10 years of educational and recreation camps for children with epilepsy in Croatia</b><br>Kristina Kuznik (Croatia)  | 13:45 - 13:45 |
| <b>Implementing and evaluating a novel model of care for patients with developmental and epileptic encephalopathies</b><br>Lauren Kelada (Australia)  | 13:45 - 13:45 |
| <b>Assessing the impact of e-learning in caregiver training on paediatric epilepsy awareness and buccal Midazolam administration: a Scottish quality improvement study</b><br>Lucrezia Maria Piccicacchi (United Kingdom) | 13:45 - 13:45 |
| <b>Building bridges: A dedicated ERN EpiCARE working group for nurses and vEEG technicians</b><br>Nicola Lawrence (United Kingdom)  | 13:45 - 13:45 |
| <b>Febrile seizures - education of educators, professional teams and parents - project of the Croatian Epilepsy Association</b><br>Nikolina Bedekovic (Croatia)   | 13:45 - 13:45 |
| <b>The Epilepsy Specialist Nurse (ESN) 360 Academy - Transforming Nurse Education and Training in Epilepsy</b><br>Rajesh Vohra (United Kingdom)   | 13:45 - 13:45 |
| <b>A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States</b><br>Amélie Lothe (France)  | 13:45 - 13:45 |
| <b>Effect of epileptogenicity on central respiratory chemoreception and heart rate</b><br>Auriane Apaire (Belgium)  | 13:45 - 13:45 |

|   |               |
|---|---------------|
| <b>When the brain stops breathing: lessons from peri-ictal respiratory disturbances</b><br>Elisa Micalizzi (Italy)  | 13:45 - 13:45 |
| <b>Post-mortem MRI may positively identify sudden unexpected death in epilepsy</b><br>Fenglai Xiao (United Kingdom)   | 13:45 - 13:45 |
| <b>Long Term Interictal Heart Rate Variability Among Temporal and Frontal Epilepsy Patients: Do Different Parameters Predict the Risk for SUDEP?</b><br>Glenda Corrêa Borges de Lacerda (Brazil)  | 13:45 - 13:45 |
| <b>Assessing the impact of SUDEP risk on families of people with Developmental and Epileptic Encephalopathies (DEEs)</b><br>Isabella Brambilla (Italy)  | 13:45 - 13:45 |
| <b>Incidence and circumstances of sudden unexpected death in epilepsy (SUDEP) in the young Australian community</b><br>Zining Liu (Australia)   | 13:45 - 13:45 |
| <b>Are Obstructive Sleep Apnoea and Sudden Unexpected Death in Epilepsy Related ?</b><br>Afonso Morgadinho (Portugal)   | 13:45 - 13:45 |
| <b>Stiripentol prevents seizures and associated death in a mouse model of SUDEP</b><br>Laurent Chancharme (France)  | 13:45 - 13:45 |
| <b>Lower mortality in a French Single-Center Large Cohort of individuals with Dravet syndrome</b><br>Maria Picilli (France)   | 13:45 - 13:45 |
| <b>A Case of Near SUDEP (Sudden Unexpected Death in Epilepsy) in a Refractory Epilepsy Patient Undergoing Epilepsy Monitoring Unit Evaluation in a Level 3 NAEC (National Association of Epilepsy Centers) Community Hospital</b><br>Neela Zalmay (United States) | 13:45 - 13:45 |
| <b>KEBIBO: Known Epileptics Better Informed for Better Outcomes</b><br>Olga Tanda (United Kingdom)  | 13:45 - 13:45 |
| <b>Relation between evolution of epilepsy, respiratory functioning and risk of SUDEP, in a mouse model of Dravet Syndrome</b><br>Diane Haddad (France)  | 13:45 - 13:45 |
| <b>The analysis of heart rate variability according to the response to antiepileptic treatment</b><br>Sawsan Daoued (Tunisia)   | 13:45 - 13:45 |
| <b>Activation of Central 5-HT<sub>2C</sub> Receptors by Bexicaserin Reduces Seizures and Respiratory Arrest in a Mouse Model of SUDEP</b><br>Sheryl Anne D. Vermudez (United States)  | 13:45 - 13:45 |
| <b>Effect of cenobamate on sudden unexpected death in epilepsy (SUDEP) risk in a Spanish cohort of a phase 3 clinical trial</b><br>Vicente Villanueva (Spain)   | 13:45 - 13:45 |
| <b>Subacute encephalopathy with seizures in alcoholics (SESA): clinical implications of an underdiagnosed syndrome</b><br>Artur Nascimento (Portugal)   | 13:45 - 13:45 |
| <b>Seizure Duration and Time-Point Cutoffs for Statistically Defining a Prolonged Seizure: a Post-Hoc Analysis of the SCORE Video-EEG Database</b><br>Cédric Laloyaux (Belgium)   | 13:45 - 13:45 |



|   |               |
|---|---------------|
| <b>Relationship Between Seizures and Periodic Generalized Nonepileptiform Discharges During Sleep</b>   | 13:45 - 13:45 |
| Irem Gul Orhan (Turkey)   |               |
| <b>Overlap Syndromes - Coincidence or a New Clinical Entity?</b>  | 13:45 - 13:45 |
| Mariana Seco (Portugal)   |               |
| <b>Application of Causal Inference to Identify Determinants of Seizure Reduction and Quality of Life in Patients with Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex Treated With Cannabidiol</b> | 13:45 - 13:45 |
| Teresa Greco (Italy)  |               |
| <b>Exploring the Efficacy and Safety of Perampanel in Epilepsia Partialis Continua: A Case Series</b>   | 13:45 - 13:45 |
| Setareh Lahsaee (Canada)  |               |
| <b>Pharmacological inhibition of the RNA demethylase FTO increases seizure resilience</b>   | 13:45 - 13:45 |
| Sujithra Srinivas (Ireland)   |               |
| <b>Early neurocognitive recovery following stereo-EEG</b>   | 13:45 - 13:45 |
| Andrew Neal (Australia)   |               |

*ILAE Neurotechnology*

13:45 - 14:45

**ILAE Neurotechnology Section - Epilepsy past and future**

|  |               |
|--|---------------|
| <b>Introduction</b>  | 13:45 - 13:50 |
| <b>An historical perspective on neurotechnology: EEG, imaging, etc.</b>      | 13:50 - 14:15 |
| Pedro Viana (United Kingdom)   |               |
| <b>Seizure monitoring with ultra-long term subscalp EEG and/or wearables</b> | 14:15 - 14:40 |
| Pedro Viana (United Kingdom)   |               |
| <b>Conclusion and Q&amp;A</b>  | 14:40 - 14:45 |

*In-Person Posters*

14:00 - 14:30

In-Person Poster Presentations

**ILAE YES Poster Tour (S2)**

|   |               |
|---|---------------|
| <b>Overcoming challenges in epilepsy clinical trials: the role of European Consortium for Epilepsy Trials</b>   | 14:00 - 14:00 |
| Sébile Tchaicha (Spain)   |               |
| <b>Efficacy and Safety of Trofinetide for the Treatment of Rett Syndrome: Results From the Pivotal Phase 3 LAVENDER Study</b>                                 | 14:00 - 14:00 |
| Kasia Dobrzynska (Switzerland)  |               |
| <b>Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut Syndrome (LennoVig): A randomized double-blind placebo-controlled trial</b> | 14:00 - 14:00 |
| Jayantee Kalita (India)   |               |
| <b>ARGUS: A Phase 3 Study of EPX-100 (Clemizole Hydrochloride) in Patients with Dravet Syndrome</b>   | 14:00 - 14:00 |
| Amit Ray (United States)  |               |
| <b>Repurposing approved drugs as a pathway to novel treatments for Lafora Disease</b>   | 14:00 - 14:00 |
| Antonella Liantonio (Italy)   |               |

|   |               |
|---|---------------|
| <b>Relutrigine Demonstrates Robust Seizure Reduction and Seizure Freedom in DEEs: Results from the EMBOLD Study</b>   | 14:00 - 14:00 |
| Antonio Gil-Nagel (Spain)   |               |
| <b>Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy</b>                | 14:00 - 14:00 |
| Steven Petrou (United States)   |               |
| <b>Biomarker-Guided Efficacy of Fenofibrate Adjuvant Therapy In Persons With Active Epilepsy: The Randomized, Placebo-Controlled Trial</b>                                  | 14:00 - 14:00 |
| Nipaben Harjivanbhai Mendapara (India)  |               |
| <b>MicroRNA-134 inhibition attenuates intrinsic and synaptic dysfunction underlying pathophysiologic properties of the hippocampus in mice with Drug-Resistant Epilepsy</b> | 14:00 - 14:00 |
| Pablo Quintana-Sarti (Ireland)  |               |

*In-Person Posters*

14:00 - 14:30

In-Person Poster Presentations

**ILAE YES Poster Tour (S1)**

|  |               |
|--|---------------|
| <b>Clinical and neurophysiological features of sleep-associated epileptic seizures</b>   | 14:00 - 14:00 |
| Sevara Kalandarova (Uzbekistan)  |               |
| <b>Epilepsy and educational outcomes: A Nationwide Cohort Study in Denmark</b>   | 14:00 - 14:00 |
| Betina Trabjerg (Denmark)  |               |
| <b>Prescription patterns of anti-seizure medications for generalized and focal epilepsy in Morocco: A cross-sectional study</b>  | 14:00 - 14:00 |
| Yassine El Adraoui (Morocco)   |               |
| <b>Evaluating Clinician Engagement and Gain of Knowledge in Online Educational Modules on Epilepsy Self-Management</b>   | 14:00 - 14:00 |
| Shawna L. Strickland (United States)   |               |
| <b>Empowering Patients in Research: First insights from 323 Participants in the European SYNGAP1 Registry</b>  | 14:00 - 14:00 |
| Kirsten Eschermann (Austria)   |               |
| <b>Development and internal validation of a Primary caregiver reported instrument for neurobehavioral assessment of children with epileptic encephalopathy (PINACLE)</b> | 14:00 - 14:00 |
|  |               |
| <b>Pediatric Epilepsy Surgery: Global Trends of Referral and Presurgical Evaluation</b>  | 14:00 - 14:00 |
| Georgia Ramantani (Switzerland)  |               |
| <b>Is felt stigma associated with suicidal risk in patients with epilepsy?</b>   | 14:00 - 14:00 |
| Sang-Ahm Lee (Korea, Republic of)  |               |
| <b>Exploring transition in the ERN EpiCARE: Insights from a survey analysis</b>  | 14:00 - 14:00 |
| Francesca Ferraro (Italy)  |               |

*ILAE YES*

14:15 - 15:15

**ILAE YES Brainstorming Session - The epileptic heart**

|                     |               |
|---------------------|---------------|
| <b>Introduction</b> | 14:15 - 14:20 |
|---------------------|---------------|

|                               |               |
|-------------------------------|---------------|
| <b>The epileptic heart</b>    | 14:20 - 15:05 |
| Terence O'Brien (Australia)   |               |
| <b>Conclusion and Q&amp;A</b> | 15:05 - 15:15 |

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (S3)**

|  |               |
|--|---------------|
| <b>Incidence and circumstances of sudden unexpected death in epilepsy (SUDEP) in the young Australian community</b>                                | 14:30 - 14:30 |
| Zining Liu (Australia)   |               |
| <b>A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States</b>                  | 14:30 - 14:30 |
| Amélie Lothe (France)  |               |
| <b>Assessing the impact of SUDEP risk on families of people with Developmental and Epileptic Encephalopathies (DEEs)</b>                           | 14:30 - 14:30 |
| Isabella Brambilla (Italy)   |               |
| <b>Activation of Central 5-HT<sub>2C</sub> Receptors by Bexicaserin Reduces Seizures and Respiratory Arrest in a Mouse Model of SUDEP</b>          | 14:30 - 14:30 |
| Sheryl Anne D. Vermudez (United States)  |               |
| <b>Lower mortality in a French Single-Center Large Cohort of individuals with Dravet syndrome</b>  | 14:30 - 14:30 |
| Maria Picilli (France)   |               |
| <b>Relation between evolution of epilepsy, respiratory functioning and risk of SUDEP, in a mouse model of Dravet Syndrome</b>                      | 14:30 - 14:30 |
| Diane Haddad (France)  |               |
| <b>Prediction of Cenobamate Efficacy in Patients with Drug-Resistant Epilepsy using Computational Electroencephalographic Biomarkers</b>           | 14:30 - 14:30 |
| <b>Quantifying Ictal Brain Connectivity Dynamics from SEEG for Epileptogenic Zone Identification in Refractory Epilepsy</b>                        | 14:30 - 14:30 |
| José Almeida (Portugal)  |               |
| <b>Automated detection of interictal epileptiform discharges in scalp EEG using convolutional autoencoders and artificial neural networks</b>      | 14:30 - 14:30 |
| Luis Carlos Martínez Ruiz (Mexico)   |               |
| <b>Resting-State EEG Functional Connectivity in Juvenile Myoclonic Epilepsy: Insights into Biomarkers and the Impact of Antiseizure Medication</b> | 14:30 - 14:30 |
| Oscar Antonio Ramos Quezada (Mexico)   |               |

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (S4)**

|   |               |
|---|---------------|
| <b>Automated Detection of High-Frequency Oscillations in EEG: Enhancing Epilepsy Diagnosis with Assyst</b>                                  | 14:30 - 14:30 |
| Armen Sargsyan (Armenia)  |               |
| <b>Single-cell RNA-seq analysis of the intra-amygdala kainic acid mouse model reveals cell-type specific mechanisms underlying epilepsy</b> | 14:30 - 14:30 |
| Javier Villegas Salmerón (Ireland)  |               |
| <b>Transcriptomic Insights into patients with Focal Cortical Dysplasia</b>  | 14:30 - 14:30 |

Shivani Sonawane (Czech Republic)

**EEG Spectral Analysis Differentiates Angelman Syndrome Genotypes**

14:30 - 14:30

Emiel Vereycken (Belgium)

**Effectiveness of the portable EEG monitoring device (Enobio 2.0) for the emergent management of epileptic seizures**

14:30 - 14:30

Estevo Santamarina (Spain)

**Asymmetry of epileptiform discharges amplitude in generalized epilepsy**

14:30 - 14:30

Joao Pizarro (United Kingdom)

**Seizure Duration and Time-Point Cutoffs for Statistically Defining a Prolonged Seizure: a Post-Hoc Analysis of the SCORE Video-EEG Database**

14:30 - 14:30

Cédric Laloyaux (Belgium)

**Neuroimaging Findings in Patients with Focal Cortical Dysplasia and Secondary Bilateral Synchrony on Interictal EEG**

14:30 - 14:30

Ana Carolina Piauilino Santos Falcão (Brazil)

**Are enlarged perivascular space a predictor of acute early post-traumatic seizures after traumatic brain injury?**

14:30 - 14:30

Gernot Hlauschek (Norway)

**Value of 7T MRI versus 3T MRI with post-processing in patients with non-lesional focal epilepsy (NLFE)**

14:30 - 14:30

O. Kukhlenko (Germany)

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (S5)**

**Therapeutic doses of cannabidiol alter body temperature in mice: Implications for anti-seizure mechanisms in Dravet syndrome**

14:30 - 14:30

Mona Heiland (Ireland)

**Hippocampal calponin-3 is Involved in the comorbidity of AD and epilepsy**

14:30 - 14:30

Wenqian Yang (China)

**Risk Factors Associated with Late-Onset Epilepsy in Persons with Dementia and Mild Cognitive Impairment**

14:30 - 14:30

Ifrah Zawar (United States)

**Improving understanding of Febrile Infection Related Epilepsy Syndrome (FIRES) in children and young people**

14:30 - 14:30

Dimitrios Champsas (United Kingdom)

**Seizure Outcome after Selective Amygdalohippocampectomy (sAHE) - 5 years after the introduction of Stereotactic Laser Thermoablation (sL-TA) in combination with Radiofrequency Thermoablation**

14:30 - 14:30

Friedhelm C Schmitt (Germany)

**Development of the Pretrained Resnet for surgical Outcome prediction using PET Hypometabolism and Excised Tissue (PROPHET): a deep learning tool to predict surgical outcome in patients undergoing epilepsy surgery**

14:30 - 14:30

Merran Courtney (Australia)

**Phenotype and genotype of pediatric epileptic patients with focal cortical dysplasia type II and brain somatic mutation in *MTOR* gene**

14:30 - 14:30

Silvia Liendo (Spain)

**Genetic causes of malformation of cortical development in children undergoing epilepsy surgery in Norway: Characterization of germline and somatic mutations** 14:30 - 14:30

Fridny Heimisdottir (Norway)

**Non-invasive Temporal Interference Stimulation of the Hippocampus Suppresses Epileptic Biomarkers in Patients with Epilepsy** 14:30 - 14:30

Adryelle do Nascimento Arantes (Czech Republic)

**The Role of Brain Biomarkers TGF and Proinflammatory Interleukins in the Clinical Course of Status Epilepticus in Pediatric Population** 14:30 - 14:30

Cornelia Calcii (Moldova)

### *Paediatric Epileptology*

15:15 - 16:15

Aud 1

#### **Platform Session - Paediatric Epileptology 1**

Kette Valente (Brazil)

Sam Gwer (Kenya)

**Introduction** 15:15 - 15:17

**Pediatric Epilepsy Surgery: Global Trends in Invasive Explorations** 15:17 - 15:25

Georgia Ramantani (Switzerland)

**Management of neonatal seizures, insights from EpiCARE Study Survey** 15:25 - 15:33

Laia Nou Fontanet (Spain)

**Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning up to 24 months of maintenance dosing in open-label extension studies** 15:33 - 15:41

Andreas Brunklaus (United Kingdom)

**High-Frequency Oscillations In Scalp EEG as Biomarkers of Epileptogenesis Following Neonatal Seizures** 15:41 - 15:49

Panagiota Karatza (Switzerland)

**Early electro-clinical features as predictors of Global Disease Outcome in patients with Epilepsy onset within the first year of life** 15:49 - 15:57

Marta Conti (Italy)

**Epileptic and developmental encephalopathy secondary to inversion-duplication of chromosome 15q: description of epilepsy characteristics and best therapeutic options** 15:57 - 16:05

Cristina Benítez Provedo (Spain)

**Conclusion and Q&A** 16:05 - 16:15

### *Drug Therapy*

15:15 - 16:15

Aud V (Pav 1)

#### **Platform Session - Drug Therapy**

Linda Dalic (Australia)

Elinor Ben-Menachem (Sweden)

**Introduction** 15:15 - 15:17

**Efficacy of azetukalner in Focal Onset Seizure (FOS) subtypes: Results from the double-blind, placebo controlled, phase 2b X-** 15:17 - 15:25

|  |               |
|--|---------------|
| <b>TOLE study</b><br>Emilio Perucca (Australia)  |               |
| <b>Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results from the open-label LILAC and LILAC-2 studies</b><br>Kasia Dobrzynska (Switzerland)                           | 15:25 - 15:33 |
| <b>Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework</b><br>Lyndsey Anderson (United States)  | 15:33 - 15:41 |
| <b>Cannabidiol inhibits neuroinflammation in kainic acid-induced epileptic mice by promoting TREM2 expression</b><br>Peng Zhang (China)  | 15:41 - 15:49 |
| <b>Cognitive effects of cenobamate as compared to perampanel: a cross-sectional multi-center study in 675 patients</b><br>Juri-Alexander Witt (Germany)  | 15:49 - 15:57 |
| <b>Vitamin D supplementation improves sleep quality in persons with drug-resistant epilepsy: Results from secondary analysis of a randomized-controlled trial</b><br>Soumya Sucharita Pattnaik (India) | 15:57 - 16:05 |
| <b>Conclusion and Q&amp;A</b>  | 16:05 - 16:15 |
| <i>Social Issues</i><br>15:15 - 16:15  | Aud VI+VII    |
| <b>Platform Session - Social Issues</b><br>Alison Kukla (United States)<br>Melody Asukile (Zambia)   |               |
| <b>Introduction</b>  | 15:15 - 15:17 |
| <b>Epilepsy and stigma: A multicenter study from Turkey</b><br>Aylin Reyhani (Turkey)  | 15:17 - 15:25 |
| <b>EpilepsyPOWER: a three-year project to favor workplace inclusion of people with epilepsy</b><br>Flavia Narducci (Italy)   | 15:25 - 15:33 |
| <b>Fill-in the dot: Advancing collaboration European patient communities for rare and complex epilepsies in the era of genetics etiologies</b><br>Isabella Brambilla (Italy)                           | 15:33 - 15:41 |
| <b>D'Unseen - Navigating what really matters: Insights from ethnographic research on Dravet Syndrome</b><br>Rima Nabbout (France)  | 15:41 - 15:49 |
| <b>Unpredictable Seizures and Disruptive Behavior in Developmental and Epileptic Encephalopathies: Interim Results of a Caregiver Survey</b><br>Andrea L. Wilkinson (United States)                    | 15:49 - 15:57 |
| <b>What Do We Know About the Challenges Faced by Women Professionals in the Epilepsy Field: A 2025 report</b><br>Ana Suller Marti (Canada)   | 15:57 - 16:05 |
| <b>Conclusion and Q&amp;A</b>  | 16:05 - 16:15 |

*Psychiatry*

15:15 - 16:15

AUD VIII

**Platform Session - Psychiatry**

W.Curt LaFrance Jr (United States)

Marco Mula (United Kingdom)

**Introduction**

15:15 - 15:17

**A data-driven MRI study of neurobehavioral comorbidities in temporal lobe epilepsy**

15:17 - 15:25

Fatemeh Fadaie (Canada)

**Neuropsychological, neurophysiological and imaging features of Juvenile Myoclonic Epilepsy: Insights into personality disorders**

15:25 - 15:33

Lucas Rainer (Austria)

**Revisiting Hughlings Jackson's dreamy state: dissociative symptoms in temporal lobe epilepsy**

15:33 - 15:41

Fiore D'Aprano (Australia)

**Towards culturally competent epilepsy care: An international comparison of self-stigma, psychological factors, and societal attitudes**

15:41 - 15:49

Izumi Kuramochi (Japan)

**Relationship between Stigma, Loneliness, Depression and Social Support and Suicidal Behavior in Patients with Epilepsy**

15:49 - 15:57

Kubra Yeni (Turkey)

**The efficacy of eye movement desensitisation and reprocessing therapy in reducing epilepsy-related anxiety**

15:57 - 16:05

Kamala Broekman-Labinac (Netherlands)

**Conclusion and Q&A**

16:05 - 16:15

*Clinical Neurophysiology*

15:15 - 18:15

AUD II

**EEG Technician Course**

Carla Bentes (Portugal)

Margitta Seeck (Switzerland)

Ana Rita Peralta (Portugal)

**Introduction**

15:15 - 15:35

Carla Bentes (Portugal)

Margitta Seeck (Switzerland)

**Minimum standards for inpatient long-term video-EEG**

15:35 - 15:57

William O. Tatum (United States)

**How to test a patient during seizures**

15:57 - 16:19

Sándor Beniczky (Denmark)

**Cortical mapping**

16:19 - 16:41

Valeria Mariani (Italy)

**Safety issues in the epilepsy monitoring unit**

16:41 - 17:03

Philippe Ryvlin (Switzerland)

**Conclusion and Q&A**

17:03 - 17:15

*ILAE Pharmacy*

16:00 - 17:00

**ILAE Pharmacy Section Session - Patient Education and the Pharmacist**

|  |               |
|--|---------------|
| <b>Introduction</b>  | 16:00 - 16:05 |
| <b>Patient Education and the Pharmacist</b><br>Janet Mifsud (Malta)  | 16:05 - 16:55 |
| <b>Conclusion and Q&amp;A</b>  | 16:55 - 17:00 |
| <i>ILAE Neurotechnology</i><br>16:00 - 17:00   |               |
| <b>ILAE Neurotechnology Section - Antiseizure therapy</b>  |               |
| <b>Introduction</b>  | 16:00 - 16:05 |
| <b>Novel modes of ASM delivery - the seizure patch</b><br>Stan Skafidas (Australia)  | 16:05 - 16:30 |
| <b>EEG-fMRI: Current state and ongoing progress</b><br>Serge Vuillemoz (Switzerland)   | 16:30 - 16:55 |
| <b>Conclusion and Q&amp;A</b>  | 16:55 - 17:00 |
| <i>Award Symposia</i><br>16:45 - 17:45   |               |
| <b>ILAE Fred Andermann Lectureship</b><br>J Helen Cross (United States)<br>Samuel Wiebe (Canada)   | Aud 1         |
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>The curse of propagation: can we know where epileptic activity comes from?</b><br>Jean Gotman (Canada)  | 16:50 - 17:35 |
| <b>Conclusion and Q&amp;A</b>  | 17:35 - 17:45 |
| <i>Epilepsy and Reproductive Health</i><br>16:45 - 18:15   |               |
| <b>What is the relationship between hormones, epilepsy and antiseizure medications?</b><br>Bruna Nucera (Italy)<br>Nathalie Jette (Canada)                 | AUD VIII      |
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>What is the relationship between reproductive hormones and epilepsy? Sex and hormonal influences on seizures and epilepsy.</b><br>Erik Taubøll (Norway) | 16:50 - 17:06 |
| <b>Hormonal therapy for epilepsy: progesterone and its derivatives for the treatment of catamenial epilepsy</b><br>Fedele Dono (Italy)                     | 17:06 - 17:22 |
| <b>Reproductive health in people with epilepsy: infertility and fertilization techniques</b><br>Barbara Mostacci (Italy)                                   | 17:22 - 17:38 |
| <b>What do we know about epilepsy care in transgender patients with epilepsy?</b><br>Emily L. Johnson (United States)                                      | 17:38 - 17:54 |
| <b>TBC</b><br>Emma Lovise Larsen (Norway)  | 17:54 - 18:10 |



|  |               |
|--|---------------|
| <b>Conclusion and Q&amp;A</b>  | 18:10 - 18:15 |
| <i>Nursing</i><br>16:45 - 18:15  | AUD III + IV  |
| <b>Managing the complexities of mood and behavior in epilepsy: Nursing perspectives</b><br>Patricia Shafer (United States)<br>Brialie Forster (Australia)                |               |
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>Lived experiences: Coping with epilepsy and emotional/behavioral challenges</b><br>Laura M'Rabet (Netherlands)  | 16:50 - 17:05 |
| <b>Role of stigma and biology on dual diagnosis of epilepsy and mood/behavior challenges</b><br>Gus Baker (United Kingdom)   | 17:05 - 17:20 |
| <b>Challenges and best practices for care of people with epilepsy and co-morbidities in outpatient and community settings</b><br>Symon Kariuki (Kenya)                   | 17:20 - 17:35 |
| <b>Managing epilepsy and co-morbidities on the EMU</b><br>Sandra Dewar (United States)   | 17:35 - 17:50 |
| <b>Management of Postictal and Behavioral Issues in the EMU</b><br>Carolyn McDonald (United States)  | 17:50 - 18:05 |
| <b>Conclusion and Q&amp;A</b>  | 18:05 - 18:15 |
| <i>Adult Epileptology</i><br>16:45 - 18:15   | Pavilion 3A   |
| <b>Blood biomarkers in epilepsy: state of the art and potential clinical application</b><br>Johan Zelano (Sweden)  |               |
| <b>Introduction</b>  | 16:45 - 16:49 |
| <b>Blood biomarkers in epilepsy: an overview and potential applications: prediction, diagnosis, and monitoring of treatment and drug safety</b><br>Johan Zelano (Sweden) | 16:49 - 17:03 |
| <b>Plasma Tau and cognitive function in late onset epilepsy</b><br>Rani Sarkis (United States)   | 17:03 - 17:17 |
| <b>Neurofilament and other blood biomarkers in status epilepticus</b><br>Stefano Meletti (Italy)   | 17:17 - 17:31 |
| <b>Blood tests to predict epilepsy after stroke and other brain lesions</b><br>Laura Abaira (Spain)  | 17:31 - 17:45 |
| <b>Conclusion and Q&amp;A</b>  | 17:45 - 18:15 |
| <i>IGAP Implementation</i><br>16:45 - 18:15  | Pavilion 3B   |
| <b>Transition from pediatric to adult care: Access to all?</b><br>Danielle Andrade (Canada)  |               |
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>The real world experience of moving from pediatric to adult care: patient and health care perceptions</b>   | 16:50 - 17:01 |

|   |               |             |
|---|---------------|-------------|
| Quratulain Zulfiqar-Ali (Canada)  |               |             |
| <b>How transition is done (or not done) in 58 countries: A global survey of the ILAE transition task force</b>              | 17:01 - 17:12 |             |
| Danielle Andrade (Canada)   |               |             |
| <b>What young patients think about transition of care before and after leaving the pediatric system?</b>                    | 17:12 - 17:23 |             |
| Jaime Carrizosa (Colombia)  |               |             |
| <b>Barriers for transition: differences between barriers perceived by low, medium and high income countries.</b>            | 17:23 - 17:34 |             |
| Jo Wilmshurst (South Africa)  |               |             |
| <b>How to empower patients and families to improve transition for all.</b>  | 17:34 - 17:45 |             |
| Rima Nabbout (France)   |               |             |
| <b>Conclusion and Q&amp;A</b>   | 17:45 - 18:15 |             |
| <i>Paediatric Epileptology</i>  |               |             |
| 16:45 - 18:15   |               | Pavilion 3C |
| <b>Developmental and epileptic encephalopathies: From bed to benchside and back</b>   |               |             |
| Kette Valente (Brazil)  |               |             |
| <b>Introduction</b>   | 16:45 - 16:50 |             |
| <b>The Roadmap to Make Developmental and Epileptic Encephalopathies Tractable and Attractive</b>                            | 16:50 - 17:06 |             |
| Majid Jafar (Iraq)  |               |             |
| <b>Best Practices in Developmental and Epileptic Encephalopathies Management: Must the Better be the Enemy of the Good?</b> | 17:06 - 17:22 |             |
| Scott Demarest (United States)  |               |             |
| <b>Minimum Viable Centers are Mandatory</b>   | 17:22 - 17:38 |             |
| Ángel Aledo-Serrano (Spain)   |               |             |
| <b>Delineating New Scales - Pros and Cons</b>   | 17:38 - 17:54 |             |
| Jenny Downs (Australia)   |               |             |
| <b>Validating and Adapting Existing Scales - Pros and Cons</b>  | 17:54 - 18:10 |             |
| Xavier Liogier d'Ardhuy (France)  |               |             |
| <b>Conclusion and Q&amp;A</b>   | 18:10 - 18:15 |             |

Monday, September 1, 2025

*Paediatric Epileptology*

08:00 - 09:30

Aud VI+VII

**Immunity, inflammation and epilepsy**

Jeffrey Britton (United States)

**Introduction**

08:00 - 08:05

**Update in treatment and surgery in Rasmussen syndrome**

08:05 - 08:25

Tiziana Granata (Italy)

**Clinical, EEG and imaging presentations of autoimmune encephalitides in adults**

08:25 - 08:45

Jeffrey Britton (United States)

**Autoimmune mechanisms in seizure disorders**

08:45 - 09:05

Christian Geis (Germany)

**FIRES in children: unraveling etiology, current treatment, and management strategies**

09:05 - 09:25

Sara Matricardi (Italy)

**Conclusion and Q&A**

09:25 - 09:30

*Epilepsy Surgery*

08:00 - 17:00

AUD II

**Full-Day Surgery Symposium - The technical landscape of epilepsy surgery**

Arthur Cukiert (Brazil)

Dario Englot (United States)

**Introduction**

08:00 - 08:10

**How I do it: LITT**

08:10 - 08:25

Robert Gross (United States)

**How I do it: SEEG-guided RF lesions**

08:25 - 08:40

Laura Tassi (Italy)

**How I use intraoperative imaging**

08:40 - 08:55

Karl Rössler (Austria)

**Is there a role for FUS in epilepsy?**

08:55 - 09:10

**Comparing the techniques for hemispherotomy**

09:10 - 09:20

Christian Dorfer (Austria)

**Radiofrequency procedures in epilepsy surgery**

09:20 - 09:30

P Sarat Chandra (India)

**Surgical commission activities 2021-2025**

09:30 - 09:40

Dario Englot (United States)

**Case Scenarios**

09:40 - 09:40

**Part I -**

09:40 - 09:45

**Moderators:**

Arthur Cukiert (Brazil)

Guy McKhann (United States)

**How we approach people with refractory epilepsy and: Perisylvian Polymicrogyria - Case I**

09:45 - 10:00

Didier Scavarda (France)

|  |               |
|--|---------------|
| <b>How we approach people with refractory epilepsy and: Perisylvian Polymicrogyria - Case II</b><br>Guoming Luan (China)                             | 10:00 - 10:15 |
| <b>How we approach people with refractory epilepsy and: Periventricular nodular heterotopia - Case I</b><br>Jim Baumgartner (United States)          | 10:15 - 10:30 |
| <b>How we approach people with refractory epilepsy and: Periventricular nodular heterotopia - Case II</b><br>Jorge Gonzalez-Martinez (United States) | 10:30 - 10:45 |
| <b>How we approach people with refractory epilepsy and: Mesial temporal sclerosis - Case I</b><br>Mario Alonso-Vanegas (Mexico)                      | 10:45 - 11:00 |
| <b>How we approach people with refractory epilepsy and: Mesial temporal sclerosis - Case II</b><br>Nitin Tandon (United States)                      | 11:00 - 11:15 |
| <b>How we approach people with refractory epilepsy and: Focal cortical dysplasia IIB - Case I</b><br>Michele Rizzi (Italy)                           | 11:15 - 11:30 |
| <b>How we approach people with refractory epilepsy and: Focal cortical dysplasia IIB - Case II</b><br>Faisal Al-Otaibi (Saudi Arabia)                | 11:30 - 11:45 |
| <b>30 Minute Coffee Break (11:45 - 12:15)</b>  | 11:45 - 12:15 |
| <b>How we approach people with refractory epilepsy and: LEATs - Case I</b><br>Bertil Rydenhag (Sweden)   | 12:15 - 12:30 |
| <b>How we approach people with refractory epilepsy and: LEATs - Case II</b><br>Sarah Ferrand-Sorbets (France)  | 12:30 - 12:45 |
| <b>Part II<br/>Moderators:</b><br>Arthur Cukiert (Brazil)<br>Kensuke Kawai (Japan)   | 12:45 - 13:00 |
| <b>How we approach people with refractory epilepsy and: Tuberous sclerosis - Case I</b><br>Howard Weiner (United States)                             | 13:00 - 13:15 |
| <b>How we approach people with refractory epilepsy and: Tuberous sclerosis - Case II</b><br>George Dorfmueller (France)                              | 13:15 - 13:30 |
| <b>How we approach people with refractory epilepsy and: Hypothalamic Hamartoma - Case I</b><br>Daniel J. Curry (United States)                       | 13:30 - 13:45 |
| <b>90 Minute Lunch Break (13:45 - 15:15)</b>   | 13:45 - 15:15 |
| <b>How we approach people with refractory epilepsy and: Hypothalamic Hamartoma - Case II</b><br>Hiroshi Shirozu (Japan)                              | 15:15 - 15:30 |
| <b>How we approach people with refractory epilepsy and: Insula epilepsy - Case I</b><br>Alexander Weil (Canada)                                      | 15:30 - 15:45 |
| <b>How we approach people with refractory epilepsy and: Insula</b>   | 15:45 - 15:55 |

|   |               |
|---|---------------|
| <b>epilepsy - Case II</b><br>Aria Fallah (United States)  |               |
| <b>How we approach people with refractory epilepsy and: Dominant TLE with normal MRI - Case I</b><br>Takamichi Yamamoto (Japan)   | 15:55 - 16:05 |
| <b>How we approach people with refractory epilepsy and: Dominant TLE with normal MRI - Case II</b><br>Guy McKhann (United States) | 16:05 - 16:15 |
| <b>30 Minute Coffee Break (16:15 - 16:45)</b>   | 16:15 - 16:45 |
| <b>Conclusion and Q&amp;A</b>   | 16:45 - 17:00 |
| <i>Drug Therapy</i><br>08:00 - 09:30  | AUD III + IV  |
| <b>The relevance of animals' models in epilepsy research and drug discovery</b>   |               |
| <b>Introduction</b>   | 08:00 - 08:05 |
| <b>The relevance of animal models of seizures or epilepsies in drug discovery</b><br>Aristea Galanopoulou (United States)         | 08:05 - 08:40 |
| <b>Mechanisms of focal seizure generation: preclinical studies based on human EEG findings</b><br>Marco de Curtis (Italy)         | 08:40 - 09:15 |
| <b>Conclusion and Q&amp;A</b>   | 09:15 - 09:30 |
| <i>Adult Epileptology</i><br>08:00 - 09:30  | Pavilion 3A   |
| <b>The enigmatic structure: Amygdala enlargement in epilepsy</b><br>Daichi Sone (Japan)   |               |
| <b>Introduction</b>   | 08:00 - 08:05 |
| <b>Multimodal neuroimaging findings in epilepsy with amygdala enlargement</b><br>Daichi Sone (Japan)                              | 08:05 - 08:25 |
| <b>Amygdala subnucleus: the role and volumetric analysis in epilepsy</b><br>Anna Elisabetta Vaudano (Italy)                       | 08:25 - 08:45 |
| <b>Neural plasticity and amygdala enlargement in epilepsy</b><br>Marian Galovic (Switzerland)                                     | 08:45 - 09:05 |
| <b>Amygdala enlargement and sudden unexpected death in epilepsy (SUDEP)</b><br>Beate Diehl (United Kingdom)                       | 09:05 - 09:25 |
| <b>Conclusion and Q&amp;A</b>   | 09:25 - 09:30 |
| <i>Epilepsy and Intellectual Disability</i><br>08:00 - 09:30  | Pavilion 3B   |
| <b>Epilepsy and neurodevelopmental comorbidities of SLC6A1-related disorders</b><br>Vincenzo Crunelli (United Kingdom)            |               |
| <b>Introduction</b>   | 08:00 - 08:10 |
| <b>Parenting siblings with SLC6A1 mutations and strategy of patient</b>   | 08:10 - 08:20 |

**organisations**

Lindsay Randall (United Kingdom)

**From genotype to protein structure to phenotype in SLC6A1-related disorders**

08:20 - 08:30

Dennis Lal (United States)

**Non-seizure characteristics of SLC6A1-related neurodevelopmental disorders**

08:30 - 08:40

Katrine Johannesen (Denmark)

**Imaging SLC6A1 function in health and disease using GABASnFR**

08:40 - 08:50

Chris Dulla (United States)

**Targeting astrocytic GAT1 dysfunction rescues absence seizures and their comorbidities**

08:50 - 09:00

Tatiana P Morais (United Kingdom)

**Conclusion and Q&A**

09:00 - 09:30

*IGAP Implementation*

08:00 - 09:30

Pavilion 3C

**From Awkward to Empowered: Having truly 'patient-centered' conversations in epilepsy care and research**

Milena Gandy (Australia)

**Introduction**

08:00 - 08:04

**Patient and Family Perspectives**

08:04 - 08:18

Torie Robinson (United Kingdom)

**Neurologist / Epileptologist Perspectives**

08:18 - 08:32

Heidi Munger Clary (United States)

**Psychologist Perspectives**

08:32 - 08:46

Milena Gandy (Australia)

**Young Epileptologist Perspectives**

08:46 - 09:00

Brad Kamitaki (United States)

Lucas Orellana (Argentina)

**Conclusion and Q&A**

09:00 - 09:30

*Clinical Neurophysiology*

08:00 - 09:30

Room 1.09

**Advanced EEG: source imaging - Part 1 (Theory)****Introduction**

08:00 - 08:05

**Basic biophysical principles of source estimation: from current dipoles to voltage maps**

08:05 - 08:45

Sándor Beniczky (Denmark)

**Clinical implementation of EEG source imaging: why, what and how?**

08:45 - 09:25

Stefan Rampp (Germany)

**Conclusion and Q&A**

09:25 - 09:30

*Social Issues*

09:45 - 11:45

Aud 1

**The Global Epilepsy Needs Study - Addressing the Unmet Needs of People with Epilepsy**

Graeme Shears (Australia)

Gus Baker (United Kingdom)

**Introduction**

09:45 - 09:50

**What are the priority unmet needs of people with epilepsy worldwide?**

09:50 - 10:15

Claire Nolan (United Kingdom)

Gus Baker (United Kingdom)

**What Matters Most to Me**

10:15 - 10:40

María Marta Bertone (Argentina)

**How can IGAP be leveraged to address the everyday unmet needs of people with epilepsy worldwide?**

10:40 - 11:05

**Multi-stakeholder Panel: Perspectives on addressing the unmet everyday needs of people with epilepsy**

11:05 - 11:40

Francesca Sofia (Italy)

J Helen Cross (United States)

Eugenia Roza (Romania)

Jessica Veach (United States)

**Conclusion and Q&A**

11:40 - 11:45

*Basic science*

09:45 - 11:45

Aud V (Pav 1)

**Primary brain tumors and epilepsy: advances on pathogenesis, interactions, and therapies**

Aristea Galanopoulou (United States)

Eleonora Aronica (Netherlands)

**Introduction**

09:45 - 09:50

**Living experience perspective**

09:50 - 10:10

Landis Wiedner (United States)

**Developmental glioneuronal tumors - molecular underpinnings of tumor- and epileptogenesis**

10:10 - 10:30

Silvia Cases-Cunillera (France)

**High grade gliomas - Molecular insights on natural history and epileptogenesis**

10:30 - 10:50

Jeffrey Noebels (United States)

**Tumor-brain interface in glioblastoma epileptogenesis**

10:50 - 11:10

Yudan Chi (China)

**Individualizing management of brain tumors and epilepsy**

11:10 - 11:30

Michael Weller (Switzerland)

**Conclusion and Q&A**

11:30 - 11:45

*ILAE YES*

12:00 - 13:00

**ILAE YES Career Development Session - How to become an editor? Internship of Epilepsia Open and Epileptic Disorders****Introduction**

12:00 - 12:05

**How to become an editor? Internship of Epilepsia Open and Epileptic Disorders**

12:05 - 12:50

Aristea Galanopoulou (United States)  
Sándor Beniczky (Denmark)

### Conclusion and Q&A

12:50 - 13:00

#### ILAE Nursing

12:00 - 13:00

#### ILAE Nursing Section Session

##### Introduction

12:00 - 12:05

##### Meeting the Care Needs of Families and Patients with a Developmental and Epileptic Encephalopathies Clinical Nurse Consultant

12:05 - 12:17

Brialie Forster (Australia)

##### Assessing Diagnostic Accuracy for Seizures and Seizure Mimics in an Unscheduled Care Setting

12:17 - 12:29

Claire Behan (Ireland)

##### Construction and Application of Medical Game-based Nursing Care Program for Medical Fear in School-age Children with Epilepsy

12:29 - 12:41

- Xinjuli, Cuijuanxin, Hewang, Shuangwang, Chenyangwu, Xiunanli, Yingyuhu, (China)

##### Advancements in Nursing Practice and Patient Support

12:41 - 12:53

Aubrey Chawira (United Kingdom)

##### Conclusion and Q&A

12:53 - 13:00

#### Basic science

12:15 - 13:45

Aud 1

#### The two sides of glia and epilepsy: the outside perspective

Andrey Mazarati (United States)

Matthew Walker (United Kingdom)

##### Introduction

12:15 - 12:20

##### Glial regulation of neuronal function on cellular level: physiology and biochemistry.

12:20 - 12:40

Milos Pekny (Sweden)

##### Glial regulation of neuronal function of a network level: glymphatic system in health and disease

12:40 - 13:00

Lucy Vivash (Australia)

##### Glial regulation of neuronal function on extracerebral level: the role of gut-brain axis

13:00 - 13:20

Andrey Mazarati (United States)

##### Therapy perspective: development of personalized glioblastoma vaccines

13:20 - 13:40

Adilia Hormigo (United States)

##### Conclusion and Q&A

13:40 - 13:45

#### Drug Therapy

12:15 - 13:45

Aud VI+VII

#### Can real word practice impact the knowledge about antiseizure medications?

Vicente Villanueva (Spain)

Jose Angel Aibar (Spain)

##### Introduction

12:15 - 12:20



|  |               |
|--|---------------|
| <b>Pros and cons of real world data and randomized control trials</b><br>Simona Lattanzi (Italy)   | 12:20 - 12:36 |
| <b>The informative role of pregnancy registries in clinical practice</b><br>Torbjorn Tomson (Sweden)   | 12:36 - 12:52 |
| <b>Real world data in Developmental and Epileptic Encephalopathies</b><br>Adam Strzelczyk (Germany)  | 12:52 - 13:08 |
| <b>Data generation in elderly and people with comorbidities</b><br>Vicente Villanueva (Spain)  | 13:08 - 13:24 |
| <b>Patients perspective of real-world data studies</b><br>Jose Angel Aibar (Spain)   | 13:24 - 13:40 |
| <b>Conclusion and Q&amp;A</b>  | 13:40 - 13:45 |
| <i>SUDEP &amp; Mortality</i><br>12:15 - 13:45  | AUD VIII      |
| <b>SUDEP again? Yes, it is not yet solved!</b><br>Lisa Bateman (United States)<br>Francisco Sales (Portugal)   |               |
| <b>Introduction</b>  | 12:15 - 12:20 |
| <b>Voices from Loss: Understanding the Needs of Those Bereaved by SUDEP</b><br>Gardiner Lapham (United States)   | 12:20 - 12:36 |
| <b>Rethinking SUDEP: Towards a Unified Classification</b><br>Roland Thijs (Netherlands)  | 12:36 - 12:52 |
| <b>Deciphering SUDEP Pathways: Unveiling Mechanisms of Death</b><br>Shobi Sivathamboo (Australia)  | 12:52 - 13:08 |
| <b>Bridging Bench to Bedside: Insights from Animal Models</b><br>Bin Gu (United States)  | 13:08 - 13:24 |
| <b>Targeting SUDEP Risk: Advances in Pharmacotherapy</b><br>Pasquale Striano (Italy)   | 13:24 - 13:40 |
| <b>Conclusion and Q&amp;A</b>  | 13:40 - 13:45 |
| <i>Status Epilepticus</i><br>12:15 - 13:45   | AUD III + IV  |
| <b>Understanding Status Epilepticus in Developmental and Epileptic Encephalopathies (DEEs): A comprehensive exploration.</b><br>Nicola Specchio (Italy)<br>Ingrid Scheffer (Australia) |               |
| <b>Introduction</b>  | 12:15 - 12:20 |
| <b>Living with the fear of Status Epilepticus: the patient perspective</b><br>Isabella Brambilla (Italy)   | 12:20 - 12:40 |
| <b>Exploration of the Clinical and Physiological Aspects of Status Epilepticus in DEEs.</b><br>Elaine C. Wirrell (United States)   | 12:40 - 13:00 |
| <b>The incidence and clinical manifestations of status epilepticus in channelopathies</b><br>Marina Trivisano (Italy)  | 13:00 - 13:20 |

**How significantly does status epilepticus contribute to neurological damage in patients with DEEs?** 13:20 - 13:40

J Helen Cross (United States)

**Conclusion and Q&A** 13:40 - 13:45

#### *In-Person Posters*

13:45 - 15:15

In-Person Poster Presentations

#### **In-Person Poster Presentations**

**Investigating Atipamezole and Atropine Effects on Absence Epilepsy: Insights from Genetic Absence Epilepsy Rat Models** 13:45 - 13:45

Ada Deniz Engin (Turkey)

**Bursting Neuronal Activity In Vivo: Insights from Pre-Surgical Microelectrode Recordings in Patients with Drug-Resistant Epilepsy** 13:45 - 13:45

Ágnes Kandrács (France)

**Proteomic and Metabolomic Signatures in Pharmacoresistant Mesial Temporal Lobe Epilepsy: Pathway Alterations and Novel Insights into Synaptic Dynamics** 13:45 - 13:45

**iEEG Epileptogenic Networks: Analyzing Preictal Inflow and Outflow Connectivity Dynamics** 13:45 - 13:45

Amirhossein Jahani (Canada)

**P2X7R Antagonists as Adjunctive Therapy for Drug-Resistant Epilepsy** 13:45 - 13:45

Ana Fernandez Martin (Ireland)

**Rescue of neuronal activity in iPSC-derived STXBP1 in vitro disease models using viral vectors** 13:45 - 13:45

Ana Rita Gomes (Belgium)

**The antioxidant and anti-inflammatory effects of *Maqui Berry* protects over seizure susceptibility and blood-brain barrier damage in aging rats** 13:45 - 13:45

Angelica Vega García (Mexico)

**Study of neuronal behaviors prior to seizures in human temporal lobe epilepsy** 13:45 - 13:45

Anthony Pinto (France)

**Automated Detection of High-Frequency Oscillations in EEG: Enhancing Epilepsy Diagnosis with Assyst** 13:45 - 13:45

Armen Sargsyan (Armenia)

**Impact of Intracerebroventricular Orexin-B on Absence Seizures in GAERS: Dose-Dependent Suppression of Spike-and-Wave Discharges** 13:45 - 13:45

Aylin Toplu (Turkey)

**IL-1 $\beta$  pathway dysregulation in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis: Epigenetic and Inflammatory Insights from a Microglia-Like Cell Model** 13:45 - 13:45

Bárbara Guerra Leal (Portugal)

**Behavior decoding delineates seizure microfeatures and associated sudden death risks in mice** 13:45 - 13:45

Bin Gu (United States)

**Focal cortical dysplasia type II in mice is associated with alterations in oligodendrocyte lineage cell differentiation and myelination** 13:45 - 13:45

Bohdana Hruskova (Czech Republic)

**BIPERIDEN MODULATES SEIZURE SUSCEPTIBILITY AND VASCULAR REMODELING AFTER TRAUMATIC BRAIN INJURY**

13:45 - 13:45

Viviam Sanabria (Brazil)

**Role of gut microbiota as biomarker and drug target in Angelman Syndrome (AS)**

13:45 - 13:45

Carmen De Caro (Italy)

**Power spectral electroencephalographic density analysis of the effects of fenfluramine in the intrahippocampal kainate mouse model of temporal lobe epilepsy**

13:45 - 13:45

Daniel Perez-Perez (Germany)

**Detection of Acute Preictal EEG Signatures Using Linear Analysis and Unsupervised Clustering**

13:45 - 13:45

Suman Das (India)

**Targeting the Sigma-1 receptor: effects of pharmacological modulation on kindling acquisition**

13:45 - 13:45

Eva-Lotta von Rüden (Germany)

**Dynamic reconfiguration of aperiodic brain activity supports cognitive functioning in epilepsy: A neural fingerprint identification**

13:45 - 13:45

Gian Marco Duma (Italy)

**Chasing metabolites from the gut to the brain: exploring metabolomic and lipidomic methods to study the gut-brain axis in epilepsy**

13:45 - 13:45

Greta Volpedo (Italy)

**A clinicopathological study of factors associated with microvacuolar changes in the cerebral white matter of patients with epilepsy**

13:45 - 13:45

Hajime Miyata (Japan)

**Characteristic Expression of Astrocyte in Hippocampal Sclerosis**

13:45 - 13:45

Masayuki Itoh (Japan)

**Single-cell RNA-seq analysis of the intra-amygdala kainic acid mouse model reveals cell-type specific mechanisms underlying epilepsy**

13:45 - 13:45

Javier Villegas Salmerón (Ireland)

**Epilepsy-Related Changes in GABA<sub>A</sub> Receptor Membrane Dynamics**

13:45 - 13:45

Joana Jesus-Ribeiro (Portugal)

**Cortical Interneuron Transplantation in a C1qa Knockout Mouse Model of Epilepsy**

13:45 - 13:45

Joseane Righes Marafiga (United States)

**The pro-epileptogenic astrocytes? Status epilepticus induces chromatin remodeling, homeostatic gene repression, and pro-inflammatory gene expression in astrocytes**

13:45 - 13:45

Alberto Javier Ramos (Argentina)

**Transcriptomic profiling of stereo-electroencephalography electrodes reveals insights into the local molecular microenvironment and epileptiform activity**

13:45 - 13:45

Julian Larkin (Ireland)

**Edaravone modulates morphological and structural alterations of microglia and astrocytes in the hippocampus after status epilepticus**

13:45 - 13:45

Kenia Pardo-Peña (Mexico)

**Modeling Developmental and Epileptic Encephalopathies in *Drosophila melanogaster* as a Rapid *In Vivo* Assay System for Antiseizure Medication Response and Neurodevelopment**

13:45 - 13:45

Konstantin L. Makridis (Germany)

**Predictive biomarkers of drug-resistant epilepsy in TSC patients- results of the EPIMARKER study**

13:45 - 13:45

Katarzyna Kotulska (Poland)

**TRPV5 exacerbates neuroinflammation induced by status epilepticus**

13:45 - 13:45

Won-Joo Kim (Korea, Republic of)

**Diverging seizure properties in rat models of SYNGAP1 and GRIN2B neurodevelopmental disorders**

13:45 - 13:45

Natalie Ling Sum Hung (United Kingdom)

**Edaravone improves short- and long-term memory retention and preserves hippocampal cells after a status epilepticus event**

13:45 - 13:45

Laura Medina-Ceja (Mexico)

**Hippocampal neuronal and glutamatergic dysfunction in the acute phase of pilocarpine-induced *status epilepticus***

13:45 - 13:45

Luciana Ramalho Pimentel-Silva (Brazil)

**Towards therapeutic innovation in temporal lobe epilepsy: focal adenosinergic modulation of hippocampal excitability**

13:45 - 13:45

Marijke Vergaelen (Belgium)

**Development and evaluation of new anticonvulsant agents: *In silico*, *in vitro* and *in vivo* study of GABA-AT inhibitors**

13:45 - 13:45

María Fernanda Camacho Merino (Mexico)

***Bmal1*-Targeting miRNAs: Implications for Circadian Regulation and Epileptogenesis**

13:45 - 13:45

Melissa Alves Braga Oliveira (Ireland)

**A Research about Orexin type-2 Receptor Protein Expression in Thalamus and Somatosensory Cortex Brain Regions in Rats with Absence Epilepsy**

13:45 - 13:45

Merve Çavuş (Turkey)

**Temporal dynamics of neural interactions and activations within arithmetic network during computation from intracranial EEG**

13:45 - 13:45

Michaela Kajsova (Czech Republic)

**Neuronal Subtypes and Their Contribution to Ictogenesis in a Mouse Model of Focal Cortical Dysplasia**

13:45 - 13:45

Michaela Kralikova (Czech Republic)

**Pathogenic Mechanisms of Anti-GABA<sub>A</sub>R Autoantibodies in Autoimmune Epilepsy: Impacts on Receptor Internalization and Neuronal Network Activity**

13:45 - 13:45

**Effect of 25 mg/kg Levetiracetam on Absence Seizure in Genetic Absence Epilepsy Rats**

13:45 - 13:45

Murat Aydın (Turkey)

**Orexin receptor type-2 distribution in prepubertal neurodevelopmental stages in Genetic Absence Epileptic Rats from Strasbourg**

13:45 - 13:45

Nursima Mutlu (Turkey)

**Evaluating the Impact of Early-Life Seizures on Alzheimer's Disease**

13:45 - 13:45

**Progression in a 5xFAD Mouse Model**

Nastaran Samimi (Australia)

**Patient derived polyclonal NMDAR antibodies cause epileptic seizures and sleep-wake disturbances in a passive transfer rat model**

13:45 - 13:45

Nihan Carcak (Turkey)

**Chemogenetic inhibition of ventrobasal thalamus exacerbates absence seizures in a genetic absence epilepsy rat model**

13:45 - 13:45

Nihan Carcak (Turkey)

**In vivo transcriptomics and proteomics analysis of SEEG electrodes from human epileptic brain**

13:45 - 13:45

Ninja Ehrnrooth (Finland)

**Dose-Dependent Effect of Atropine on Absence Seizures of Genetic Absence Epilepsy Rats**

13:45 - 13:45

Omer Saka (Turkey)

**Unraveling the Molecular Mechanisms of Post-Traumatic Epilepsy Using Multi-Omics Analysis**

13:45 - 13:45

Pablo Casillas-Espinosa (Australia)

**Development of a Novel Programmable Device for *In Vivo* Induction of Traumatic Brain Injury as a Model of Post-Traumatic Epilepsy**

13:45 - 13:45

Paola Viridiana Martínez Beltrán (Mexico)

**The Functional microRNA Landscape of Dravet Syndrome: Postnatal Development and Regulation of Voltage-Gated Sodium Channels**

13:45 - 13:45

Petra Bencurova (Ireland)

**Involvement of autophagy and mitophagy processes in epileptogenesis**

13:45 - 13:45

Cristiana Pareo (Italy)

**Natural history of seizures and seizure-associated spreading depolarizations in rodent models of epilepsy**

13:45 - 13:45

Rob Wykes (United Kingdom)

**Core clock machinery and circadian-driven neuroinflammatory markers profile in a mouse model of Dravet syndrome**

13:45 - 13:45

Radharani Benvenutti (Ireland)

**Gut-based interventions improve neurological consequences of acute brain injury in mice**

13:45 - 13:45

Rossella Di Sapia (Italy)

**The Effect of Cannabidiol Oil on Absence Epilepsy Seizures in a Genetic Rat Model**

13:45 - 13:45

Seyhmus Gavas (Turkey)

**Disease-modifying Effects of Vitamin B12 Treatment in a Rat Model of Genetic Absence Epilepsy**

13:45 - 13:45

Sila Aydın (Turkey)

**tRNA-derived RNA fragment changes in CSF and plasma in a rat model of temporal lobe epilepsy**

13:45 - 13:45

Marie Soukupova (Italy)

**Transcriptomic Insights into patients with Focal Cortical Dysplasia**

13:45 - 13:45

Shivani Sonawane (Czech Republic)

**Association between seizure reduction during ketogenic diet treatment of epilepsy and changes in circulatory metabolites and**

13:45 - 13:45

**gut microbiota composition**

Stefanie Prast-Nielsen (Sweden)

**Deciphering GDNF Signaling Pathways in Absence Seizures**

13:45 - 13:45

Sandra H. Vaz (Portugal)

**Assessing the heritability and cross-generational susceptibility to acquired epileptogenesis in a rat model of temporal-lobe epilepsy**

13:45 - 13:45

Tamara L Baker (Australia)

**Microglial Bmal1 downregulation leads to higher seizure susceptibility and altered hippocampal cytokine and chemokine signaling**

13:45 - 13:45

Tammy Strickland (Ireland)

**Biophysical characterization of pathological GAT1 (SLC6A1) A288V and S295L mutants associated with SLC6A1-neurodevelopmental disorders**

13:45 - 13:45

Tiziana Romanazzi (Italy)

**Sex-based differences of alpha-synuclein levels in a genetic animal model of absence epilepsy**

13:45 - 13:45

Talat Taygun Turan (Turkey)

**Epileptogenesis- and epilepsy-associated changes in Sigma-1 receptor expression in chronic mouse models of temporal lobe epilepsy**

13:45 - 13:45

Victoria Magna Stocker (Germany)

**Expression and quantification of STXBP1 splice variants in rodent and primate brain tissues**

13:45 - 13:45

Yana Van Den Herrewegen (Belgium)

**Thalamic orchestration of telencephalic oscillations and ictogenesis**

13:45 - 13:45

Ya-Chin Yang (Taiwan, China)

**Behavioral Effects of High Ambient Temperature in Genetic Absence Epilepsy Rats with or without Levetiracetam Treatment**

13:45 - 13:45

Elif Sude Barutcu (Turkey)

**A survey to assess the effects of extreme temperatures on children with epilepsy**

13:45 - 13:45

Ismail Hakki Akbeyaz (Turkey)

**Therapeutic doses of cannabidiol alter body temperature in mice: Implications for anti-seizure mechanisms in Dravet syndrome**

13:45 - 13:45

Mona Heiland (Ireland)

**Impact of high body temperature on characteristics of absence seizures and locomotor activity in a genetic rat model**

13:45 - 13:45

Berna Özen (Turkey)

**Improved Psychiatric and Cognitive Outcomes Following the Switch from Levetiracetam to Brivaracetam**

13:45 - 13:45

Khaled Bassam Zammar (Qatar)

**Brivaracetam Adjunctive Therapy in Paediatric and Adult Patients With Focal-Onset Seizures in Mid-European Countries: 12-Month, Real-World Outcomes from the BRIVA-REG Study**

13:45 - 13:45

Vasilios K. Kimiskidis (Greece)

**Cenobamate in Pediatric Patients with Drug Resistant Epilepsy: Real-World Data from a European Multicenter Retrospective Study**

13:45 - 13:45

Konstantin L. Makridis (Germany)

|  |               |
|--|---------------|
| <b>Vormatrigine Demonstrates Potent Antiseizure Activity Across Three Acute Models with Highest Predictive Validity for Focal Onset Seizures</b>                                   | 13:45 - 13:45 |
| Kris Kahlig (United States)  |               |
| <b>Different effects of structurally similar dibenzazepine family on neuronal networks; Microelectrode array study</b>   | 13:45 - 13:45 |
| Kunihiko Araki (Germany)   |               |
| <b>Clinical evaluation of reversible visual impairment induced by high-dose antiseizure medication</b>   | 13:45 - 13:45 |
| Shun Imamura (Japan)   |               |
| <b>Short-term efficacy of fenfluramine in Lennox-Gastaut syndrome and related intractable epilepsies</b>   | 13:45 - 13:45 |
| Yu Kobayashi (Japan)   |               |
| <b>Parry-Romberg Syndrome and Epilepsy: Unveiling the Crucial Role of Immunosuppression</b>  | 13:45 - 13:45 |
| Ana Lidia Neves (Portugal)   |               |
| <b>A Stratified Analysis of Efficacy and Safety of Fenfluramine in Patients With Dravet Syndrome</b>   | 13:45 - 13:45 |
| Lieven Lagae (Belgium)   |               |
| <b>Stiripentol as and adjunctive therapy for refractory epilepsy caused by SLC6A1-NDD</b>  | 13:45 - 13:45 |
| Lindsay Randall (United Kingdom)   |               |
| <b>Safety, efficacy and pharmacokinetic analysis of intravenous VAL-1221 treatment in Lafora disease</b>   | 13:45 - 13:45 |
| Lorenzo Muccioli (Italy)   |               |
| <b>Effectiveness of Cenobamate on seizures in focal epilepsy: a single center real-world observation</b>   | 13:45 - 13:45 |
| Luca Fernando (Italy)  |               |
| <b>Re-analysis of trials of brivaracetam using Epilepsy DOOR to holistically account for benefits and harms of anti-seizure medications for people with epilepsy</b>               | 13:45 - 13:45 |
| Lucy Vivash (Australia)  |               |
| <b>Preclinical Findings of Relutrigine, a Functional State Sodium Channel Modulator, Point to Anticonvulsant Potential in Dravet Syndrome</b>                                      | 13:45 - 13:45 |
| Lyndsey Anderson (United States)   |               |
| <b>Trends in Antiseizure Medication Prescriptions for Children in France (2014-2023): Shift to Newer Generations, Reduced Teratogenic Risks, and Growing Generic Prescriptions</b> | 13:45 - 13:45 |
| Mathieu Kuchenbuch (France)  |               |
| <b>Long-Term Efficacy, Safety, and Retention of Cannabidiol in Pediatric Drug-Resistant Epilepsy</b>   | 13:45 - 13:45 |
| Mathieu Kuchenbuch (France)  |               |
| <b>Cardiac Arrest Following Lacosamide Intoxication in an Adolescent</b>   | 13:45 - 13:45 |
| Gen Furukawa (Japan)   |               |
| <b>Drug repurposing based on integrated in silico and in vitro approach to find a therapy for KCNA2-related disorders</b>  | 13:45 - 13:45 |
| Manuel Marinelli (Italy)   |               |
| <b>Benefits beyond-seizures of optimized seizure control after cenobamate initiation</b>   | 13:45 - 13:45 |
| Manuel Toledo (Spain)  |               |

|  |               |
|--|---------------|
| <b>Pyridoxine and brivaracetam adherence in epilepsy</b><br>Marcus Ng (Canada)   | 13:45 - 13:45 |
| <b>Effectiveness, adherence and safety of cenobamate in patients diagnosed with focal refractory epilepsy: results of the CiFES study</b><br>María Rosario Ruiz Perelló (Spain)  | 13:45 - 13:45 |
| <b>Evaluating the Cognitive Effects of Cenobamate in Real-World Settings: A Literature-Based Analysis</b><br>Maria Brás Monteiro (Portugal)  | 13:45 - 13:45 |
| <b>Felbamate as a Therapeutic Alternative to Drug-Resistant Genetic Generalized Epilepsy: A Systemic Review and Meta-Analysis</b><br>Yitao Ma (United States)  | 13:45 - 13:45 |
| <b>Utility and safety of anti-seizure medication withdrawal during long term video-EEG</b><br>Melanie Sanchez (Argentina)  | 13:45 - 13:45 |
| <b>Corticosteroids in pharmacoresistant epilepsy: A single-center experience with oral methylprednisolone therapy</b><br>Maria Gonzalez-Ubilla (Chile)   | 13:45 - 13:45 |
| <b>Timing Matters: Evaluating the Start of Home Antiseizure Medications After Hospital Admission</b><br>Meriem Bensalem-Owen (United States)   | 13:45 - 13:45 |
| <b>POWER1 - A Double-Blind, Randomized, Multicenter Phase 2/3 Study Evaluating the Efficacy and Safety of Vismaglin in Adults with Focal Onset Seizures</b><br>Michael Steidle (United States)   | 13:45 - 13:45 |
| <b>AAV gene therapy at neonatal age in a mouse model of STXBP1 haploinsufficiency</b><br>Natalia Rodriguez (Belgium)   | 13:45 - 13:45 |
| <b>Cenobamate and QT Interval: A Prospective Study on Cardiac Safety</b><br>Nathalia Barros Ferreira (Portugal)  | 13:45 - 13:45 |
| <b>Impact of Cenobamate on Sodium Levels and Antiseizure Medication Adjustment: A 12-Month Prospective Study</b><br>Ana Brás (Portugal)  | 13:45 - 13:45 |
| <b>A single-centre, open-label pilot study to assess the efficacy and safety of Cannabidiol oral solution as an adjunctive treatment for pediatric subjects with Developmental and Epileptic Encephalopathy</b><br>Nicola Pietrafusa (Italy) | 13:45 - 13:45 |
| <b>Biomarker-Guided Efficacy of Fenofibrate Adjuvant Therapy In Persons With Active Epilepsy: The Randomized, Placebo-Controlled Trial</b><br>Nipaben Harjivanbhai Mendapara (India)   | 13:45 - 13:45 |
| <b>Efficacy of Stiripentol Beyond Generalized Tonic-Clonic Seizures: A Retrospective Analysis of Dravet and Non-Dravet Patient Records</b><br>Nuria Lamagrande Casanova (Spain)  | 13:45 - 13:45 |
| <b>MicroRNA-134 inhibition attenuates intrinsic and synaptic dysfunction underlying pathophysiologic properties of the hippocampus in mice with Drug-Resistant Epilepsy</b><br>Pablo Quintana-Sarti (Ireland)                                | 13:45 - 13:45 |
| <b>Role of metformin as an add-on therapy to standard anti-seizure medications in persons with active epilepsy in a randomized controlled trial</b>  | 13:45 - 13:45 |



Soumya Sucharita Pattnaik (India)

**What's on With Cenobamate? A Portuguese Series of Adult Patients with Generalized Epilepsies and Combined Focal and Generalized Epilepsies** 13:45 - 13:45

Paula Breia (Portugal)

**Hyponatremia in patients on therapy with Carbamazepine, Oxcarbazepine or Eslicarbazepine** 13:45 - 13:45

Petar Vasilev (Bulgaria)

**Global Seizure Rescue Medication Landscape: Availability & Reimbursement** 13:45 - 13:45

Patricia Shafer (United States)

**Efficacy and Tolerability of Cannabidiol in Adult Patients with Lennox-Gastaut Syndrome: A Retrospective Review** 13:45 - 13:45

Pyae Aung (United Kingdom)

**Sodium blockers challenge: the effects of Lacosamide versus Cenobamate on heart rate variability (HRV) in patients with drug-resistant epilepsy** 13:45 - 13:45

Paolo Quintieri (Italy)

**The Bright Side of Drug Load: How Third-Generation Antiseizure Medications Reshape Treatment Strategies in People with Epilepsy** 13:45 - 13:45

Roberta Roberti (Italy)

**Electrophysiologic, behavioral, molecular and pharmacologic characterisation of a prolonged febrile seizure paradigm in the *Scn1a*(+/-)<sup>tm1K<sup>ea</sup></sup> mouse model of Dravet syndrome** 13:45 - 13:45

Rafael Parcianello Cipolat (Ireland)

**Preliminary results of efficacy and adverse effects of fenfluramine treatment in a tertiary care hospital** 13:45 - 13:45

Petruta Renata Dodu (Spain)

**Impact of Fenfluramine on Convulsive Seizure Frequency in Dose-Capped Patients With Dravet Syndrome** 13:45 - 13:45

Rima Nabbout (France)

**Cenobamate early adoption in patients with drug-resistant epilepsy** 13:45 - 13:45

Rita Agosto (Italy)

**Long-term Evaluation of the Safety Profile of Highly Purified Cannabidiol: Analysis of Plasma Levels of THC** 13:45 - 13:45

Antonella Riva (Italy)

**Overcoming challenges in epilepsy clinical trials: the role of European Consortium for Epilepsy Trials** 13:45 - 13:45

Sébile Tchaicha (Spain)

**Evaluation of psychiatric and behavioral adverse effects in persons with epilepsy on levetiracetam monotherapy versus those on levetiracetam with concomitant clobazam therapy** 13:45 - 13:45

Sanskriti Rupayana (India)

**Seizure Reductions and Tolerability in Participants With Developmental and Epileptic Encephalopathies Newly Exposed to Bexicaserin: Interim Results From the Phase 1b/2a PACIFIC Open-Label Extension** 13:45 - 13:45

Shikha Polega (United States)

**Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants** 13:45 - 13:45

Steven Petrou (United States)

**Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy**

13:45 - 13:45

Steven Petrou (United States)

**Evaluation of cognitive impairment in persons with epilepsy (PWE) on levetiracetam (LEV) versus sodium valproate (SV) monotherapy**

13:45 - 13:45

Swathi Kona (India)

**Cenobamate in super-refractory post-stimulation epilepsy after acute viral encephalitis-case report and literature review**

13:45 - 13:45

Peiyu Wang (China)

**Freedon study: Real-life outcomes of cenobamate at different lines of treatment**

13:45 - 13:45

Vicente Villanueva (Spain)

**Efficacy and tolerability of Cenobamate: real-world experience from an Italian tertiary center**

13:45 - 13:45

Veronica Viola (Italy)

**Influence of titration schedules on safety and effectiveness of eslicarbazepine acetate in Asian patients with focal epilepsy**

13:45 - 13:45

Yaroslav Winter (Germany)

**Evaluation of the effectiveness and dosage-relationship of Pirampanel in patients aged  $\geq 12$  years with focal epilepsy: a real-world retrospective observational study from southern China**

13:45 - 13:45

Lu Yu (China)

**Cenobamate in Developmental and Epileptic Encephalopathies and Generalized Epilepsies: A Case Report on Epilepsy with Myoclonic-Atonic Seizures and Systematic Review of Current Evidence**

13:45 - 13:45

Zafeirenia Vlakou (Greece)

**Immune dysfunction, infection risk, and mortality with anti-seizure medications**

13:45 - 13:45

Angus D Macleod (United Kingdom)

**Epilepsy and educational outcomes: A Nationwide Cohort Study in Denmark**

13:45 - 13:45

Betina Trabjerg (Denmark)

**EPIPORT - Epidemiologic population-based study to assess prevalence of epilepsy in Portugal**

13:45 - 13:45

Carla Bentes (Portugal)

**The Value of Rare Disease Registries: insights from an ERN-EpiCARE Center**

13:45 - 13:45

Claudia Conti (Italy)

**Prevalence, comorbidities and mortality of epilepsy in an older Chinese population: The Shanghai Aging Study**

13:45 - 13:45

Ding Ding (China)

**Sociodemographic differences in stroke as an etiology of late onset epilepsy: Results from a multi-center cohort**

13:45 - 13:45

Emily L. Johnson (United States)

**Describing the Population of Patients with Prolonged Seizures: Results from a Global Real-World Point-In-Time Study**

13:45 - 13:45

Eugen Trinkla (Austria)

**Semiology and classification of functional seizures in two public**

13:45 - 13:45

**and private hospital settings**

Gabriele Vilyte (South Africa)

**Is school performance in children with epilepsy lower than in children with other chronic diseases?**

13:45 - 13:45

Jakob Christensen (Denmark)

**Well-being in School-Aged Children with Epilepsy by use of Antiseizure Medication**

13:45 - 13:45

Josefine Klakk (Denmark)

**Spectrum of the clinical, radiological and electrophysiological profile of Patient with Epilepsy in North East India**

13:45 - 13:45

Ashok Kumar (India)

**Predictors of first anti-seizure medication prescribed in a cohort of adults with newly diagnosed epilepsy**

13:45 - 13:45

Leah J. Blank (United States)

**Information Needs of People Considering Surgery for Epilepsy Management: A Scoping Review**

13:45 - 13:45

Maren Kimura (Canada)

**Optimal Approach to Standardized Documentation in Epilepsy Clinics: A Scoping Review**

13:45 - 13:45

Shahab Marzoughi (Canada)

**Prescription patterns of anti-seizure medications for generalized and focal epilepsy in Morocco: A cross-sectional study**

13:45 - 13:45

Yassine El Adraoui (Morocco)

**Clinical Characteristics and Antiseizure Medication Use in People with Newly Diagnosed Epilepsy Worldwide: Does Money Decide?**

13:45 - 13:45

Zhibin Chen (Australia)

**Comparison of the course of epilepsy and the provision of medical care to pediatric patients with epilepsy during the COVID-19 pandemic and during the full-scale war in Ukraine**

13:45 - 13:45

Andriy Dubenko (Ukraine)

**Predictors of outcome in patients with super refractory status epilepticus- a multicentre study**

13:45 - 13:45

Ashalatha Radhakrishnan (India)

**Prevalence of Post-Traumatic Epilepsy and Risk Factors Associated with its Development**

13:45 - 13:45

Leonor Francisco (Portugal)

**Understanding and Optimising the Seizure Emergency Pathway**

13:45 - 13:45

Noem Sain (Belgium)

**Lennox-Gastaut Syndrome. Situation analysis and Family Journey**

13:45 - 13:45

Elvira Vacas Montero (Ireland)

**Improving Lives in Dravet Syndrome: Overcoming Challenges in the Family Journey**

13:45 - 13:45

Victor Soto Insuga (Spain)

**The "Chapeau de Gendarme (CG) sign: clinical characteristics and medical and surgical outcome**

13:45 - 13:45

Yarinet Acosta-Santos (Mexico)

**Morphometric analysis of oligodendroglial cells in the cerebral white matter of surgical specimens from epilepsy patients**

13:45 - 13:45

Ai Sugie (Japan)

|  |               |
|--|---------------|
| <b>Long-term outcome of temporal lobe epilepsy surgery in adults - a single centre experience</b><br>Adam Kalina (Czech Republic)  | 13:45 - 13:45 |
| <b>A Tale of Two Modalities: Discordance between MRI and Histopathology in Epilepsy</b><br>Julie L Youssefi (United States)  | 13:45 - 13:45 |
| <b>Developing a New Endovascular Electroencephalogram Electrode (EP-01) for a Minimally Invasive Method for Seizure Localization: Clinical Feasibility Trial</b><br>Kota Araki (Japan) | 13:45 - 13:45 |
| <b>Voxel-based morphometric analysis for perforating artery injury and postoperative motor deficit in peri-rolandic epilepsy</b><br>Atsuhiko Ninomiya (Japan)                          | 13:45 - 13:45 |
| <b>Late onset epilepsy and epilepsy surgery: clinical characteristics and long-term postsurgical outcomes</b><br>Attila Racz (Germany)   | 13:45 - 13:45 |
| <b>Psychosocial impact of paediatric epilepsy surgery - a single centre experience</b><br>Anne Vagner Jakobsen (Denmark)   | 13:45 - 13:45 |
| <b>Electrical, metabolic, and genetic cascades in focal epilepsy</b><br>Aaron E.L. Warren (United States)  | 13:45 - 13:45 |
| <b>Trends in epilepsy surgery - single center experience over 20 years</b><br>Christian Vollmar (Germany)  | 13:45 - 13:45 |
| <b>[<sup>18</sup>F]FDG PET/MRI in the presurgical evaluation of Pediatric Focal Epilepsies</b><br>Concetta Luisi (Italy)   | 13:45 - 13:45 |
| <b>De novo psychogenic non-epileptic seizures in neurosurgical patients with drug-resistant epilepsy</b><br>Diana Komarova (Russian Federation)  | 13:45 - 13:45 |
| <b>Prognostic factors and outcomes in patients with TLE</b><br>Igor Trifonov (Russian Federation)  | 13:45 - 13:45 |
| <b>Non-Invasive Diagnostic Modalities for MRI Negative Epilepsy: A Meta Analysis</b><br>Shady Georgy (Egypt)   | 13:45 - 13:45 |
| <b>Non-Thalamic Deep Brain Stimulation as a Promising Avenue in Epilepsy Treatment. systematic review and meta-analysis</b><br>Shady Georgy (Egypt)                                    | 13:45 - 13:45 |
| <b>Hippocampal transections for mesial temporal lobe epilepsy</b><br>Elina Kudieva (Russian Federation)  | 13:45 - 13:45 |
| <b>The Role of Very Early Postoperative Seizures in Long-Term Outcomes of Temporal Lobectomy</b><br>Elma Paredes Aragon (Mexico)   | 13:45 - 13:45 |
| <b>Challenges to Epilepsy Surgery Referral in Mexico: Results From a Nationwide Survey of Primary Care Physicians and Specialists</b><br>Elma Paredes Aragon (Mexico)                  | 13:45 - 13:45 |
| <b>Selective Amygdalohippocampectomy (sAHE) by Stereotactic Laser Thermoablation (sL-TA) results in Functional Shift in Non-Verbal Memory</b><br>Friedhelm C Schmitt (Germany)         | 13:45 - 13:45 |

|   |               |
|---|---------------|
| <b>Temporal lobe epilepsy (TLE) patients perform better in vestibulo-dependent spatial orientation after Stereotactic Laser-Thermoablation (sL-TA) compared to "classical" resective surgery and to non-operated patients</b> | 13:45 - 13:45 |
| Friedhelm C Schmitt (Germany)   |               |
| <b>Seizure Outcome after Selective Amygdalohippocampectomy (sAHE) - 5 years after the introduction of Stereotactic Laser Thermoablation (sL-TA) in combination with Radiofrequency Thermoablation</b>                         | 13:45 - 13:45 |
| Friedhelm C Schmitt (Germany)   |               |
| <b>Collapse of interictal suppressive networks precedes seizure spread</b>  | 13:45 - 13:45 |
| Ghassan Makhoul (United States)   |               |
| <b>Clinical Utilization of High Frequency Oscillation Rate and Network Properties in Epilepsy Surgical Decisions: A Pilot Study</b>   | 13:45 - 13:45 |
| Dorsa Ghaffari (United States)  |               |
| <b>Do classical semiology predict the post-operative outcome in patients with temporal lobe epilepsy?</b>   | 13:45 - 13:45 |
| Bharanidharan Gurumurthy (India)  |               |
| <b>Neuropathological spectrum of drug-resistant TLE in Russian Federation</b>   | 13:45 - 13:45 |
| Alla Guekht (Russian Federation)  |               |
| <b>The Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19): Introducing the Russian Version</b>   | 13:45 - 13:45 |
| Alla Guekht (Russian Federation)  |               |
| <b>Awake craniotomy in pediatric epilepsy patients - feasibility and safety</b>   | 13:45 - 13:45 |
| Lisa Evju Hauger (Norway)   |               |
| <b>Disparities in pediatric epilepsy surgery evaluation for Hispanic/Latino patients in the United States</b>   | 13:45 - 13:45 |
| Ann Hyslop (United States)  |               |
| <b>Translating abnormality metrics to clinical end-users with Z-Brains</b>  | 13:45 - 13:45 |
| Ian Goodall-Halliwell (Canada)  |               |
| <b>Clinicopathological characteristics of patients surgically treated for focal epilepsy and generalized seizures</b>   | 13:45 - 13:45 |
| Keiya Iijima (Japan)  |               |
| <b>The Correlation of Cortical Mapping and Neuroimaging Findings in Patients with Epilepsy</b>  | 13:45 - 13:45 |
| Irem Gul Orhan (Turkey)   |               |
| <b>Neuropsychiatric approach in forced normalization after epilepsy surgery: a case report</b>  | 13:45 - 13:45 |
| Isabella Schnorr Paglioli (Brazil)  |               |
| <b>Emergent lesionectomy with Electrocorticography in focal status epilepticus: a case report</b>   | 13:45 - 13:45 |
| Isha Snehal (United States)   |               |
| <b>Optimizing Seizure Outcomes with Vagus Nerve Stimulation: Analysis of Programming Parameters in Drug-Refractory Epilepsy</b>   | 13:45 - 13:45 |
| Jasmine Parihar (India)   |               |
| <b>Intraoperative ultrasonography (IoUS) in surgical epilepsy management; an underutilized cost effective tool</b>  | 13:45 - 13:45 |
| Javeria Nooraine (India)  |               |

|   |               |
|---|---------------|
| <b>Is Presurgical Evaluation Really Necessary in Cavernomas with Refractory Epilepsy?</b>   | 13:45 - 13:45 |
| Jonathan U. Macias-Lopez (Mexico)   |               |
| <b>Predictive Value of Preoperative FDG-PET Hypometabolism for Postoperative Visual Field Defects in Temporal Lobe Epilepsy Surgery</b>   | 13:45 - 13:45 |
| Takuichiro Higashi (Japan)  |               |
| <b>Surgical outcome in patients with mesial temporal lobe epilepsy and unilateral hippocampal sclerosis associated with calcified neurocysticercosis</b>  | 13:45 - 13:45 |
| Karen Karol Vásquez Quicaño (Brazil)  |               |
| <b>Intermediate 3 Hz frequency stimulations to induce seizures during S-EEG in 3 pediatric patients</b>   | 13:45 - 13:45 |
| Karine Ostrowsky-Coste (France)   |               |
| <b>Stereotactic radiofrequency ablation for treatment of epilepsy</b>   | 13:45 - 13:45 |
| Kostiantyn Kostiuk (Ukraine)  |               |
| <b>Seizure outcomes in patients with burned-out hippocampus syndrome operated after noninvasive investigation</b>   | 13:45 - 13:45 |
| Leslie Ortega Hernandez (Brazil)  |               |
| <b>Usefulness of stereoelectroencephalography (SEEG) in patients with bitemporal epilepsy diagnosed by videoelectroencephalogram (VEEG): Experience in high complexity center in Argentina</b>                              | 13:45 - 13:45 |
| Juan Jerez Torres (Argentina)   |               |
| <b>Outcomes of Epilepsy Surgery over 25 Years: Insights from an Epilepsy Referral Center</b>  | 13:45 - 13:45 |
| Marco Almeida (Portugal)  |               |
| <b>Social cognition in temporal lobe epilepsy patients: long-term outcome after epilepsy surgery</b>  | 13:45 - 13:45 |
| Martin Šimčík (Czech Republic)  |               |
| <b>Development of the Pretrained Resnet for surgical Outcome prediction using PET Hypometabolism and Excised Tissue (PROPHET): a deep learning tool to predict surgical outcome in patients undergoing epilepsy surgery</b> | 13:45 - 13:45 |
| Merran Courtney (Australia)   |               |
| <b>The vigilance state influences the connectivity of the epileptogenic networks: an SEEG study allowing to better define the epileptogenic zone</b>  | 13:45 - 13:45 |
| Niccolo' Biagioli (Italy)   |               |
| <b>iEEG connectivity analysis to localize epileptogenic tissue: Systematic review and Meta-analysis from ILAE Epilepsy Surgery Networks Taskforce</b>   | 13:45 - 13:45 |
| Nishant Sinha (United States)   |               |
| <b>Mastery in Anatomy: The Most Effective Surgical Technique in Patients with Recurrent Temporal Lobe Epilepsy</b>  | 13:45 - 13:45 |
| Ömer Mert Özpişkin (Turkey)   |               |
| <b>Epilepsy surgery improves postoperative developmental rates in children with drug-resistant</b>  | 13:45 - 13:45 |
| Tomonori Ono (Japan)  |               |
| <b>Can task-induced gamma band activity streamline language mapping during stereo-EEG?</b>  | 13:45 - 13:45 |
| Parveen Sagar (Australia)   |               |

|  |               |
|--|---------------|
| <b>Analyzing Barriers and Challenges in a Specialized Epilepsy Surgery Center in Chile: Working Towards Access and Opportunity</b><br>Romina Moya (Chile)  | 13:45 - 13:45 |
| <b>Mesial Temporal Lobe Epilepsy: A Ten-Year Retrospective Cohort Study of Challenges, Treatment and Outcomes</b><br>Rui Lopes (Portugal)  | 13:45 - 13:45 |
| <b>Late seizure recurrence after anterior temporal lobectomy in patients with mesial temporal sclerosis: The prevalence and its prognostic factors</b><br>Sang-Ahm Lee (Korea, Republic of)                              | 13:45 - 13:45 |
| <b>Surgical outcomes in 90 patients with drug-resistant temporal lobe epilepsy secondary to cerebral cavernous malformations: case series</b><br>Santiago Gómez-Castro (Mexico)  | 13:45 - 13:45 |
| <b>Impact of initial seizure semiology on seizure free outcome after temporal lobe epilepsy surgery</b><br>Selina Trapp (Germany)  | 13:45 - 13:45 |
| <b>SEEG-guided thermocoagulation outcome in drug-resistant focal epilepsy</b><br>Suphasit Seoratanaphunt (Thailand)  | 13:45 - 13:45 |
| <b>Results of screening diagnosis of cognitive impairment in neurosurgical patients with drug-resistant epilepsy using MoCA</b><br>Dmitrii Shalygin (Russian Federation)   | 13:45 - 13:45 |
| <b>Phenotype and genotype of pediatric epileptic patients with focal cortical dysplasia type II and brain somatic mutation in <i>MTOR</i> gene</b><br>Silvia Liendo (Spain)  | 13:45 - 13:45 |
| <b>Spectral factorization-based identification of seizure onset zone by the Janashia-Lagvilava algorithm - preliminary data</b><br>Sofia Kasradze (Georgia)  | 13:45 - 13:45 |
| <b>How epilepsy aetiology, focal cortical dysplasia <i>versus</i> a low-grade epilepsy associated tumour, impacts neurocognitive and behavioral outcome after early frontal lobe surgery</b><br>Sophie Blanchet (France) | 13:45 - 13:45 |
| <b>Successful resective surgery for posttraumatic extratemporal epilepsy: Six case reports</b><br>Battugs Sormoo (Mongolia)  | 13:45 - 13:45 |
| <b>Epileptic Seizures in Brain Metastases: Treatment Approaches and Disease Progression</b><br>Ghena Tabateb (Germany)   | 13:45 - 13:45 |
| <b>Relevance of the Wada Test in the Pre-Surgical Evaluation of Patients with Temporal Epilepsy Due to Hippocampal Sclerosis</b><br>Francisca Costa (Portugal)   | 13:45 - 13:45 |
| <b>Stereo-EEG guided radiofrequency thermocoagulation for drug-resistant focal epilepsy: Initial results from 15 patients at a tertiary Epilepsy Center</b><br>Valeri Borger (Germany)                                   | 13:45 - 13:45 |
| <b>Epicenters of postoperative atrophies are associated with seizure outcomes in temporal lobe epilepsy</b><br>Zhoukang Wu (China)   | 13:45 - 13:45 |
| <b>From Subdural Grids to Stereo-EEG. A single centre experience of the first 100 Stereo EEG cases</b>   | 13:45 - 13:45 |

Yazeed Aldhfyhan (Saudi Arabia)

**Passive Auditory fMRI for Language Lateralization in Presurgical Evaluation of Temporal Lobe Epilepsy: A Retrospective Single-Center Study**

13:45 - 13:45

Yoji Okahara (Japan)

**Cortical hypometabolism partially reflects local atrophy in temporal lobe epilepsy and enhanced performance in predicting postoperative seizure outcomes with multiparametric MRI radiomics**

13:45 - 13:45

Yuming Li (China)

**Non-invasive Temporal Interference Stimulation of the Hippocampus Suppresses Epileptic Biomarkers in Patients with Epilepsy**

13:45 - 13:45

Adryelle do Nascimento Arantes (Czech Republic)

**Long-Term Outcomes in Patients with Generalized Tonic-Clonic Seizures Following VNS Therapy: Interim CORE-VNS 36 Months**

13:45 - 13:45

Ana Suller Marti (Canada)

**Patient-controlled neurostimulation using the epicranial EASEE device**

13:45 - 13:45

Andreas Schulze-Bonhage (Germany)

**Neurophysiological markers and predictors of effectiveness of vagus nerve stimulation (VNS) in people with drug resistant epilepsy**

13:45 - 13:45

Anna Scarabello (Italy)

**Feasibility of transcranial direct current stimulation for focal onset seizures using a novel device at Ghent University Hospital in Belgium**

13:45 - 13:45

Chloé Algoet (Belgium)

**Is VNS-CBD combined therapy effective in DEEs? Results from a small group of pediatric patients**

13:45 - 13:45

Daniele Gironi (Italy)

**Clinical Profile of Pediatric and Adult Patients Treated with Deep Brain Stimulation for Drug-Resistant Epilepsy in a Public Referral Hospital in Mexico City**

13:45 - 13:45

Lily Rivera-Figueroa (Mexico)

**Unlocking the gut-brain connection: The role of vagus nerve stimulation in epilepsy and depression**

13:45 - 13:45

Greetje Huisman (Netherlands)

**Vagus Nerve Stimulation (VNS): Who Benefits most in the Long Run?**

13:45 - 13:45

Jitupam Baishya (India)

**The Journey of Medicaid Enrollees with Drug-Resistant Epilepsy (DRE) to Neuromodulation**

13:45 - 13:45

Kathryn Evans (United States)

**First-in-Human Study for Drug-Resistant Epilepsy: Usability and Efficacy of a Novel Optoelectronic Vagus Nerve Stimulation Device Over a 3-Month Follow-Up**

13:45 - 13:45

Kristl Vonck (Belgium)

**Effect of intensity and frequency on vagus nerve stimulation-induced pupil dilation response in refractory epilepsy**

13:45 - 13:45

Ana Marta Dias (Belgium)



|   |               |
|---|---------------|
| <b>Modulation of Global Neuronal Network Metrics in Patients Undergoing Focal Neurostimulation Therapy by a Novel Implantable Device</b>  | 13:45 - 13:45 |
| Matthias Dümpelmann (Germany)   |               |
| <b>Sleep Quality in Children with Confirmed Genetic Epilepsy undergoing Vagus Nerve Stimulation</b>   | 13:45 - 13:45 |
| Maxine Dibue (United Kingdom)   |               |
| <b>Long-Term Adjunctive VNS Therapy Use in Patients with Genetic Epilepsy - 24 M CORE-VNS Outcomes</b>  | 13:45 - 13:45 |
| Nicola Specchio (Italy)   |               |
| <b>Comparison of Healthcare Services and Cost Over the 2-Year Periods Immediately Before and After Vagus Nerve Stimulation (VNS) Implantation Among Medicaid Enrollees with Drug-Resistant Epilepsy {DRE}</b> | 13:45 - 13:45 |
| Paul Trueman, PhD (United Kingdom)  |               |
| <b>Forecasting epileptic seizures by monitoring the cortical response to electrical stimulation</b>   | 13:45 - 13:45 |
| Petroula Laiou (United Kingdom)   |               |
| <b>CORE-VNS: Dosing and Titration of VNS Therapy in Contemporary Clinical Practice</b>  | 13:45 - 13:45 |
| Ryan Verner (United States)   |               |
| <b>Autonomic nervous system modulation and cardiac instability evaluation in drug-resistant epilepsy patients submitted to VNS Therapy™</b>   | 13:45 - 13:45 |
| Sofia Gago (Portugal)   |               |
| <b>Vagus Nerve Stimulator in Genetic Epilepsies: A Single Center Experience</b>   | 13:45 - 13:45 |
| Syndi Seinfeld (United States)  |               |
| <b>Treating ADHD in Children with Epilepsy: Proceed with Caution or with Confidence?</b>  | 13:45 - 13:45 |
| Katarina Alajbegovic (United States)  |               |
| <b>Analysis of patients with epilepsy in the pediatric neurology outpatient clinic of an university hospital in Brazil</b>  | 13:45 - 13:45 |
| Aline Chacon Pereira (Brazil)   |               |
| <b>Evaluation of Ketogenic Diet Compliance and Quality of Life in Pediatric Patients with Pharmacoresistant Epilepsy and Their Caregivers</b>   | 13:45 - 13:45 |
| Ana Damaschin (Romania)   |               |
| <b>Predictors of neuropsychiatric disease and seizure outcome in tuberous sclerosis</b>   | 13:45 - 13:45 |
| Dr Ankith Bhasi (India)   |               |
| <b>Lennox-Gastaut Syndrome criteria: linking clinical and electroencephalographic features</b>  | 13:45 - 13:45 |
| Anna Falco (Italy)  |               |
| <b>Thalamic volumetrics in paediatric focal epilepsy demonstrate more significant abnormalities in patients undergoing SEEG compared to those undergoing resective surgery</b>                                | 13:45 - 13:45 |
| Aswin Chari (United Kingdom)  |               |
| <b>Review of stiripentol use in Lennox-Gastaut Syndrome</b>   | 13:45 - 13:45 |
| Benjamin Serraz (France)  |               |
| <b>The Role of Genetic Awareness in Shortening the Diagnostic</b>   | 13:45 - 13:45 |

**Timeline for Dravet Syndrome**

Bárbara Filho Caetano da Silva (Brazil)

**Infantile spasms, does genetics matter?**

13:45 - 13:45

Beatriz Henriques (Portugal)

**Mitochondrial Epilepsy: Gene-Specific Epileptic Phenotypes and Functional Associations**

13:45 - 13:45

Burcu Karakayalı (Turkey)

**Assessing Sleep Problems for Patients with Drug-resistant Epilepsy Using Caregiver-reported Survey Data**

13:45 - 13:45

Hyewon Woo (Korea, Republic of)

**Functional seizures in children: clinical characteristics and comorbidities. Experience of 2 third level centers**

13:45 - 13:45

Carla Chicco (Argentina)

**Long-term follow-up of patients with Dravet syndrome by a multidisciplinary team**

13:45 - 13:45

Carolina Munoz-Castro (Chile)

**Optimizing Management of Convulsive Status Epilepticus in Pediatric Intensive Care: A Retrospective Study**

13:45 - 13:45

Chahnez Triki (Tunisia)

**The autonomic nervous system imbalance in infant epileptic spasm syndorme**

13:45 - 13:45

Chahnez Triki (Tunisia)

**Infantile spasms: diagnosis, treatment and neurogenetics**

13:45 - 13:45

Chrysanthi Tsimakidi (Greece)

**The VISTA Study: Videos of Infantile Spasms for Triaging and Assessment**

13:45 - 13:45

Christine Shrock (United States)

**Compound heterozygous mutations in the SSPOP gene lead to epilepsy and developmental disorders**

13:45 - 13:45

Fan Zhang (China)

**Sleep quality in children with epilepsy - a cross-sectional study**

13:45 - 13:45

Constança Soares dos Santos (Portugal)

**Ketogenic Diet for refractory childhood epilepsy: 25 year experience of a tertiary center in Portugal**

13:45 - 13:45

Constança Soares dos Santos (Portugal)

**'Age does not matter'. Efficacy of cenobamate in the treatment of children with drug-resistant epilepsy**

13:45 - 13:45

Cristina Benítez Provedo (Spain)

**Seizure-like events in a pediatric emergency department: eight years after**

13:45 - 13:45

Cristina Pereira (Portugal)

**Imaging markers associated with cognitive and motor functions in Sturge-Weber syndrome: A multivariate analysis in a prospective study**

13:45 - 13:45

Csaba Juhasz (United States)

**Clinical and Therapeutic Profile of Adolescents with Epilepsy: A Retrospective Analysis**

13:45 - 13:45

Catarina Luis (Portugal)

**Real-World use of stiripentol in the USA**

13:45 - 13:45

Delphine Vandame (France)  
Benjamin Serraz (France)

**Design of a Phase 3 Multicenter Study (BeeLine) to Assess the Efficacy and Safety of Radiprodil, a Targeted Investigational Therapy for Patients With GRIN-related Neurodevelopmental Disorder**

13:45 - 13:45

Danielle Veenma (Netherlands)

**Preemptive Intervention Strategies for TSC-Associated Epilepsy in Pediatric Patients: A Retrospective Cohort Study**

13:45 - 13:45

Daad Alsowat (Saudi Arabia)

**Management of Epilepsy in IQSEC2-Related Encephalopathy: A Case Study**

13:45 - 13:45

Danilo Nonkulovski (North Macedonia)

**SEMA6B -related progressive myoclonic epilepsy with response to the use of zonisamide: a case report**

13:45 - 13:45

Büşra Filiz Genç (Turkey)

**Results of DIAVEY, the European post-marketing safety study on stiripentol use**

13:45 - 13:45

Elena Cardenal-Muñoz (France)  
Benjamin Serraz (France)

**The neuroprotective role of interleukin-1 receptor antagonist in damaged brain of children with status epilepticus**

13:45 - 13:45

Elena Capestru (Moldova)

**Efficacy of Cannabidiol in Epilepsy Associated with Germline mTOR Pathway Mutations**

13:45 - 13:45

Elena Gonzalez-Alguacil (Spain)

**Epileptic and neurodevelopmental outcome at 24 months after neonatal hypoxic-ischemic encephalopathy**

13:45 - 13:45

Elisa Rolleri (Italy)

**Hippocampal proteome of Cdkl5-deficient mice features disturbed metabolic processes: Insights into molecular mechanisms and potential therapeutic targets for CDKL5 deficiency disorder**

13:45 - 13:45

Erva Ghani (Ireland)

**Pediatric Epilepsy Surgery: Global Trends of Referral and Presurgical Evaluation**

13:45 - 13:45

Georgia Ramantani (Switzerland)

**Clinical clusters of pediatric patients with status epilepticus: insights from a large single-center case-cohort study in Switzerland**

13:45 - 13:45

Georgia Ramantani (Switzerland)

**Substantial improvements in overall seizure burden and seizure free days in patients with Dravet syndrome treated with zorevunersen: Results from Phase 1/2a and open-label extension studies**

13:45 - 13:45

J Helen Cross (United States)

**Brain Volumetric Differences in Pediatric Epilepsy: A Focus on Genetic Etiology**

13:45 - 13:45

Yun Jung Hur (Korea, Republic of)

**Uncovering Emergency Care Processes for Paediatric Neurologic Patients using Process Mining**

13:45 - 13:45

Henna Aro (Finland)

**Qualitative Research to Assess Caregivers' Perspectives on Signs**

13:45 - 13:45

**and Symptoms of GRIN-related Neurodevelopmental Disorder**

Hillary Savoie (United States)

**Effectiveness of benzodiazepines based on seizure frequency in benign convulsions with mild gastroenteritis**

13:45 - 13:45

Young Ok Kim (Korea, Republic of)

**Focal Seizures and Transverse Myelitis: A Pediatric Case Report of Anti-MOG Antibody-Associated Encephalomyelitis**

13:45 - 13:45

Isabella Orlando (Italy)

**Long-term Follow-up of Effects on Insulin Resistance in Children with Epilepsy Before and After Ketogenic diet: Prevalence and Risk factors**

13:45 - 13:45

Yun Jin Lee (Korea, Republic of)

**EMPEROR Phase 3 study design: Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome**

13:45 - 13:45

Joseph Sullivan (United States)

**Selective potentiation of NaV1.1 channels by small molecule XPC-A in Dravet mice suppresses spontaneous seizures, prevents SUDEP, and increases Long Term Potentiation**

13:45 - 13:45

J P Johnson (Canada)

**Long-term prognosis of patients with childhood absence epilepsy**

13:45 - 13:45

Jun Tohyama (Japan)

**Alternating hemiplegia of childhood mimicking epilepsy**

13:45 - 13:45

Justyna Paprocka (Poland)

**The natural history of convulsive seizures in SCN1A Dravet Syndrome**

13:45 - 13:45

Philippa Karoly (Australia)

**Empowering Patients in Research: First insights from 323 Participants in the European SYNGAP1 Registry**

13:45 - 13:45

Kirsten Eschermann (Austria)

**Novel NSD1 variant associated with Sotos syndrome in a patient with Klinefelter syndrome (48, XXYY): case report**

13:45 - 13:45

Nadezhda Kvaskova (Russian Federation)

**Results of a Long-Term Post-Marketing Surveillance Study on Stiripentol Safety and Efficacy in a Large Cohort of Japanese Patients**

13:45 - 13:45

Laurent Chancharme (France)

**Algorithms and Red Flags for Early Diagnosis of Epileptic Encephalopathy Based on the 2022 Epilepsy Syndrome Classification: Enhancing Early Selection and Improving Care in Kazakhstan**

13:45 - 13:45

Leila Dairbayeva (Kazakhstan)

**Can Animation Series combat Epilepsy stigma and misconceptions among University students?**

13:45 - 13:45

A Alghazali (Egypt)

**Knowledge and Attitudes Toward Epilepsy Among University Students in Arab Countries: A Cross-Sectional Study**

13:45 - 13:45

A Alghazali (Egypt)

**Sports and epilepsy. Training for safe and inclusive practice**

13:45 - 13:45

Francisco Astorino (Argentina)

**The impact of living with epilepsy in Rio de Janeiro Metropolitan**

13:45 - 13:45

**Region/RJ, Brazil: an approach through oral history interviews**

Maria Emilia Cosenza Andraus (Brazil)

**Sociological study of the uses of adapted physical activity in the care of severe epilepsy at the Institut La Teppe**

13:45 - 13:45

Axel Lion (France)

**Epilepsy and Education - Children with Epilepsy Out of School Survey in Zambia**

13:45 - 13:45

Betty Barbara Nsachilwa (Zambia)

**Access to epilepsy surgery for refractory epilepsy in the city of Cali: Experiences of caregivers of children and adolescents**

13:45 - 13:45

Christian Andres Rojas Ceron (Colombia)

**Knowledge, perceptions, and attitudes of cali public school teachers in preschool, elementary, and high school regarding epilepsy in 2023**

13:45 - 13:45

Christian Andres Rojas Ceron (Colombia)

**Effects of drug-resistant epilepsy on patients' social adjustment and quality of life**

13:45 - 13:45

Diana Komarova (Russian Federation)

**Exploring the Power of Virtual Reality: A Captivating Approach to Cognitive Therapy for Students**

13:45 - 13:45

Dzenana Rustempasic (Bosnia and Herzegovina)

**Knowledge, attitudes and misconceptions about epilepsy among students in North Macedonia**

13:45 - 13:45

Danijela Vojtikiv Samoilovska (North Macedonia)

**Barriers and Consequences of Prior Authorization for Neurologic Medications: A Scoping Review**

13:45 - 13:45

Evelyn Gotlieb (United States)

**Exploring transition in the ERN EpiCARE: Insights from a survey analysis**

13:45 - 13:45

Francesca Ferraro (Italy)

**Epilepsy Camp**

13:45 - 13:45

Monika Kukuruzović (Croatia)

**A cost analysis of ketogenic diet therapy in epilepsy management**

13:45 - 13:45

Neha Kaul (Australia)

**Mobile Application for Epilepsy Management: A Multidisciplinary Approach**

13:45 - 13:45

Nathalia Barros Ferreira (Portugal)

**Costs of epilepsy in Mexico**

13:45 - 13:45

Norma Patricia Hernández-Vanegas (Mexico)

**Uncertainty and Quality of Life in Adult Epilepsy Patients**

13:45 - 13:45

Patricia Braga (Uruguay)

**IBE Workshop: Women and Epilepsy in Latin America: exploring the unmet needs of women with epilepsy**

13:45 - 13:45

María Marta Bertone (Argentina)

**Affordable alternatives after Levetiracetam daily defined dose revision: Emerging anti-seizure drugs for epilepsy**

13:45 - 13:45

Rahul Ranjan (India)

**Impact of Ramadan fasting on patients with epilepsy: Clinical and Laboratory Study**

13:45 - 13:45

Sally Shaaban (Egypt)

**Physical Activity Levels of Adults with Epilepsy in the United Kingdom** 13:45 - 13:45

Sarah Collard (United Kingdom)

**Effect of Ramadan lifestyle changes among Patients with Epilepsy in the Eastern Mediterranean Region: A Multicenter Study** 13:45 - 13:45

Abas Tilako (Iraq)

**Navigating Regulatory Challenges for Cannabinoid Use in Refractory Epilepsy: A Case Study from Japan's Unique Legal Framework** 13:45 - 13:45

Ichiro Takumi (Japan)

**Do Socioeconomic Disparities Impact Care Among Women with Epilepsy?** 13:45 - 13:45

Ana Victoria Mourao de Meira (Canada)

**A Multimodal Pre-trained Deep Neural Network for Automated Seizure Detection and Localization** 13:45 - 13:45

Nan Lin (China)

**Interictal functional connectivity at high frequencies discriminates epileptogenic tissue and predicts outcome in drug-resistant epilepsy** 13:45 - 13:45

Christos Stergiadis (United Kingdom)

#### ILAE Nursing

13:45 - 14:45

#### ILAE Nursing Section Session

**Introduction** 13:45 - 13:50

**'Less is More'; Addressing Polypharmacy to Enhance Epilepsy Care** 13:50 - 14:05

Anne Gough (Ireland)

**The Relationship Between Stigma and Psychological Distress Among Chinese Youth with Epilepsy: The Mediating Role of Physical Activity** 14:05 - 14:20

Shuagzi Li (China)

**The CPFT Epilepsy Emergency Clinic** 14:20 - 14:35

Aubrey Chawira (United Kingdom)

**Conclusion and Q&A** 14:35 - 14:45

#### In-Person Posters

14:00 - 14:30

In-Person Poster Presentations

#### ILAE YES Poster Tour (M2)

**EMPEROR Phase 3 study design: Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome** 14:00 - 14:00

Joseph Sullivan (United States)

**Selective potentiation of NaV1.1 channels by small molecule XPC-A in Dravet mice suppresses spontaneous seizures, prevents SUDEP, and increases Long Term Potentiation** 14:00 - 14:00

J P Johnson (Canada)

**Seizure freedom in children and youth with epilepsy in The Norwegian Mother, Father and Child Cohort Study** 14:00 - 14:00

Truls Vikin (Norway)

|   |               |
|---|---------------|
| <b>The VISTA Study: Videos of Infantile Spasms for Triaging and Assessment</b>  | 14:00 - 14:00 |
| Christine Shrock (United States)  |               |
| <b>BDNF Rescue of Absence Seizures and Associated Comorbidities: Uncovering Shared Mechanisms</b>   | 14:00 - 14:00 |
| Tatiana P Morais (United Kingdom)   |               |
| <b>The Role of Genetic Awareness in Shortening the Diagnostic Timeline for Dravet Syndrome</b>  | 14:00 - 14:00 |
| Bárbara Filho Caetano da Silva (Brazil)   |               |
| <b>Differential tractography of language circuitry : A promising tool for pediatric epilepsy surgery</b>  | 14:00 - 14:00 |
| Vera Dinkelacker (France)   |               |
| <b>Electro-clinical and neuroimaging influence on postsurgical cognitive outcome 12 months after epilepsy surgery in children with drug-resistant epilepsy and hypothalamic hamartoma</b> | 14:00 - 14:00 |
| Maria Violeta Fariña Jara (Spain)   |               |
| <b>“Don't Stimulate, I'm Sleeping!” Sleep-Disordered Breathing in Children with Vagus Nerve Stimulation</b>   | 14:00 - 14:00 |
| Nuria Lamagrande Casanova (Spain)   |               |

*In-Person Posters*

14:00 - 14:30

In-Person Poster Presentations

**ILAE YES Poster Tour (M1)**

|   |               |
|---|---------------|
| <b>Functional Connectivity Abnormalities Mediating Verbal Fluency Deficits in Newly Diagnosed Epilepsy Patients</b>   | 14:00 - 14:00 |
| Fangzhou Liu (China)  |               |
| <b>Connectivity-based activity flow mapping predicts altered declarative memory states in drug-resistant epilepsy</b>   | 14:00 - 14:00 |
| Donna Gift Cabalo (Canada)  |               |
| <b>Distributed hypometabolism associated with focal cortical dysplasia reflects structural connectivity of the human brain</b>                                    | 14:00 - 14:00 |
| Emma Macdonald-Laurs (Australia)  |               |
| <b>Metabolic machine learning for temporal lobe epilepsy lateralisation</b>   | 14:00 - 14:00 |
| Jack Lam (Canada)   |               |
| <b>Neurodegenerative Biomarkers and Cognitive Impairment in Temporal Lobe Epilepsy: Insights from PET Imaging</b>   | 14:00 - 14:00 |
| Xianghe Liu (China)   |               |
| <b>Lesion phenotypes in different focal cortical dysplasia subtypes and locations</b>   | 14:00 - 14:00 |
| Ella Sahlas (Canada)  |               |
| <b>Structural and functional connectome-based predictive models (CPM) for temporal lobe epilepsy with hippocampal sclerosis (TLE-HS)</b>                          | 14:00 - 14:00 |
| Alejandro Hugo Nasimbera (Argentina)  |               |
| <b>Patient-controlled neurostimulation using the epicranial EASEE device</b>  | 14:00 - 14:00 |
| Andreas Schulze-Bonhage (Germany)   |               |
| <b>First-in-Human Study for Drug-Resistant Epilepsy: Usability and Efficacy of a Novel Optoelectronic Vagus Nerve Stimulation Device Over a 3-Month Follow-Up</b> | 14:00 - 14:00 |

Kristl Vonck (Belgium)

**Forecasting epileptic seizures by monitoring the cortical response to electrical stimulation**

14:00 - 14:00

Petroula Laiou (United Kingdom)

*ILAE Neurotechnology*

14:15 - 15:15

**ILAE Neurotechnology Section - EEG Debate: Is the routine EEG losing relevance?**

**Introduction**

14:15 - 14:20

**Yes - we should move away from routine EEG in favor of other technologies**

14:20 - 14:45

Lizbeth Hernandez Ronquillo (Canada)

**No - Routine EEG will evolve and become better and better**

14:45 - 15:10

Sushma Goyal (United Kingdom)

**Conclusion and Q&A**

15:10 - 15:15

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (M3)**

**Clinical clusters of pediatric patients with status epilepticus: insights from a large single-center case-cohort study in Switzerland**

14:30 - 14:30

Georgia Ramantani (Switzerland)

**Edaravone modulates morphological and structural alterations of microglia and astrocytes in the hippocampus after status epilepticus**

14:30 - 14:30

Kenia Pardo-Peña (Mexico)

**Quantifying focal hypermetabolism in suspected non-convulsive status epilepticus: a single-centre cohort study**

14:30 - 14:30

Jeroen Gijls (Belgium)

**Status epilepticus epidemiology in France: insight from the French National Health Data System**

14:30 - 14:30

Quentin Calonge (France)

**Epilepsy stands nearby: a pilot CT perfusion study on post-stroke non convulsive status epilepticus**

14:30 - 14:30

Elena Merli (Italy)

**Peri-Ictal MRI Abnormalities and Frequency of Epileptiform Discharges in Status Epilepticus: A Prospective Study**

14:30 - 14:30

Pilar Bosque Varela (Austria)

**Status Epilepticus in Adults with Developmental and Epileptic Encephalopathies**

14:30 - 14:30

Stefano Meletti (Italy)

**Accelerated brain atrophy during new-onset refractory status epilepticus**

14:30 - 14:30

Cyril F. Simmen (Switzerland)

**Neuroprognostication after cardiac arrest: the added value of a standardized EEG reactivity protocol**

14:30 - 14:30

Alice Ballabeni (Italy)



*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (M4)**

|   |               |
|---|---------------|
| <b>Clinico-electrographic spectrum and predictors of outcome in resistant idiopathic generalized epilepsy- is it a zebra among the horses?</b>                                | 14:30 - 14:30 |
| Nandana Jayakumari (India)  |               |
| <b>Seizure Type at Relapse as a Predictor of Recurrence Etiology in New Onset Epilepsy</b>  | 14:30 - 14:30 |
| Cecilia Catania (Switzerland)   |               |
| <b>Highlights and differences between frontal lobe seizures and functional seizures from video-electroencephalography (VEEG) findings</b>                                     | 14:30 - 14:30 |
| Anilu Daza Restrepo (Argentina)   |               |
| <b>Lipid profile and apolipoprotein E isoforms in adults with drug-resistant epilepsy treated with modified Atkins diet</b>   | 14:30 - 14:30 |
| Daniela Dias Dinis (Portugal)   |               |
| <b>Impact of modified Atkins diet on serum concentrations of antiseizure medications in an adult population- a balancing act</b>  | 14:30 - 14:30 |
| Maria Carlos Pereira (Portugal)   |               |
| <b>Prevalence of poststroke epilepsy (pse) after 5 years and SeLECT score results</b>   | 14:30 - 14:30 |
| Maria Jose Hernandez Garcia (Spain)   |               |
| <b>Clinical characteristics of Juvenil Myoclonic Epilepsy and risk factors for drug-resistant patients</b>  | 14:30 - 14:30 |
| Maria Inês Silva (Portugal)   |               |
| <b>Low-level mosaic SCN2A variant causing early infantile onset epileptic encephalopathy: characterization using heterologous cell expression and neurons from iPSC cells</b> | 14:30 - 14:30 |
| Antonella Riva (Italy)  |               |
| <b>The GABAA-Receptor Portal: A Comprehensive Online Database and Webtool of Homologous Variants</b>  | 14:30 - 14:30 |
| Rebekka Staal Dahl (Denmark)  |               |
| <b>An integrated single-cell and spatial transcriptomic atlas of human hippocampus in patients with temporal lobe epilepsy and hippocampal sclerosis</b>                      | 14:30 - 14:30 |
| Jiayao Li (China)   |               |

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (M5)**

|  |               |
|--|---------------|
| <b>From complexity to bedside, navigating towards the limits of language processing in the brain: mapping postictal aphasia in stereo-electroencephalography</b> | 14:30 - 14:30 |
| Ionut-Flavius Bratu (France)   |               |
| <b>Relationship Between Memory and Altered Consciousness in Focal Seizures: Aura as a Key Marker</b>   | 14:30 - 14:30 |
| Nuria Campora (Argentina)  |               |
| <b>"Wipe your face, smile, laugh...strike a pose!" Lesser known semiologies of the Cingulate network. A Stereo-EEG and signal processing study</b>               | 14:30 - 14:30 |
| Sasha Dionisio (Saudi Arabia)  |               |

|   |               |
|---|---------------|
| <b>Performance of independent component analysis in localizing seizure onset from scalp-EEG</b>   | 14:30 - 14:30 |
| Jeanne Benoit (France)  |               |
| <b>Subclinical epileptiform activity indicates E-I imbalance in association with accelerated aging</b>  | 14:30 - 14:30 |
| Andras Horvath (Hungary)  |               |
| <b>Region-specific postictal spreading depolarization observed in LFP microwire recordings from depth-electrode-implanted epilepsy patients</b>       | 14:30 - 14:30 |
| Adrián Gutiérrez Gómez (Germany)  |               |
| <b>The Contribution of Functional Connectivity and Graph Theory to Anatomico-Electro-Clinical correlation during Pre-Surgical Evaluation</b>          | 14:30 - 14:30 |
| Lorenzo Ferri (Italy)   |               |
| <b>Neural correlate of the sense of agency in voluntary movement in patients with non-epileptic motor functional paroxysmal events</b>                | 14:30 - 14:30 |
| Mayra Jazmín Morales Armenta (Mexico)   |               |
| <b>SLC6A1-related neurodevelopmental disorders: prevalence and characterization of non-epileptic findings</b>   | 14:30 - 14:30 |
| Sebastian Silva Soto (Denmark)  |               |
| <b>Genetic Susceptibility for Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorders in Children Born to Women with Epilepsy</b>      | 14:30 - 14:30 |
| Mathilde Kinge-Rasmussen (Norway)   |               |
| <i>Adult Epileptology</i>   |               |
| 15:15 - 16:15   | Aud 1         |
| <b>Platform Session - Adult Epileptology 1</b>  |               |
| Edward Bertram (United States)  |               |
| Silvia Abente (Paraguay)  |               |
| <b>Introduction</b>   | 15:15 - 15:17 |
| <b>Seizures and epilepsy in untreated cerebral cavernous malformations: a prospective, population-based cohort study</b>                              | 15:17 - 15:25 |
| Abel Clemens Adriaan Sandmann (Netherlands)   |               |
| <b>Subclinical EEG patterns in patients with focal epilepsy predict the presence of clinically manifest seizures</b>                                  | 15:25 - 15:33 |
| Lorena Franco-Rubio (Spain)   |               |
| <b>Leveraging MEG and sEEG to investigate the association between Small Sharp Spikes and epileptiform discharges in mesial temporal lobe epilepsy</b> | 15:33 - 15:41 |
| Stephen P. Klaus (Ireland)  |               |
| <b>The effects of music intervention on inhibitory control in frontal lobe epilepsy patients</b>  | 15:41 - 15:49 |
| Yongjun Li (China)  |               |
| <b>Effect of Advancing Reperfusion Therapies in Post-Stroke Epilepsy</b>  | 15:49 - 15:57 |
| Catarina Guedes Vaz (Portugal)  |               |
| <b>Mapping the structural connectome of temporal lobe epilepsy variants to improve surgical outcomes</b>  | 15:57 - 16:05 |
| Sami Obaid (Canada)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:05 - 16:15 |

*Clinical Neurophysiology*

15:15 - 16:15

Aud V (Pav 1)

**Platform Session - Clinical Neurophysiology**

Noel Isaias Plascencia (Mexico)

**Introduction**

15:15 - 15:17

**The role of EEG in the prediction of post-stroke seizures**

15:17 - 15:27

Kai Michael Schubert (Switzerland)

**EEG features in vanishing white matter disease: a retrospective analysis of pediatric and adult patients**

15:27 - 15:37

Giulia Battaglia (Italy)

**Quantitative EEG and risk of post-stroke epilepsy following acute ischemic stroke**

15:37 - 15:47

Sara Parreira (Portugal)

**An Investigation into the Accuracy of Interictal Epileptiform Discharges Source Localization Using Different Electrode Densities**

15:47 - 15:57

Daniel Mansilla (Canada)

**Interictal scalp electroencephalography characteristics may predict cognitive decline in people with late-onset epilepsy**

15:57 - 16:07

Lu Lu (China)

**Conclusion and Q&A**

16:07 - 16:15

*Paediatric Epileptology*

15:15 - 18:45

Aud VI+VII

**DEE vs progressive deterioration - have we made progress?****Introductory talk**

15:15 - 15:25

Christophe Lucas (France)

**DEE with SWAS**

15:25 - 15:25

**Definitions revisited - The range of presentation.**

15:25 - 15:55

Roberto Horacio Caraballo (Argentina)

**Management options & outcomes - have we moved forward?**

15:55 - 16:25

Bernardo Dalla Bernardina (Italy)

**PME**

16:25 - 16:25

**The Progressive Myoclonus Epilepsies- whats in a definition?**

16:25 - 16:55

Samuel Berkovic (Australia)

**Gene therapy for the treatment of the PMEs: from preclinical studies to clinical trials.**

16:55 - 17:25

José M. Serratosa (Spain)

**Rasmussens**

17:25 - 17:25

**50 years of Rasmussens - where are we now?**

17:25 - 17:55

J Helen Cross (United States)

**New horizons in the research and treatment of Rasmussen's Syndrome.**

17:55 - 18:25

Coral Stredny (United States)

**Conclusion and Q&A**

18:25 - 18:45

*IGAP Implementation*

15:15 - 16:15

AUD VIII

**Platform Session - IGAP Implementation**

Jaideep Kapur (United States)

Action Amos (Malawi)

**Introduction**

15:15 - 15:17

**A systematic review and meta-synthesis of integrated care for mental health in epilepsy by The ILAE Integrated Mental Health Care Pathways Task Force**

15:17 - 15:25

Milena Gandy (Australia)

**Adolescence and epilepsy. Educational and promotional program through strategies towards reducing the stigma among teenagers at school**

15:25 - 15:33

Francisco Astorino (Argentina)

**Epilepsy12 - Measuring and improving care for children with epilepsies, England/Wales, 2009-2023**

15:33 - 15:41

Colin Dunkley (United Kingdom)

**Implementation of the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders (IGAP) in Kazakhstan: Progress, Challenges, and Future Directions**

15:41 - 15:49

Leila Dairbayeva (Kazakhstan)

**Conclusion and Q&A**

15:57 - 16:05

*Neuropsychology*

15:15 - 16:15

AUD III + IV

**Platform Session - Neuropsychology**

Sarah Wilson (Australia)

Colin Reilly (Sweden)

**Introduction**

15:15 - 15:17

**Cognition is supported by the dynamic redistribution of information through brain networks: evidence from the Australian Epilepsy Project**

15:17 - 15:25

Chris Tailby (Australia)

**The impact of clinical and demographic factors on trajectories of decline in verbal memory in people with focal epilepsy**

15:25 - 15:33

Sallie Baxendale (United Kingdom)

**Hippocampal volume correlates negatively with episodic memory performance in newly diagnosed pediatric patients with self-limited epilepsy with centrotemporal spikes**

15:33 - 15:41

Alexandre N. Datta (Switzerland)

**Neuropsychological profile of late onset epilepsy of unknown aetiology: insights into cognitive functioning**

15:41 - 15:49

Alessia Casarini (Italy)

**Neurocognitive outcomes of *in utero* exposure to antiseizure medication: an Australian cohort study**

15:49 - 15:57

Eliza Honybun (Australia)

**Patterns of long-term cognitive decline following epilepsy surgery**

15:57 - 16:05

Isha Puntambekar (United Kingdom)

**Conclusion and Q&A**

16:05 - 16:15

*ILAE YES*

16:00 - 17:00

**ILAE YES Brainstorming Session - Neuropsychiatric profiles of epilepsy patients**

|   |               |
|---|---------------|
| <b>Introduction</b>   | 16:00 - 16:05 |
| <b>Neuropsychiatric profiles of epilepsy patients</b><br>Katia Lin (Brazil) | 16:05 - 16:50 |
| <b>Conclusion and Q&amp;A</b>   | 16:50 - 17:00 |

*ILAE Nursing*

16:00 - 17:00

**ILAE Nursing Section Session**

|  |               |
|--|---------------|
| <b>Introduction</b>  | 16:00 - 16:05 |
| <b>Building Sustainable Epilepsy Care in High-Turnover Settings: A Protocol Driven Nurse-Led Model</b><br>Debbie Mak Yee Tung (Hong Kong)  | 16:05 - 16:17 |
| <b>Understanding and Improving Knowledge Gaps on Women's Issues and Epilepsy: A Global Perspective for Healthcare Professionals</b><br>Lucretia Long (United States)<br>Carmella Redhead (Canada)<br>Michelle Phillip-Duncan (Trinidad and Tobago) | 16:17 - 16:29 |
| <b>Improving Access and Involvement in Reproductive Health Planning</b><br>Janine Winterbottom (United Kingdom)  | 16:29 - 16:41 |
| <b>Multidisciplinary Epilepsy/Pregnancy Consultations</b><br>Nadine VAN DYK (France)   | 16:41 - 16:53 |
| <b>Conclusion and Q&amp;A</b>  | 16:53 - 17:00 |

*Epilepsy in Older People*

16:45 - 18:15

Aud 1

**What is late-onset epilepsy? From controversy to consensus**

Vineet Punia (United States)

Ifrah Zawar (United States)

|  |               |
|--|---------------|
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>Current concepts, controversies and operational definitions of Late-onset epilepsy in the literature.</b><br>Vineet Punia (United States)                                   | 16:50 - 17:10 |
| <b>Late-onset epilepsy around the world: Insights on variability in the diagnostic and management practices from an international survey.</b><br>Rohit Marawar (United States) | 17:10 - 17:30 |
| <b>Psychiatric comorbidities of late-onset epilepsy - Evidence and burden of the hidden iceberg.</b><br>Heather Angus-Leppan (United Kingdom)                                  | 17:30 - 17:50 |
| <b>Chicken or the Egg? The bidirectional borderlands of late-onset epilepsy and neurodegeneration.</b><br>Terence O'Brien (Australia)<br>Ifrah Zawar (United States)           | 17:50 - 18:10 |
| <b>Conclusion and Q&amp;A</b>  | 18:10 - 18:15 |

*Terminology and Classification*

16:45 - 18:15

Aud V (Pav 1)

**Consensus terminology for functional dissociative seizures**

W.Curt LaFrance Jr (United States)

Francisca Sá (Portugal)

**Introduction**

16:45 - 16:50

**Terminology: Why for Functional?**

16:50 - 17:06

Markus Reuber (United Kingdom)

**Terminology: Why for Dissociative?**

17:06 - 17:22

Deniz Ertan (France)

**Terminology: Why for Seizure?**

17:22 - 17:38

Chrisma Pretorius (South Africa)

**Terminology: Why not Psychogenic?**

17:38 - 17:54

W.Curt LaFrance Jr (United States)

**Public Involvement: Patient Perspective**

17:54 - 18:10

Peter Gilli (Canada)

**Conclusion and Q&A**

18:10 - 18:15

*Award Symposia*

16:45 - 18:15

AUD III + IV

**Award Symposium: ILAE Journal Awards**

Fernando Cendes (Brazil)

Sándor Beniczky (Denmark)

Merab Kokaia (Sweden)

**Introduction**

16:45 - 16:50

**Epilepsia Prize for Clinical Research - Proof of concept: Portable ultra-low-field MRI for the diagnosis of epileptogenic brain pathologies**

16:50 - 17:00

Tobias Bauer (Germany)

**Presentation of Award: Epilepsia Prize for Clinical Research**

17:00 - 17:05

Fernando Cendes (Brazil)

Stéphane Auvin (France)

**Epilepsia Prize for Basic Science - Pathogenic MTOR somatic variant causing focal cortical dysplasia drives hyperexcitability via overactivation of neuronal GluN2C NMDA receptors**

17:05 - 17:15

Louison Pineau (France)

**Presentation of Award: Epilepsia Prize for Basic Science**

17:15 - 17:20

Stéphane Auvin (France)

Fernando Cendes (Brazil)

**Epileptic Disorders - Characteristics of motion signal profiles of tonic-clonic, tonic, hyperkinetic, and motor seizures extracted from nocturnal video recordings**

17:20 - 17:30

Petri Ojanen (Finland)

**Presentation**

17:30 - 17:35

Sándor Beniczky (Denmark)

**Epilepsia Open Prize for Clinical Research - Metabolic connectivity as a predictor of surgical outcome in mesial temporal lobe epilepsy**

17:35 - 17:45

Ondřej Strýček (Czech Republic)

|  |  |               |
|--|--|---------------|
| <b>Presentation of Award: Epilepsia Open Prize for Clinical Research</b>   |  | 17:45 - 17:50 |
| Merab Kokaia (Sweden)  |  |               |
| Piero Perucca (Australia)  |  |               |
| <b>Epilepsia Open Prize for Basic Science - Spatial and Amplitude Dynamics of Neurostimulation: Insights from the Acute Intrahippocampal Kainate Seizure Mouse Model</b> |  | 17:50 - 18:00 |
| Thomas Foutz (United States)   |  |               |
| <b>Presentation of Award: Epilepsia Open Prize for Basic Science</b>   |  | 18:00 - 18:05 |
| Piero Perucca (Australia)  |  |               |
| Merab Kokaia (Sweden)  |  |               |
| <b>Conclusion and Q&amp;A</b>  |  | 18:05 - 18:15 |
| <i>Social Issues</i>   |  |               |
| 16:45 - 18:15  |  | Pavilion 3A   |
| <b>The Economics of Epilepsy (EOE) in the IGAP era</b>   |  |               |
| Gagandeep Singh (India)  |  |               |
| Ding Ding (China)  |  |               |
| <b>Introduction</b>  |  | 16:45 - 16:50 |
| <b>Expenditure on epilepsy: a lay-persons perspective</b>  |  | 16:50 - 17:01 |
| Patricia Braga (Uruguay)   |  |               |
| <b>The perspective of someone with drug-resistant epilepsy</b>   |  | 17:01 - 17:12 |
| Lara Jehi (United States)  |  |               |
| <b>The perspective of a primary healthcare provider in resource-limited settings</b>   |  | 17:12 - 17:23 |
| Mashina Chomba (Zimbabwe)  |  |               |
| <b>The perspective of a healthcare manager</b>   |  | 17:23 - 17:34 |
| Shivani Kalra (India)  |  |               |
| <b>A policy-maker's notes</b>  |  | 17:34 - 17:45 |
| Ryan Wagner (South Africa)   |  |               |
| <b>Conclusion and Q&amp;A</b>  |  | 17:45 - 18:15 |
| <i>Drug Therapy</i>  |  |               |
| 16:45 - 18:15  |  | Pavilion 3B   |
| <b>Revisiting drug resistant epilepsy</b>  |  |               |
| Aristea Galanopoulou (United States)   |  |               |
| Daniel Friedman (United States)  |  |               |
| <b>Introduction</b>  |  | 16:45 - 16:50 |
| <b>DRE - A clinician's view</b>  |  | 16:50 - 17:00 |
| Emilio Perucca (Australia)   |  |               |
| <b>DRE - A pharmacologist's view</b>   |  | 17:00 - 17:10 |
| Heidrun Potschka (Germany)   |  |               |
| <b>DRE - A geneticist's view</b>   |  | 17:10 - 17:20 |
| Gabriele Lignani (United Kingdom)  |  |               |
| <b>DRE - A moving target?</b>  |  | 17:20 - 17:30 |
| Luisa Rocha (Mexico)   |  |               |
| <b>Living with DRE</b>   |  | 17:30 - 17:40 |
| Landis Wiedner (United States)   |  |               |

|  |               |
|--|---------------|
| <b>Conclusion and Q&amp;A</b>  | 17:40 - 18:15 |
| <i>Genetics</i><br>16:45 - 18:15   | Pavilion 3C   |
| <b>Aetiology-specific spectrum of epilepsy syndromes: Redefining diagnosis and management</b><br>Nicola Specchio (Italy)   |               |
| <b>Introduction</b>  | 16:45 - 16:50 |
| <b>The Evolution of Epilepsy Classification: Overview of Etiology-Specific Epilepsy Syndromes and their impact on clinical practice</b><br>Nicola Specchio (Italy) | 16:50 - 17:10 |
| <b>Bridging Genetics, Imaging, and Functional effect</b><br>Ingrid Scheffer (Australia)  | 17:10 - 17:30 |
| <b>Should Etiology Drive Classification in All Settings?</b><br>Stéphane Auvin (France)  | 17:30 - 17:50 |
| <b>Addressing Global Challenges in ESSE Implementation</b><br>Jo Wilmshurst (South Africa)   | 17:50 - 18:10 |
| <b>Conclusion and Q&amp;A</b>  | 18:10 - 18:15 |



Tuesday, September 2, 2025

*Paediatric Epileptology*

08:00 - 09:30

Aud VI+VII

**Video Session - Seizure semiology in Paediatric Epilepsies****Introduction**

08:00 - 08:05

**Seizure semiology in neonates**

08:05 - 08:30

Ronit Pressler (United Kingdom)

**Seizure semiology in children with generalized epilepsies**

08:30 - 08:55

Nicola Specchio (Italy)

**Focal seizures semiology. Is it the same as in adults?**

08:55 - 09:20

Alexis Arzimanoglou (Spain)

**Conclusion and Q&A**

09:20 - 09:30

*SUDEP & Mortality*

08:00 - 09:30

Pavilion 3A

**SUDEP & Seizure safety counselling: A tale of six countries**

Rohit Shankar (United Kingdom)

**Introduction**

08:00 - 08:05

**An evidence-based approach to develop SUDEP surveys**

08:05 - 08:11

Rohit Shankar (United Kingdom)

**SUDEP counselling: tales from UK & Ireland**

08:11 - 08:17

Rohit Shankar (United Kingdom)

**SUDEP counselling: tales from Norway**

08:17 - 08:23

Oliver Henning (Norway)

**SUDEP counselling: tales from Sweden**

08:23 - 08:29

Torbjorn Tomson (Sweden)

**SUDEP communication: tales from Hungary**

08:29 - 08:35

Anna Kelemen (Hungary)

**SUDEP counselling: tales from Spain**

08:35 - 08:41

Vicente Villanueva (Spain)

**Conclusion and Q&A**

08:41 - 09:30

*Social Issues*

08:00 - 09:30

Pavilion 3B

**Actions to reduce the burden of caregivers of people with epilepsy across the world**

Elvira Vacas Montero (Ireland)

**Introduction**

08:00 - 08:04

**The Burden of Caregivers Of People With Epilepsy Around The World**

08:04 - 08:18

Manuel Toledo (Spain)

**Actions To Reduce the Burden of Caregivers Across the World**

08:18 - 08:32

Anchor Hung (Hong Kong)

**Actions To Reduce the Burden of Caregivers Across the World**

08:32 - 08:46

|   |               |
|---|---------------|
| María Marta Bertone (Argentina)   |               |
| <b>Actions To Reduce the Burden of Caregivers Across the World</b>  | 08:46 - 09:00 |
| Laura Weidner (United States)   |               |
| <b>Conclusion and Q&amp;A</b>   | 09:00 - 09:30 |
| <i>Epilepsy Surgery</i>   |               |
| 08:00 - 09:30   | Pavilion 3C   |
| <b>Ablation in epilepsy surgery - different approaches in different syndromes - Is this justified?</b>  |               |
| Friedhelm C Schmitt (Germany)   |               |
| <b>Introduction</b>   | 08:00 - 08:03 |
| <b>Hypothalamic Hamartoma - stereotactic laser thermoablation</b>   | 08:03 - 08:15 |
| Daniel J. Curry (United States)   |               |
| <b>Hypothalamic Hamartoma - radiofrequency thermoablation</b>   | 08:15 - 08:27 |
| Hiroshi Shirozu (Japan)   |               |
| <b>Hypothalamic Hamartoma - MRIguided Focus Ultrasound</b>  | 08:27 - 08:39 |
| John Ragheb (United States)   |               |
| <b>Hypothalamic Hamartoma - the "classical" endoscopic approach</b>   | 08:39 - 08:51 |
| Wirginia Maixner (Australia)  |               |
| <b>Mesial Temporal Lobe Epilepsy - stereotactic laser thermoablation</b>  | 08:51 - 09:03 |
| Friedhelm C Schmitt (Germany)   |               |
| <b>MTLE - SEEGuided-radiofrequency-thermoablation</b>   | 09:03 - 09:15 |
| Stéphane Jean (China)   |               |
| <b>MTLE - the "classical" resective approach"</b>   | 09:15 - 09:27 |
| Kostas N. Fountas (Greece)  |               |
| <b>Conclusion and Q&amp;A</b>   | 09:27 - 09:30 |
| <i>Clinical Neurophysiology</i>   |               |
| 08:00 - 09:30   | Room 1.09     |
| <b>Advanced EEG: source imaging - Part 2 (Hands-on)</b>   |               |
| <b>Introduction</b>   | 08:00 - 08:05 |
| <b>Source imaging cases</b>   | 08:05 - 08:45 |
| Sándor Beniczky (Denmark)   |               |
| <b>Source imaging cases</b>   | 08:45 - 09:25 |
| Stefan Rampp (Germany)  |               |
| <b>Conclusion and Q&amp;A</b>   | 09:25 - 09:30 |
| <i>Paediatric Epileptology</i>  |               |
| 09:45 - 11:45   | Aud 1         |
| <b>Epilepsy Surgery in Children: Pushing the Limits</b>   |               |
| Elaine C. Wirrell (United States)   |               |
| Julia Jacobs-LeVan (Canada)   |               |
| <b>Introduction</b>   | 09:45 - 09:50 |
| <b>Patient story - focus on journey to get to epilepsy surgery and what benefits they saw with surgery, also which comorbidities persisted/worsened</b> | 09:50 - 10:00 |

Emma Nott (United Kingdom)

**Does one size fit all when defining drug resistance? Balancing surgical risk and maximizing neurobehavioral outcomes** 10:00 - 10:18

Deepak Gill (Australia)

**Should non-curative surgery be the last resort?** 10:18 - 10:36

Ana Paula Goncalves (Brazil)

**What is the role of less invasive surgical options?** 10:36 - 10:54

Martin Tisdall (United Kingdom)

**Challenges and lessons of building a pediatric epilepsy surgery program in a resource-limited region** 10:54 - 11:12

Manjari Tripathi (India)

**What are the benefits of epilepsy surgery beyond just seizure control?** 11:12 - 11:30

Georgia Ramantani (Switzerland)

**Conclusion and Q&A** 11:30 - 11:45

#### Neuropsychology

09:45 - 11:45

Aud V (Pav 1)

#### **Translating new frontiers in cognitive and psychological disorders to improved patient outcomes**

Genevieve Rayner (Australia)

Rosa Michaelis (Germany)

**Introduction** 09:45 - 09:55

**Can you fix both at once please? The cognitive load of mental health problems as a person with epilepsy** 09:55 - 10:15

Leonie Wollscheid (Germany)

**The state-of-the art for understanding cognitive disorders in epilepsy** 10:15 - 10:35

Robyn Busch (United States)

**Next generation cognitive prehabilitation and rehabilitation for all persons with epilepsy** 10:35 - 10:55

Honor Coleman (Australia)

Shivani Sharma (United Kingdom)

**New ways of understanding psychiatric comorbidities in epilepsy** 10:55 - 11:15

Genevieve Rayner (Australia)

**Technology-assisted mental health care in epilepsy - friend or foe?** 11:15 - 11:35

Gus Baker (United Kingdom)

**Conclusion and Q&A** 11:35 - 11:45

#### ILAE YES

12:00 - 13:00

#### **ILAE YES Career Development Session - Changing epilepsy care through entrepreneurship**

**Introduction** 12:00 - 12:05

**Changing epilepsy care through entrepreneurship** 12:05 - 12:50

**Conclusion and Q&A** 12:50 - 13:00

*ILAE Nursing*

12:00 - 13:00

**ILAE Nursing Section Session**

|  |               |
|--|---------------|
| <b>Introduction</b>  | 12:00 - 12:05 |
| <b>Cultural Barriers and Coping Strategies in Epilepsy Care in Resource-Limited Areas: A Qualitative Study</b>       | 12:05 - 12:20 |
| Lin Lan (China)<br>Gao Ruixue (China)<br>Yin Li (China)  |               |
| <b>10 Years of Educational and Recreation Camps for Children with Epilepsy in Croatia</b>                            | 12:20 - 12:35 |
| - N Bedekovic, K Kuznik, M Malenica, M Kukuruzovic, I Separovic, T Trbojevic (Croatia)                               |               |
| <b>Exploring the Experience of Stigma Among Children and Adolescents with Epilepsy in China: A Qualitative Study</b> | 12:35 - 12:50 |
| - Zhaojing (China)   |               |
| <b>Conclusion and Q&amp;A</b>  | 12:50 - 13:00 |

*Paediatric Epileptology*

12:15 - 13:45

Aud 1

**Self-Limited Focal Epilepsies in Infants and Children: Diagnostic and management challenges**

Elaine C. Wirrell (United States)

Lynette Sadleir (New Zealand)

|   |               |
|---|---------------|
| <b>Introduction</b>   | 12:15 - 12:20 |
| <b>Impact of the diagnosis of an Infantile or Childhood SeLFE on families</b> | 12:20 - 12:36 |
| <b>Making the diagnosis of Neonatal and Infantile SeLFEs</b>                  | 12:36 - 12:52 |
| Jithangi Wanagasinghe (Sri Lanka)   |               |
| <b>Management of neonatal and infantile SeLFEs - what is the evidence?</b>    | 12:52 - 13:08 |
| Kelly G. Knupp (United States)  |               |
| <b>Making the diagnosis of childhood SeLFEs</b>                               | 13:08 - 13:24 |
| Ana Coan (Brazil)   |               |
| <b>Management of Childhood SeLFEs - what is the evidence?</b>                 | 13:24 - 13:40 |
| Julia Jacobs-LeVan (Canada)   |               |
| <b>Conclusion and Q&amp;A</b>   | 13:40 - 13:45 |

*Other*

12:15 - 13:45

Aud V (Pav 1)

**IGAP: From adoption to implementation**

Francesca Sofia (Italy)

Alla Guekht (Russian Federation)

|   |               |
|---|---------------|
| <b>Introduction</b>   | 12:15 - 12:20 |
| <b>IGAP - Overview and Update</b>                                 | 12:20 - 12:25 |
| <b>IGAP in The Americas</b>                                       | 12:25 - 12:35 |
| María Marta Bertone (Argentina)<br>Keryma Acevedo (Chile)         |               |
| <b>Past, Present and Future IGAP Initiatives in Latin America</b> | 12:35 - 12:35 |

|   |               |
|---|---------------|
| <b>IGAP in Africa - Introducing the African Trendsetters leading IGAP implementation actions</b>              | 12:35 - 12:45 |
| Action Amos (Malawi)<br>Enat Yewnetu (Ethiopia)   |               |
| <b>IGAP in Europe - EpiAlliance - IGAP Consensus and Implementation Plan in Spain</b>                         | 12:45 - 12:55 |
| Elvira Vacas Montero (Ireland)<br>José M. Serratosa (Spain)   |               |
| <b>IGAP in Asia Oceania - Implementing IGAP Policy Initiatives in Asia Oceania - Focus on The Philippines</b> | 12:55 - 13:00 |
| Leonor Cabral-Lim (Philippines)   |               |
| <b>IGAP in Asia Oceania - Implementing IGAP Policy Initiatives in Asia Oceania - Progress in Australia</b>    | 13:00 - 13:05 |
| Piero Perucca (Australia)   |               |
| <b>Panel Discussion and Audience Q&amp;A</b>  | 13:05 - 13:25 |
| <b>Closing Speech - IGAP - Call to Action</b>   | 13:25 - 13:40 |
| Roberto Horacio Caraballo (Argentina)   |               |
| <b>Conclusion and Q&amp;A</b>   | 13:40 - 13:45 |
| <i>Other</i><br>12:15 - 13:45   | Aud VI+VII    |
| <b>Epilepsy Quiz</b>  |               |
| <i>Epilepsy in Emergencies</i><br>12:15 - 13:45   | AUD VIII      |
| <b>Controversies for the epileptologist in the ICU</b>  |               |
| Andrea Rossetti (Switzerland)<br>Elan Guterman (United States)  |               |
| <b>Introduction</b>   | 12:15 - 12:20 |
| <b>cEEG is more efficient than rEEG ("more is better")</b>  | 12:20 - 12:40 |
| Adam Strzelczyk (Germany)   |               |
| <b>rEEG is as good as cEEG ("less is more")</b>   | 12:40 - 13:00 |
| Andrea Rossetti (Switzerland)   |               |
| <b>Use general anesthetics promptly in SE ("early is better")</b>   | 13:00 - 13:20 |
| Pia De Stefano (Switzerland)  |               |
| <b>Use general anesthetics parsimoniously in SE ("late is better")</b>  | 13:20 - 13:40 |
| Elan Guterman (United States)   |               |
| <b>Conclusion and Q&amp;A</b>   | 13:40 - 13:45 |
| <i>Drug Therapy</i><br>12:15 - 13:45  | AUD II        |
| <b>Advancing the role of the pharmacist in the care and management of the patient with epilepsy</b>           |               |
| H Steve White (United States)<br>Cecilie Johannessen-Landmark (Norway)  |               |
| <b>Introduction</b>   | 12:15 - 12:20 |
| <b>The pharmacist's role in bridging the gap in healthcare access in epilepsy: a patient's perspective</b>    | 12:20 - 12:36 |
| Matthew Attard (Malta)  |               |

|  |                                |
|--|--------------------------------|
| <b>The development of an asynchronous and synchronous epilepsy management training program for the community pharmacist</b>                                      | 12:36 - 12:52                  |
| Michelle Guignet (United States)   |                                |
| <b>Experience from a Pharmacology team at a national epilepsy center to improve patient treatment, Inter-professional collaboration, education and research.</b> | 12:52 - 13:08                  |
| Cecilie Johannessen-Landmark (Norway)  |                                |
| <b>Role of the Clinical Pharmacist Practitioner in Epilepsy Ambulatory Care: Perspectives from a US Veterans Administration Epilepsy Center of Excellence</b>    | 13:08 - 13:24                  |
| Barry Gidal (United States)  |                                |
| <b>How pharmacists are improving access to care and antiseizure medications in low resource countries</b>  | 13:24 - 13:40                  |
| Anne Anokye (Ghana)  |                                |
| <b>Conclusion and Q&amp;A</b>  | 13:40 - 13:45                  |
| <i>Epilepsy Surgery</i>  |                                |
| 12:15 - 13:45  | AUD III + IV                   |
| <b>Is intracranial EEG necessary in lesional epilepsy for resective or neuromodulation procedures?</b>   |                                |
| Michael Sperling (United States)   |                                |
| Faisal Al-Otaibi (Saudi Arabia)  |                                |
| <b>Introduction</b>  | 12:15 - 12:20                  |
| <b>Personal experience with SEEG</b>   | 12:20 - 12:40                  |
| Sandra Ferreira (Portugal)   |                                |
| <b>EEG is necessary to define the epileptogenic zone even when MRI, clinical symptoms, semiology, and scalp EEG are concordant</b>                               | 12:40 - 13:00                  |
| Fabrice Bartolomei (France)  |                                |
| <b>Intracranial EEG is not necessary to define the epileptogenic zone when MRI, clinical symptoms, semiology, and scalp EEG are concordant</b>                   | 13:00 - 13:20                  |
| Michael Sperling (United States)   |                                |
| <b>Is intracranial EEG needed prior to performing neuromodulation procedures?</b>  | 13:20 - 13:40                  |
| Joon Kang (United States)  |                                |
| <b>Conclusion and Q&amp;A</b>  | 13:40 - 13:45                  |
| <i>In-Person Posters</i>   |                                |
| 13:45 - 15:15  | In-Person Poster Presentations |
| <b>In-Person Poster Presentations</b>  |                                |
| <b>Post-Stroke Seizures: A Comparative Analysis of Early and Late Onset Seizures in a Single-Center Retrospective Study</b>                                      | 13:45 - 13:45                  |
| Yoonkyung Lee (Korea, Republic of)   |                                |
| <b>Caregiver burden in patients with Developmental and Epileptic Encephalopathies. An online survey analysis</b>   | 13:45 - 13:45                  |
| Laura Abraira (Spain)  |                                |
| <b>Brain changes in sleep-related hypermotor epilepsy observed from wakefulness and N2 sleep: a matched case-control study</b>                                   | 13:45 - 13:45                  |
| Yongjun Li (China)   |                                |
| <b>Neuro-ophthalmological changes in temporal lobe epilepsy and its surgical treatment</b>   | 13:45 - 13:45                  |

Maksim Rusnak (Russian Federation)

**Déjà vu: A focal sign in Juvenile Myoclonic Epilepsy**

13:45 - 13:45

Maria Rosa Andrade Ferreira (Portugal)

**Off-label use of cenobamate in Refractory status epilepticus: a series of cases**

13:45 - 13:45

María Carrasco Sevilla (Spain)

**Impact of modified Atkins diet on serum concentrations of antiseizure medications in an adult population- a balancing act**

13:45 - 13:45

Maria Carlos Pereira (Portugal)

**Prevalence of poststroke epilepsy (pse) after 5 years and SeLECT score results**

13:45 - 13:45

Maria Jose Hernandez Garcia (Spain)

**“Clinical and videoelectroencephalogram characterization in non-epileptic psychogenic seizures”**

13:45 - 13:45

Marco Alvarado (Mexico)

**Self-management for people with epilepsy and a history of negative health events (SMART): A randomized controlled effectiveness trial**

13:45 - 13:45

Martha Sajatovic (United States)

**SISCOM Hyper and Hypoperfused Regions: Signal Processing Insights and Correlation with Stereo-EEG**

13:45 - 13:45

Maryam Alherz (Saudi Arabia)

**Predictive Performance of Diagnostic Algorithm for Seizure Outcome in Autoimmune Epilepsy: Multicenter Cohort Study in Japan**

13:45 - 13:45

Maya Tojima (Japan)

**Lipid profile and apolipoprotein E isoforms in adults with drug-resistant epilepsy treated with modified Atkins diet**

13:45 - 13:45

Daniela Dias Dinis (Portugal)

**Impact of epilepsy type on delivery and neonatal outcomes in pregnant women with epilepsy**

13:45 - 13:45

Shahla Malikova (Azerbaijan)

**Diagnostic Challenges and New Clinical Insights into Bilateral Perisylvian Epilepsy**

13:45 - 13:45

Meshari Alsudayri (Saudi Arabia)

**Approach to First Seizures in the Emergency Department: The Key Role of EEG**

13:45 - 13:45

Miguel Saianda Duarte (Portugal)

**Prodromal Olfactory Loss as a Predictor of Seizure Occurrence in Temporal Lobe Epilepsy**

13:45 - 13:45

Mohammed Alshammari (Saudi Arabia)

**Clinico-electrographic spectrum and predictors of outcome in resistant idiopathic generalized epilepsy- is it a zebra among the horses?**

13:45 - 13:45

Nandana Jayakumari (India)

**Focal Drug-Resistant Epilepsy As The Only Clinical Manifestation In Multiple Sclerosis: A Case Report**

13:45 - 13:45

Nirmeen Kishk (Egypt)

**Beyond migraine: the hidden epilepsy of cortical malformations**

13:45 - 13:45

Aliona Nogai (Moldova)

|   |               |
|---|---------------|
| <b>Attitude and anxiety level of caregivers of epilepsy patients: a cross sectional study at Neurology Polyclinic Zainoel Abidin General Hospital Banda Aceh</b>          | 13:45 - 13:45 |
| Nova Dian Lestari (Indonesia)   |               |
| <b>Cortical lateralization of ictal cardiovascular autonomic dysfunction in stimulation-induced seizures</b>  | 13:45 - 13:45 |
| Anna Marchenko (Russian Federation)   |               |
| <b>EPISTAR: Educational Patient Information Sheet To Achieve Retention of Information</b>   | 13:45 - 13:45 |
| Olga Tanda (United Kingdom)   |               |
| <b>Exploring the roles of nesfatin-1 and ghrelin as potential biomarkers in human epilepsy</b>  | 13:45 - 13:45 |
| Ozgun Yetkin (Poland)   |               |
| <b>Patterns of long-term pharmacoresponse in different etiologies of epilepsy</b>   | 13:45 - 13:45 |
| Pamela Regina Henning (Brazil)  |               |
| <b>Clinical and histopathological characteristics of temporal lobe epilepsy patients with hyperkinetic seizures</b>   | 13:45 - 13:45 |
| Petr Fabera (Czech Republic)  |               |
| <b>Eye Closure Sensitivity: A Form of Photosensitivity in Generalized Genetic Epilepsy</b>  | 13:45 - 13:45 |
| Ram Baboo (United States)   |               |
| <b>Characterization of complex motor automatisms in focal epilepsy: a case series</b>   | 13:45 - 13:45 |
| Roxana Matus-Mayorga (Nicaragua)  |               |
| <b>Impact of epileptiform activity during sleep on the cognitive performance of patients with epilepsy</b>  | 13:45 - 13:45 |
| Samuel López-Maza (Spain)   |               |
| <b>Long-term prognosis in Traumatic Brain Injury: Do early seizures and prophylactic antiseizure medications influence outcomes?</b>                                      | 13:45 - 13:45 |
| Sara Lima (Portugal)  |               |
| <b>A comparison of treatment response definitions in newly diagnosed focal epilepsy: Reflections on the current International League Against Epilepsy (ILAE) criteria</b> | 13:45 - 13:45 |
| Sarah Barnard (Australia)   |               |
| <b>Clinical and neurophysiological features of sleep-associated epileptic seizures</b>  | 13:45 - 13:45 |
| Sevara Kalandarova (Uzbekistan)   |               |
| <b>Blood melatonin content in patients with sleep-related epileptic seizures</b>  | 13:45 - 13:45 |
| Sevara Kalandarova (Uzbekistan)   |               |
| <b>Reassessing Developmental and Epileptic Encephalopathies in Adulthood: Insights from a Transition Clinic</b>   | 13:45 - 13:45 |
| Silvia Maio (Italy)   |               |
| <b>Autoimmune epilepsy: diagnosis and management</b>  | 13:45 - 13:45 |
| Sirine Frikha (Tunisia)   |               |
| <b>Post-stroke seizures and epilepsy : main risk factors</b>  | 13:45 - 13:45 |
| Sirine Frikha (Tunisia)   |               |
| <b>Does co-medication with methylphenidate and lisdexamfetamine influence seizure control in focal epilepsy? A case study</b>   | 13:45 - 13:45 |



Kristin Sjølie Thygesen (Denmark)

**Surgical Treatment of Drug-Resistant Focal Epilepsy Associated with Cortical Dysplasia in Adults: A Case Series**

13:45 - 13:45

Stephanie Pino (Argentina)

**Examining the Staff Interaction and Understanding of the Current Digital Health System Framework for Epilepsy and Neurology in St. James's Hospital Dublin**

13:45 - 13:45

Stephen P. Klaus (Ireland)

**Patient perspectives on antiseizure medication discontinuation: a mixed-methods exploration of risk perception, tolerance, and counseling**

13:45 - 13:45

Samuel Terman (United States)

**The safety and efficacy of ketogenic diet therapy among adolescents and adults with refractory epilepsy: a systematic review and meta-analysis**

13:45 - 13:45

Tania Farrar (Australia)

**Quality of Life in People with Epilepsy depending on educational level in Georgia**

13:45 - 13:45

Tamar Jishkariani (Georgia)

**Pallister-Hall syndrome: the not so dark side of hypothalamic hamarthoma-related epilepsy**

13:45 - 13:45

Teresa Santana (Portugal)

**Tau Deposition: A Potential Marker of Sleep and Memory Impairment in Focal Drug-Resistant Epilepsy**

13:45 - 13:45

Thaera Arafat (Canada)

**Does Ramadhan Observance Affect Quality-of-Life in Epileptic Patients? A Multi-center Study in Indonesia**

13:45 - 13:45

Theodore Amadeo Nathan (Indonesia)

**Comparative Diagnostic Accuracy of Long-Term Video EEG and Standard EEG in Predicting Seizure Recurrence After Epilepsy Surgery**

13:45 - 13:45

Tassanai Intravooth (Germany)

**Ictal coughing with stereotypical asymmetric tonic posture**

13:45 - 13:45

Martin Tomasek (Czech Republic)

**Two-Year Experience of a Newly Established Epilepsy Monitoring Unit in a Resource-Limited Setting**

13:45 - 13:45

Fridha Viridiana Villalpando Vargas (Mexico)

**Understanding the cause and effect of homelessness and epilepsy**

13:45 - 13:45

Tze Hong Yong (Ireland)

**Distinct Functional Connectivity Network in Two Subtypes of Temporal Lobe Epilepsy Across East China**

13:45 - 13:45

Shimin Xu (China)

**Towards Standardized Seizure Forecast Algorithm Development and Evaluation**

13:45 - 13:45

Ana Sofia Carmo (Portugal)

**Artificial intelligence-based tool for spike-and-wave discharge detection in genetic absence epilepsy rats**

13:45 - 13:45

Bekir Arda Yildirim (Turkey)

**Applying Generative Large Language Models to Calculate Seizure Frequency for People with Epilepsy**

13:45 - 13:45

Ben Holgate (United Kingdom)

**Network dynamic changes before epileptic seizures: Physiological correlates and network modeling**

13:45 - 13:45

Brian Nicolas Medina Leandro (Spain)

**Deep learning for the identification of pro-ictal states in human temporal lobe epilepsy using microelectrodes**

13:45 - 13:45

Brieg Oudeacoumar (France)

**Navigating BrainFocus iEEG: A Cloud-based Software to Assist Clinicians in Identifying Seizure Onset Zone(s) in Drug-resistant Patients**

13:45 - 13:45

Carlota Maria Pagès Portabella (Spain)

**Noisy Spontaneous Firing May Modulate Seizure Threshold: Insights from Seizure Simulations with Density-Based Neural Mass Models**

13:45 - 13:45

Chou-Ching Lin (Taiwan, China)

**Intracranial Spike activity from N3 and N2 sleep-stages best localizes the Seizure-Onset-Zone**

13:45 - 13:45

Daniel Lachner-Piza (Canada)

**Advancing Epilepsy Care: Free and Intuitive Electrical Source Imaging Software for Underserved Communities**

13:45 - 13:45

David Alvarez (Mexico)

**Can ChatGPT 4.0 Diagnose Epilepsy? A Study on Artificial Intelligence's Diagnostic Capabilities**

13:45 - 13:45

Francesco Brigo (Italy)

**Artificial Intelligence vs. Human Expertise: Evaluating ChatGPT 4.0 in Epileptic Seizure and Epilepsy Diagnosis and Classification**

13:45 - 13:45

Francesco Brigo (Italy)

**Spectral and entropy dynamics of ictal vs. interictal generalized spike-and-wave discharges in absence epilepsy**

13:45 - 13:45

Evelin Daniela Ramírez-Ponce (Mexico)

**Effectiveness of Vagal Nerve Stimulation in Drug-Resistant Epilepsy: An Analysis Using Quantum Algorithms and Artificial Intelligence**

13:45 - 13:45

Giada Pauletto (Italy)

**In silico evaluation of cenobamate**

13:45 - 13:45

Glenda Corrêa Borges de Lacerda (Brazil)

**Ultradian seizure pattern detection on presurgical monitoring data: An unsupervised machine learning approach**

13:45 - 13:45

Gonçalo Costa (Portugal)

**Design and in silico study of voltage-gated sodium channel blockers: Neuroprotection and anticonvulsant actions**

13:45 - 13:45

Juan Alberto Guevara Salazar (Mexico)

**Exploring the epilepsy-depression relationship using Artificial Intelligence on Real-World Data in Germany, France, Italy and Spain**

13:45 - 13:45

John Paul Leach (Italy)

**Quantifying Ictal Brain Connectivity Dynamics from SEEG for Epileptogenic Zone Identification in Refractory Epilepsy**

13:45 - 13:45

José Almeida (Portugal)

**Online educational survey uncovers knowledge and practice gaps in**

13:45 - 13:45

**focal epilepsy amongst European neurologists and psychiatrists**

Lionel Thevathasan (United Kingdom)

**Focal Epilepsy: Virtual patient simulation improves European neurologists' performance in diagnosis and management but uncovers inertia in recognizing and managing breakthrough nocturnal seizures and drug-resistant epilepsy**

13:45 - 13:45

Lionel Thevathasan (United Kingdom)

**Virtual patient simulation improves diagnosis and management by European neurologists but uncovers low recognition and inertia in treatment of drug-resistant focal epilepsy**

13:45 - 13:45

Lionel Thevathasan (United Kingdom)

**Online medical education improves specialists' knowledge of add-on antiseizure medications in people with focal epilepsy**

13:45 - 13:45

Lionel Thevathasan (United Kingdom)

**Online medical education improves specialists' knowledge and competence of management in people with focal epilepsy**

13:45 - 13:45

Lionel Thevathasan (United Kingdom)

**Continuing medical education curriculum improves European specialists' knowledge, competence and confidence on management of focal epilepsy**

13:45 - 13:45

Lionel Thevathasan (United Kingdom)

**Quantitative EEG Features Predict Treatment Response in New-Onset Focal Epilepsy: A Machine Learning Approach Across Seven Epilepsy Centers**

13:45 - 13:45

Lorenzo Ricci (Italy)

**Leveraging digital application database to help patient recruitment in clinical trials**

13:45 - 13:45

Ludovic Ampe (Belgium)

**Automated detection of interictal epileptiform discharges in scalp EEG using convolutional autoencoders and artificial neural networks**

13:45 - 13:45

Luis Carlos Martínez Ruiz (Mexico)

**Deep Learning detection of drug-resistance in patients with epilepsy using routine EEG data**

13:45 - 13:45

Manuel Alanís-Bernal (Spain)

**Resting-State EEG Functional Connectivity in Juvenile Myoclonic Epilepsy: Insights into Biomarkers and the Impact of Antiseizure Medication**

13:45 - 13:45

Oscar Antonio Ramos Quezada (Mexico)

**Seizure Detection in Epilepsy: a clinical evaluation of a connected multimodal monitoring shirt**

13:45 - 13:45

Oumayma Gharbi (Canada)

**Connectomics-driven Machine Intelligence for Enhanced Diagnosis, Prognosis, and Treatment of Neurological Diseases using Multimodal Imaging**

13:45 - 13:45

Piyush Swami (France)

**Smarter Than Before?: Comparison of GPT-4o and GPT-3.5 in Epilepsy Case Management**

13:45 - 13:45

Pushpraj Poonia (India)

**Exploring comorbidities in Developmental and Epileptic Encephalopathies through using data mining in electronic health records: the example of sleep disorders**

13:45 - 13:45

Rima Nabbout (France)

**Bridging the Gap in Tonic Seizure Detection: A Systematic Review and Meta-Analysis of Automatic Detection Systems** 13:45 - 13:45

José Rodrigo Quintero Valdez (Mexico)

**Radiomics Analysis with Machine Learning to Differentiate LEAT and Developmental Abnormalities** 13:45 - 13:45

Shao-An Yu (Taiwan, China)

**Development and Validation of a Seizure Alert Detection Collar for Assistance Dogs** 13:45 - 13:45

Shelley Brady (Ireland)

**Co-creation of new electronic clinical outcome assessments (eCOAs) in Dravet syndrome** 13:45 - 13:45

Simona Giorgi (Spain)

**High Performance Privacy-preserving Video-based Detection of Generalized Tonic-Clonic Seizures** 13:45 - 13:45

Vicente Mayer Garção (Portugal)

**Lampsy: An “Invisibles” Approach to Real-time Tonic-clonic Seizure Detection based on Edge Computing** 13:45 - 13:45

Vicente Mayer Garção (Portugal)

**Very high-frequency oscillations detector in routine stereo-EEG** 13:45 - 13:45

Zuzana Vasickova (Czech Republic)

**Alfa-gamma phase-amplitude coupling in Eyelids Myoclonia with Absences reveals fronto-central abnormal interactions after eye-closures** 13:45 - 13:45

Laura Madrassi (Italy)

**Region-specific postictal spreading depolarization observed in LFP microwire recordings from depth-electrode-implanted epilepsy patients** 13:45 - 13:45

Adrián Gutiérrez Gómez (Germany)

**Increased activity of inhibitory interneurons at ictal onset in human temporal lobe seizures** 13:45 - 13:45

Alejandro Hugo Nasimbera (Argentina)

**Characterizing the Photoparoxysmal Response: Toward Operational Criteria for Interpretation and Classification** 13:45 - 13:45

Alioth Guerrero-Aranda (Mexico)

**Subclinical epileptiform activity indicates E-I imbalance in association with accelerated aging** 13:45 - 13:45

Andras Horvath (Hungary)

**Neural correlate of the sense of agency in voluntary movement in patients with non-epileptic motor functional paroxysmal events** 13:45 - 13:45

Mayra Jazmín Morales Armenta (Mexico)

**Brain Network Responses to Evoked and Spontaneous Arousals in NREM Sleep** 13:45 - 13:45

Barbora Matouskova (Czech Republic)

**Performance of independent component analysis in localizing seizure onset from scalp-EEG** 13:45 - 13:45

Jeanne Benoit (France)

**A simple, transparent and versatile parametric algorithm for automatic detection of sleep K complexes (KC) from unstaged sleep EEG** 13:45 - 13:45

|  |               |
|--|---------------|
| Chrysanthi Tsimakidi (Greece)  |               |
| <b>“Diagnostic Yield of Electroencephalogram in Adults with Epilepsy”: A prospective study from South India</b>  | 13:45 - 13:45 |
| Gopal Krishna Dash (India)   |               |
| <b>Spike detection in the wild: screening of suspected temporal lobe epilepsy cases using a tailored 2-channel wearable EEG</b>                                  | 13:45 - 13:45 |
| Daniel Filipe Borges (Portugal)  |               |
| <b>Effects of Caloric Restriction and Ketogenic Diet on mTOR and GATOR signaling axes</b>  | 13:45 - 13:45 |
| Dilsad Turkdogan (Turkey)  |               |
| <b>EEG Spectral Analysis Differentiates Angelman Syndrome Genotypes</b>  | 13:45 - 13:45 |
| Emiel Vereycken (Belgium)  |               |
| <b>Effectiveness of the portable EEG monitoring device (Enobio 2.0) for the emergent management of epileptic seizures</b>  | 13:45 - 13:45 |
| Estevo Santamarina (Spain)   |               |
| <b>Event-based seizure detection in iEEG using neuromorphic hardware</b>   | 13:45 - 13:45 |
| Flavia Davidhi (Switzerland)   |               |
| <b>From complexity to bedside, navigating towards the limits of language processing in the brain: mapping postictal aphasia in stereo-electroencephalography</b> | 13:45 - 13:45 |
| Ionut-Flavius Bratu (France)   |               |
| <b>Comparison of EEG after sleep deprivation and melatonin induction in children of different ages: a randomized controlled trial</b>                            | 13:45 - 13:45 |
| Greta Gustafsson (Sweden)  |               |
| <b>The Electrical Sei-Zaw: Unraveling the Autonomic Spectrum of Ictal Bradycardia and Tachycardia</b>  | 13:45 - 13:45 |
| Ima Ebong (United States)  |               |
| <b>Serial EEG findings in CRADD syndrome with epilepsy: the search for electrophysiologic signature</b>  | 13:45 - 13:45 |
| Jose Mendes-Ribeiro (Portugal)   |               |
| <b>Exploring Hippocampal High-Frequency-Oscillations in human organotypic brain slices cultures</b>  | 13:45 - 13:45 |
| Jan Heckelmann (Germany)   |               |
| <b>Asymmetry of epileptiform discharges amplitude in generalized epilepsy</b>  | 13:45 - 13:45 |
| Joao Pizarro (United Kingdom)  |               |
| <b>Ictal patterns of eyelid myoclonia</b>  | 13:45 - 13:45 |
| Laura Guilhoto (Brazil)  |               |
| <b>A Retrospective Review of Clinical and EEG Features in Adults with Lennox-Gastaut Syndrome</b>  | 13:45 - 13:45 |
| Lina Nashef (United Kingdom)   |               |
| <b>The Contribution of Functional Connectivity and Graph Theory to Anatomico-Electro-Clinical correlation during Pre-Surgical Evaluation</b>                     | 13:45 - 13:45 |
| Lorenzo Ferri (Italy)  |               |
| <b>Hippocampal Spindle Rates Correlate with Cognitive Functions in Pediatric Patients with Epilepsy</b>  | 13:45 - 13:45 |
| Margarita Maltseva (Canada)  |               |

|  |               |
|--|---------------|
| <b>Visual evoked potentials : Normative values from healthy Senegalese adults</b>  | 13:45 - 13:45 |
| Marième Diop-Sène (Senegal)  |               |
| <b>Music Modulatory Effects on Intracerebral EEG</b>   | 13:45 - 13:45 |
| Martin Pail (Czech Republic)   |               |
| <b>Predictive Value of EEG in the Suspicion of Brain Lesions Undetected by CT in the Acute Phase</b>   | 13:45 - 13:45 |
| Miguel Saianda Duarte (Portugal)   |               |
| <b>Screening for cognitive impairment in generalized epilepsy</b>  | 13:45 - 13:45 |
| Nodira M. Tychibaeva (Uzbekistan)  |               |
| <b>Relationship Between Memory and Altered Consciousness in Focal Seizures: Aura as a Key Marker</b>   | 13:45 - 13:45 |
| Nuria Campora (Argentina)  |               |
| <b>Photoparoxysmal response as a predictive biomarker in epilepsy</b>  | 13:45 - 13:45 |
| Natalia Olaru (Moldova)  |               |
| <b>Acoustic dynamics of music: a potential mechanism for neuromodulation in epilepsy</b>   | 13:45 - 13:45 |
| Ondřej Strýček (Czech Republic)  |               |
| <b>Ictal eye closure in focal epileptic seizures: sEEG retrospective observational study from a tertiary epilepsy centre</b>   | 13:45 - 13:45 |
| Paola Vassallo (United Kingdom)  |               |
| <b>Quantitative EEG analysis in patients with autism spectrum disorder</b>   | 13:45 - 13:45 |
| Sung Koo Kim (Korea, Republic of)  |               |
| <b>Evaluating the Utility of Routine Outpatient Electroencephalography: Insights from 18 months</b>  | 13:45 - 13:45 |
| Gonçalo Videira (Portugal)   |               |
| <b>Graph theory-based comparison of interictal epileptiform discharge (IED) networks in drug-resistant focal epilepsy patients with resting-state networks in healthy controls: a magnetoencephalography study</b> | 13:45 - 13:45 |
| Kenchaiiah Raghavendra (India)   |               |
| <b>An electric source imaging approach demonstrating diagnostic value of nasopharyngeal electrodes in temporal lobe epilepsy</b>   | 13:45 - 13:45 |
| Yun Ho Choi (Korea, Republic of)   |               |
| <b>"Wipe your face, smile, laugh...strike a pose!" Lesser known semiologies of the Cingulate network. A Stereo-EEG and signal processing study</b>   | 13:45 - 13:45 |
| Sasha Dionisio (Saudi Arabia)  |               |
| <b>Epileptic activity in localized RDA - findings from simultaneous scalp and intracranial EEG recordings</b>  | 13:45 - 13:45 |
| Hiroshi Shigeto (Japan)  |               |
| <b>Exploring mechanisms of self-control in epilepsy - modulation of epileptic spikes by emotion and relaxation</b>   | 13:45 - 13:45 |
| Siegward Elsas (Switzerland)   |               |
| <b>Machine Learning Analysis Reveals Dynamic Remodeling of Hippocampal Interictal Spikes in Temporal Lobe Epilepsy</b>   | 13:45 - 13:45 |
| Vladimir Sladky (United States)  |               |
| <b>Not everything that is rhythmic is a seizure: EEG in the cognitive fluctuations of LBD</b>  | 13:45 - 13:45 |

Stefano Meletti (Italy)

**Normal physiological rhythms recorded on stereoelectroencephalography (SEEG)**

13:45 - 13:45

Stephen Coyle (Australia)

**Impact of Hippocampal Interictal Epileptiform Discharges on Frontal Spindles and Spindle-Slow Oscillation Coupling During Sleep**

13:45 - 13:45

Taira Uehara (Japan)

**Cross-stitching rhythm - a benign form of frontal midline theta EEG activity**

13:45 - 13:45

Alejandra Vasquez (United States)

**Pathological finding of EEG in patients with migraine**

13:45 - 13:45

Biljana Živadinović (Serbia)

**Direct Electrical Stimulation of the Seizure Onset Zone Affects Interictal Electrophysiological Biomarkers**

13:45 - 13:45

Zuzana Formankova (Czech Republic)

**Utility of Responsive Neurostimulation in Reducing Antiseizure Medication Exposure During Two Pregnancies in a Single Patient**

13:45 - 13:45

Aisha Abdulrazaq (United States)

**Contraception for Women with Epilepsy - A Systematic Review of Antiseizure Medication and Hormonal Contraceptive Interactions**

13:45 - 13:45

Bruna Nucera (Italy)

**Breastfeeding patterns among women with and without epilepsy - A nation-wide study from Denmark**

13:45 - 13:45

Julie Werenberg Dreier (Denmark)

**Use of new-generation antiseizure drugs in women with juvenile myoclonic epilepsy**

13:45 - 13:45

Mariana Peschard-Franco (Mexico)

**Epilepsy Clinical Support Coordinator Certification System in Japan**

13:45 - 13:45

Eiji Nakagawa (Japan)

**Prevalence of Sexual Dysfunction in Patients with Epilepsy: A Cross-Sectional Study from a Tertiary Care Facility**

13:45 - 13:45

Parampreet Singh Kharbanda (India)

**Clinical practice guidelines for women with epilepsy: A systematic review**

13:45 - 13:45

Hye Jeong Lee (Korea, Republic of)

**Maternal AEDs now-child development later, what are the results&**

13:45 - 13:45

Dmitrii Shalygin (Russian Federation)

**Late onset epilepsy in cerebral small vessel diseases**

13:45 - 13:45

Nodira, Manzura Tuychibaeva, Abdurakhmanova (Uzbekistan)

**DeRitis ratio as a novel biomarker for post-stroke seizures**

13:45 - 13:45

Albin Gačnik (Slovenia)

**Stability in Cognitive Functioning, Psychological and Lifestyle-Related Factors in Older Adults with Focal Epilepsy**

13:45 - 13:45

Anna Miley Åkerstedt (Sweden)

**Use of perampanel in elderly patients with focal epilepsy and atherosclerotic lesions of brachiocephalic arteries**

13:45 - 13:45

Sergey Burd (Russian Federation)

|  |               |
|--|---------------|
| <b>Sleep quality and sleep-wake cycle dysregulation in late onset epilepsy of unknown origin: an actigraphic study</b>   | 13:45 - 13:45 |
| <b>Dementia is an under-recognized cause of late-onset unexplained epilepsy</b><br>Dong Wook Kim (Korea, Republic of)  | 13:45 - 13:45 |
| <b>Assessing the Risk of Early Post- Stroke Seizures After Thrombectomy: A Retrospective study</b><br>Ibrahim Farhood (Germany)  | 13:45 - 13:45 |
| <b>Risk Factors Associated with Late-Onset Epilepsy in Persons with Dementia and Mild Cognitive Impairment</b><br>Ifrah Zawar (United States)  | 13:45 - 13:45 |
| <b>Comprehensive Profiling of Late-Onset Epilepsy: Demographics, Clinical Features, Diagnostic Patterns, and Treatment Approaches</b><br>Imran Ali (United States)   | 13:45 - 13:45 |
| <b>A study of characteristics of acute symptomatic seizure related to acute ischemic stroke compared to poststroke epilepsy</b><br>Kei-ichiro Takase (Japan)   | 13:45 - 13:45 |
| <b>What is new in New onset Seizures in Octogenarians?</b><br>Lakshmi Priya Lalitha (India)  | 13:45 - 13:45 |
| <b>Study of demographic, clinical and prognostic variables in older adults with Status Epilepticus: comparative analysis between different age groups</b>  | 13:45 - 13:45 |
| <b>Recurrence of status epilepticus: clinical, demographic, prognostic and outcome predictors</b>  | 13:45 - 13:45 |
| <b>Comparison of Standard and Extended 3-Hour EEG in Elderly with Acute Confusion</b><br>Sabine Teifurova (Latvia)   | 13:45 - 13:45 |
| <b>The Electroencephalography Federal University of Rio de Janeiro/Democratic Republic of Congo/University of Oxford Study Group: results of a two-year collaboration</b><br>Maria Emilia Cosenza Andraus (Brazil) | 13:45 - 13:45 |
| <b>Comparison of epilepsy diagnosis and management in rural Indian populations with and without a smartphone application (Epilepsy Treatment Aid)</b><br>Divya Ganjoo (India)                                      | 13:45 - 13:45 |
| <b>CareEpilepsy Ethiopia: A Model for IGAP Implementation in Low-Resource Settings</b><br>Enat Yewnetu (Ethiopia)  | 13:45 - 13:45 |
| <b>Evaluating Epilepsy Knowledge Among Patients in a Mexican Tertiary Care Center: A Pilot Study Using a Translated Epilepsy Patient Knowledge Questionnaire (EPKQ)</b><br>Irene Gómez-Oropeza (Mexico)            | 13:45 - 13:45 |
| <b>Management of seizure clusters: Pre analysis of an open-label trial of benzodiazepines in a tertiary neurology care center in Mexico</b><br>Irene Gómez-Oropeza (Mexico)  | 13:45 - 13:45 |
| <b>Reliability of noninvasive video-EEG telemetry in the differential diagnosis of paroxysmal events: one center study</b><br>Katarina Pavlovic (Serbia)   | 13:45 - 13:45 |
| <b>Knowledge, attitudes, and perceptions of epilepsy among school teachers in Georgia</b>  | 13:45 - 13:45 |



Marina Lazariashvili (Georgia)

**CHALLENGES AND GAPS IN EPILEPSY CARE IN THE REPUBLIC OF MOLDOVA**

13:45 - 13:45

Liliana Iuhtimovschi (Moldova)

**Epidemiological Profile and Treatment Status of Epilepsy Patients in Chhattisgarh, India: A Baseline Analysis**

13:45 - 13:45

Mamta Singh (India)

**Multidisciplinary Management of Adult Patients with Tuberous Sclerosis Complex: Insights from an Epilepsy Clinic Cohort**

13:45 - 13:45

Daniela Dias Dinis (Portugal)

**Unfavorable public attitude towards people with epilepsy in Ethiopia: a systematic review and meta-analysis study**

13:45 - 13:45

Mengesha Biresaw (Hungary)

**Superstitions and beliefs related to the outcomes of epilepsy treatment in Thailand**

13:45 - 13:45

Pornpiroon Muangsiri (Thailand)

**Quantitative EEG biomarkers for post-malarial epilepsy**

13:45 - 13:45

Rasesh Joshi (United States)

**Advancements in Epilepsy Surgery in Chile: A Review of National Program Outcomes During and Post-Pandemic (2019-2024)**

13:45 - 13:45

Reinaldo Uribe-San-Martin (Chile)

**Home-Based vs. Clinic-Based Care for Epilepsy: A Cost-Effectiveness Study**

13:45 - 13:45

Shivani Kalra (India)

**Patient Experience with Telephonic Consultations in Korean Epilepsy Care: A Survey Study**

13:45 - 13:45

Jae Wook Cho (Korea, Republic of)

**Evaluating Clinician Engagement and Gain of Knowledge in Online Educational Modules on Epilepsy Self-Management**

13:45 - 13:45

Shawna L. Strickland (United States)

**Knowledge Gains in Epilepsy Specialist and Non-Specialist Clinicians Following Online Educational Modules**

13:45 - 13:45

Shawna L. Strickland (United States)

**Locally sourced materials as a substitute for commercial products in EEG acquisition within low and middle-income countries**

13:45 - 13:45

Stephen Coates (United Kingdom)

**A community-based model for bridging Epilepsy treatment gap in resource limited setting: An Observational Study**

13:45 - 13:45

Hemant Kumar Tiwari (India)

**How Much Training is Required to Diagnose and Treat Epilepsy? A Serendipitous Study**

13:45 - 13:45

Victor Patterson (United Kingdom)

**The role of early introduction of rituximab in an adult patient with FIRES: a pathway to improved outcomes**

13:45 - 13:45

Amélia Mendes (Portugal)

**Kappa Free Light Chain index as biomarker in autoimmune encephalitis presenting with seizures**

13:45 - 13:45

António Costa (Portugal)

**Exploring the long-term effects of COVID-19 in patients with**

13:45 - 13:45

**epilepsy: a multicenter Italian observational study**

Clarissa Corniello (Italy)

**Improving understanding of Febrile Infection Related Epilepsy Syndrome (FIRES) in children and young people**

13:45 - 13:45

Dimitrios Champsas (United Kingdom)

**Electroencephalography features in children exhibiting neurological manifestations of SARS-CoV-2 infection**

13:45 - 13:45

Elena Capestru (Moldova)

**Plasma Inflammatory Markers May Assist Early Diagnosis of Pharmacoresistance**

13:45 - 13:45

Glenda Corrêa Borges de Lacerda (Brazil)

**Epileptogenesis disrupts diurnal molecular dynamics of key extracellular matrix components in the mouse hippocampus**

13:45 - 13:45

Yiyue Jiang (Ireland)

**Reading-induced seizures secondary to autoimmune encephalitis**

13:45 - 13:45

Loreto Rios-Pohl (Chile)

**Relationship between febrile seizures in children and complete blood count inflammatory indices**

13:45 - 13:45

Mohammad Ali Saeed Hassan Ali (Egypt)

**Zolpidem prevents cognitive impairment and reduces ictal activity in a rat model of GABA<sub>A</sub>R antibody-mediated encephalitis**

13:45 - 13:45

Manoj Upadhy (United Kingdom)

**Cytokines expression in blood plasma from drug resistance epilepsy patients**

13:45 - 13:45

Patricia Campos Bedolla (Mexico)

**Temporal Dynamics of TNF- $\alpha$  and IL-1 $\beta$  Levels in Relation to Epileptiform Activity in a 4-AP Rat Model of Epilepsy**

13:45 - 13:45

Salvador Mauricio Martinez-Gallegos (Mexico)

**The seizure outcomes of paediatric probable antibody-negative autoimmune encephalitis: a retrospective case series**

13:45 - 13:45

Vivien, Wai Yin Li (Hong Kong)

**Sweet taste as the initial manifestation of Temporal Lobe Epilepsy**

13:45 - 13:45

Isabella Lince-Rivera (Colombia)

**Navigating Treatment Challenges in pediatric GAD65-Antibody-Mediated Encephalitis**

13:45 - 13:45

Lisa Cardellini (Germany)

**Optimizing Early Pediatric Epilepsy Diagnosis Through Nurse-Led Consultations**

13:45 - 13:45

Laia Nou Fontanet (Spain)

**Understanding and Modeling the Dravet Syndrome Diagnostic Pathway: DS'coverED Study Results**

13:45 - 13:45

Loucas Christodoulou (United Kingdom)

**Drug-resistant epilepsy in children - impact on cognitive functions and clinical evolution**

13:45 - 13:45

Ludmila Feghiu (Moldova)

**Cannabidiol as add-on therapy for patients with refractory childhood epilepsy (CBD-uN1que): study protocol for a series of n-of-1 trials**

13:45 - 13:45

Marit van de Wiel (Netherlands)

|  |               |
|--|---------------|
| <b>Dravet Syndrome in Colombia: Insights into Current Diagnosis and Treatment Practices</b>  | 13:45 - 13:45 |
| Maria José Polania Puentes (Colombia)  |               |
| <b>Genetic movement disorders with epilepsy</b>  | 13:45 - 13:45 |
| Maša Malenica (Croatia)  |               |
| <b>Unraveling lissencephaly: insights from clinical, neurophysiological and imaging features</b>   | 13:45 - 13:45 |
| Maria Carlos Pereira (Portugal)  |               |
| <b>Electroencephalographic aspects of encephalopathies in children at Albert Royer children's hospital in Dakar, Senegal</b>   | 13:45 - 13:45 |
| Marième Diop-Sène (Senegal)  |               |
| <b>Corticosteroids therapy in children and young adults with Developmental and Epileptic Encephalopathies (DEEs) and Drug Resistant Epilepsies (DREs): a multicenter retrospective study</b> | 13:45 - 13:45 |
| Massimiliano Celario (Italy)   |               |
| <b>A qualitative study on precision medicine in epilepsy: the clinician's view</b>   | 13:45 - 13:45 |
| Matthias De Wachter (Belgium)  |               |
| <b>Effect of vigabatrin add on EEG compared to placebo in Lennox-Gastaut Syndrome</b>  | 13:45 - 13:45 |
| Mohammad Firoz Nizami (India)  |               |
| <b>Video-game induced orofacial reflex myoclonus</b>   | 13:45 - 13:45 |
| Meri Papajani (Albania)  |               |
| <b>Heterogeneous Knowledge of Childhood Seizures and Epilepsy Care in Canadian Healthcare Providers: Identifying the Gaps</b>  | 13:45 - 13:45 |
| Michelle Kregel (Canada)   |               |
| <b>Neonatal Parechovirus Meningoencephalitis: Risk of Acute Symptomatic Seizures and Infantile Spasms</b>  | 13:45 - 13:45 |
| Nicole Arvanitis (United States)   |               |
| <b>Clinical Profile, Treatment Response, and Outcomes in Children with Drug-Resistant Epilepsy at Chiang Mai University Hospital</b>   | 13:45 - 13:45 |
| Natrujee Wiwattanadittakun (Thailand)  |               |
| <b>Evaluating Paediatric to Adult Epilepsy Programs; Patient Engagement and Ongoing Sustainability</b>   | 13:45 - 13:45 |
| Nicole Dendekker (Canada)  |               |
| <b>Semiological Differences Of Functional Seizures Between Pediatrics and Adults: Video Electroencephalography Analysis</b>  | 13:45 - 13:45 |
| Nirmeen Kishk (Egypt)  |               |
| <b>When science meets hope: Dramatic efficacy of ketogenic diet in a child with ALG13-CDG (congenital disorders of glycosylation) related epileptic encephalopathy</b>                       | 13:45 - 13:45 |
| Nitika Gautam (United Kingdom)   |               |
| <b>"Don't Stimulate, I'm Sleeping!" Sleep-Disordered Breathing in Children with Vagus Nerve Stimulation</b>  | 13:45 - 13:45 |
| Nuria Lamagrande Casanova (Spain)  |               |
| <b>Febrile Seizures Revealing Familial Cavernomatosis and Diagnostic Dilemmas</b>  | 13:45 - 13:45 |
| Nur Aydinli Çerçi (Turkey)   |               |
| <b>Late-onset infantile epileptic spasms: Etiology and electroclinical description</b>   | 13:45 - 13:45 |

Nuria Campora (Argentina)

**Intrahippocampal sleep spindles in pediatric epilepsy patients** 13:45 - 13:45

Pavlina Cabounova (Czech Republic)

**The impact of seizure first aid education on prehospital management of pediatric status epilepticus and hospital morbidity** 13:45 - 13:45

Pawan Kashyape (United Arab Emirates)

**Association Between the Temporal Progression of Amplitude Burden and Epileptiform Discharge Scores with Relapse in Children with Infantile Epileptic Spasms Syndrome** 13:45 - 13:45

Masahiro Umeda (Japan)

**Hypnic Negative Myoclonia: A Novel Case of Ictal Negative Motor Signs During Sleep** 13:45 - 13:45

Radu-Ştefan Perjoc (Romania)

**Serial organization of movements in children with various forms of epilepsy** 13:45 - 13:45

Rimma Gamirova (Russian Federation)

**Heart rate variability changes over time: longitudinal observation in Dravet Syndrome to track SUDEP risk trajectories** 13:45 - 13:45

Romina Venditti (Italy)

**Reflective Practice in Pediatric Neurology: A Qualitative Analysis of Shared Challenges and Strategic Responses** 13:45 - 13:45

Suzanne M Nevin (Australia)

**Incontinentia Pigmenti and neurological involvement: A focus on epilepsy** 13:45 - 13:45

Sana Frikha (Tunisia)

**Design and Baseline Characteristics of an Open-label, Multicenter, Phase 1b/2a Study of Radiprodil in Patients With Focal Cortical Dysplasia Type II or Tuberous Sclerosis Complex** 13:45 - 13:45

Sergiusz Jozwiak (Poland)

**Infantile Epileptic Spasms Syndrome (IESS): Experience at a Single Institution over 32 years** 13:45 - 13:45

Shishir Doble (Canada)

**Identification of Serum Biomarkers in Pediatric Patients with Drug-Resistant Epilepsy in a Third Level Hospital** 13:45 - 13:45

Sandra Orozco-Suárez (Mexico)

**Test protocol for responsiveness and awareness during seizures of children under three years of age** 13:45 - 13:45

Stephan Wüstenhagen (Denmark)

**Diagnosing Lennox-Gastaut Syndrome - Experience from a UK tertiary complex epilepsy service** 13:45 - 13:45

Susan Harvey (United Kingdom)

**BDNF Rescue of Absence Seizures and Associated Comorbidities: Uncovering Shared Mechanisms** 13:45 - 13:45

Tatiana P Morais (United Kingdom)

**Factors implicated in the delayed diagnosis of Epilepsy with Eyelid Myoclonia (Jeavons syndrome)** 13:45 - 13:45

Juan E. Toro Perez (Canada)

**Real-life Experience with Fenfluramine and Purified Cannabidiol Treatment for Refractory Epilepsy: A Single-center Retrospective Pilot Data** 13:45 - 13:45

Ondřej Horák (Czech Republic)

**Identification of Heterozygous *HNRNPU* Variants in a Patient with Early Onset Intractable Epilepsy and Developmental Delay**

13:45 - 13:45

Tamar Kipiani (Georgia)

**Seizure freedom in children and youth with epilepsy in The Norwegian Mother, Father and Child Cohort Study**

13:45 - 13:45

Truls Vikin (Norway)

**Robust Risk Factor Analysis for the Safe Withdrawal of Anti-Seizure Medication in Patients with Childhood-Onset Epilepsy Followed-Up for Over 10 Years**

13:45 - 13:45

Tae-Sung Ko (Korea, Democratic People's Republic of)

**Pediatric Tuberous Sclerosis Complex: Epilepsy Phenotypes and Genetic Correlations in a Tertiary Center Cohort**

13:45 - 13:45

Francisca Costa (Portugal)

**Differential tractography of language circuitry : A promising tool for pediatric epilepsy surgery**

13:45 - 13:45

Vera Dinkelacker (France)

**Electro-clinical and neuroimaging influence on postsurgical cognitive outcome 12 months after epilepsy surgery in children with drug-resistant epilepsy and hypothalamic hamartoma**

13:45 - 13:45

Maria Violeta Fariña Jara (Spain)

**Features of seizures in children with epilepsy of different age groups**

13:45 - 13:45

Olga Sukhonosova (Ukraine)

**Investigation of the actual status of febrile seizures plus**

13:45 - 13:45

Yukiko Osawa (Japan)

**Acetazolamide as a Solution for Faramacoresistant Jeavons Syndrome**

13:45 - 13:45

Željka Rogač (Montenegro)

**Developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS)-current perspectives and our experiences**

13:45 - 13:45

Matilda Kovac Sizgoric (Croatia)

**Improved quality of life in children with drug-resistant epilepsies after earlier vagal nerve stimulator implantation**

13:45 - 13:45

Zvonka Rener-Primec (Slovenia)

**Reinforcement Learning Deficits in Epilepsy and Their Implications for Anhedonia**

13:45 - 13:45

Arjun Ramaswamy (United Kingdom)

**Psychopathological profile (SCL-90-R) of patients with Non-Epileptic Paroxysmal Seizures and Epilepsy**

13:45 - 13:45

Mayra Jazmín Morales Armenta (Mexico)

**Get a Grip on Anxiety when your child has epilepsy - a pilot study**

13:45 - 13:45

Anne Vagner Jakobsen (Denmark)

**Prevalence and associated factors of caregiving burden among caregivers of adults with epilepsy in Malaysia - A cross-sectional study**

13:45 - 13:45

Ching Soong Khoo (Malaysia)

**Survey on Expectations and Challenges for Psychiatric epileptologist in Transition of Japanese Patients with Childhood-**

13:45 - 13:45

**Onset Epilepsy**

Go Taniguchi (Japan)

**Recruitment strategies and initial participation outcomes at the civilian university site of a post-traumatic epilepsy mental health treatment trial: CoCarePTE**

13:45 - 13:45

Heidi Munger Clary (United States)

**Clinical presentation of new-onset psychogenic non-epileptic seizures after epilepsy surgery**

13:45 - 13:45

Maimi Ogawa (Japan)

**Insomnia preceding post-ictal psychosis during video-EEG**

13:45 - 13:45

Miguel de Oliveira Carvalho (Portugal)

**Is felt stigma associated with suicidal risk in patients with epilepsy?**

13:45 - 13:45

Sang-Ahm Lee (Korea, Republic of)

**Translation, validation, and reliability testing of the Arabic version of the Epilepsy Self-Stigma Scale (ESSS-A) and Its clinical correlation**

13:45 - 13:45

Sally Shaaban (Egypt)

**Personality disorders in patients with idiopathic generalized epilepsy**

13:45 - 13:45

Swathy Krishnan AR (India)

**Sex disparities in veterans with psychogenic non-epileptic seizures. Do women pay a higher toll?**

13:45 - 13:45

M.Raquel Lopez (United States)

**Exploring short-term mortality disparities in status epilepticus: a study across two centers in Salzburg and Jakarta**

13:45 - 13:45

Adrian Ridski Harsono (Indonesia)

**Characterisation of the intraamygdala kainic acid model of temporal lobe epilepsy in female mice**

13:45 - 13:45

Alexandre Seixas Nascimento (Ireland)

**Neuroprognostication after cardiac arrest: the added value of a standardized EEG reactivity protocol**

13:45 - 13:45

Alice Ballabeni (Italy)

**Refractory Status Epilepticus outcome - A retrospective study from a Portuguese Hospital**

13:45 - 13:45

Ana Rita Peralta (Portugal)

**Favorable outcome in the case of an adult male with prolonged myoclonic status epilepticus following out-of-hospital resuscitation**

13:45 - 13:45

Anca Adriana Arbune (Romania)

**The impact of "the new" definition of status epilepticus on prevalence and clinical features of status epilepticus in children - a tertiary center experience**

13:45 - 13:45

Ruzica Kravljanac (Serbia)

**The Role of Brain Biomarkers TGF and Proinflammatory Interleukins in the Clinical Course of Status Epilepticus in Pediatric Population**

13:45 - 13:45

Cornelia Calcii (Moldova)

**Accelerated brain atrophy during new-onset refractory status epilepticus**

13:45 - 13:45

Cyril F. Simmen (Switzerland)

|   |               |
|---|---------------|
| <b>Cenobamate for the treatment of focal-onset refractory and super-refractory status epilepticus. A multicenter case series</b>                  | 13:45 - 13:45 |
| Daniel Campos-Fernandez (Spain)   |               |
| <b>Epilepsy stands nearby: a pilot CT perfusion study on post-stroke non convulsive status epilepticus</b>  | 13:45 - 13:45 |
| Elena Merli (Italy)   |               |
| <b>Super-refractory non-convulsive status epilepticus after cerebral fat embolism: clinical, electrophysiological and neuroradiological study</b> | 13:45 - 13:45 |
|   |               |
| <b>Prognosis in patients with status epilepticus</b>  | 13:45 - 13:45 |
| Sung Eun Kim (Korea, Republic of)   |               |
| <b>Clinical heterogeneity of non-convulsive status epilepticus</b>  | 13:45 - 13:45 |
| Gordana Kiteva-Trenchevska (North Macedonia)  |               |
| <b>Clinical-EEG variables and etiology in elderly patients with nonconvulsive status epilepticus</b>  | 13:45 - 13:45 |
| Gloria Maria Tedrus (Brazil)  |               |
| <b>Ictal-interictal Continuum Following Coil Embolization of Cerebral Aneurysms</b>   | 13:45 - 13:45 |
| Qi Huang (China)  |               |
| <b>Status epilepticus at a Tertiary Neurology Care Center in Mexico: A retrospective cohort from 2020 to 2024</b>                                 | 13:45 - 13:45 |
| Irene Gómez-Oropeza (Mexico)  |               |
| <b>Similar EEG patterns in different manifestations of NCSE, <i>true beauty is only skin (EEG) deep</i></b>                                       | 13:45 - 13:45 |
| Jose Mendes-Ribeiro (Portugal)  |               |
| <b>Comparison of outcome of status epilepticus in tuberculous meningitis and scrub typhus</b>   | 13:45 - 13:45 |
| Jayantee Kalita (India)   |               |
| <b>Quantifying focal hypermetabolism in suspected non-convulsive status epilepticus: a single-centre cohort study</b>                             | 13:45 - 13:45 |
| Jeroen Gijs (Belgium)   |               |
| <b>EEG and Seizure Characteristics During and After New Onset Refractory Status Epilepticus</b>   | 13:45 - 13:45 |
| Ji Yeoun Yoo (United States)  |               |
| <b>Focal aware status epilepticus: treatment and prognosis in a bicentric study</b>   | 13:45 - 13:45 |
| Jordi Ciurans (Spain)   |               |
| <b>Detection and Duration Analysis of Post-Ictal Generalised EEG Suppression with Two-Channel EEG</b>   | 13:45 - 13:45 |
| Joe Davies (United Kingdom)   |               |
| <b>New-Onset Refractory Status Epilepticus as a Presentation of Anti-SOX1 Antibody Encephalitis</b>   | 13:45 - 13:45 |
| Jin-Sun Jun (Korea, Republic of)  |               |
| <b>Frontal meningoencephalocele as a cause of super-refractory status epilepticus: a unique case report</b>                                       | 13:45 - 13:45 |
| Kato Van Rooy (Belgium)   |               |
| <b>Nonconvulsive Status Epilepticus Secondary to Insulinoma-Induced Hypoglycemia: A Case Report</b>   | 13:45 - 13:45 |
| Betty Gómez Arias (Colombia)  |               |

|  |               |
|--|---------------|
| <b>Circulating miR-146a and mir-134 as potential therapeutic biomarkers in Refractory Status Epilepticus - an exploratory study</b><br>Lígia Palhete-Ferreira (Portugal)             | 13:45 - 13:45 |
| <b>Predictive Factors of Refractoriness in Status Epilepticus - A Retrospective Study</b><br>Maria Rosa Andrade Ferreira (Portugal)  | 13:45 - 13:45 |
| <b>Cenobamate for new-onset refractory and super-refractory status epilepticus: a report of four cases</b><br>Marina Romozzi (Italy)   | 13:45 - 13:45 |
| <b>Cell blood count to predict New-Onset Refractory Status Epilepticus long-term outcomes: a multicenter study</b><br>Martin Guillemaud (France)                                     | 13:45 - 13:45 |
| <b>From EMS Call to Initial Medical Care: Analysis and Insights into Response Times in Status Epilepticus Emergencies in Iran</b><br>Mohsen Farjoud Kouhanjani (Germany)             | 13:45 - 13:45 |
| <b>Association of lateralized rhythmic delta activity stereotyped morphology with peri-ictal MRI abnormalities</b><br>Nicolas Jannone-Pedro (Austria)                                | 13:45 - 13:45 |
| <b>Discrepancy and consistency between electroencephalography and brain imaging in nonconvulsive status epilepticus: a case series</b><br>Naoki Nitta (Japan)                        | 13:45 - 13:45 |
| <b>Peri-Ictal MRI Abnormalities and Frequency of Epileptiform Discharges in Status Epilepticus: A Prospective Study</b><br>Pilar Bosque Varela (Austria)                             | 13:45 - 13:45 |
| <b>Status epilepticus epidemiology in France: insight from the French National Health Data System</b><br>Quentin Calonge (France)  | 13:45 - 13:45 |
| <b>Managing Status Epilepticus in Eastern Mediterranean Region (EMR): Current Status and Solutions</b><br>Raidah Al-Baradie (Saudi Arabia)   | 13:45 - 13:45 |
| <b>Prognostic Value of Neutrophil to Lymphocyte Ratio in Status Epilepticus: A Retrospective Cohort Study</b><br>Sara Lima (Portugal)  | 13:45 - 13:45 |
| <b>A clinical and electrographic evaluation of new-onset refractory status epilepticus (NORSE) compared with non-NORSE RSE</b><br>Seren Hawksworth (United Kingdom)                  | 13:45 - 13:45 |
| <b>Effectiveness of the seizure code in urgent epileptic seizures to avoid status epilepticus at a private tertiary hospital in Mexico</b><br>Sofía Lucila Rodríguez Rivera (Mexico) | 13:45 - 13:45 |
| <b>Status Epilepticus in Adults with Developmental and Epileptic Encephalopathies</b><br>Stefano Meletti (Italy)   | 13:45 - 13:45 |
| <b>Therapeutic Efficacy of mRNA Drug on Kainic Acid-Induced Seizures in Mice</b><br>Ruyan Chen (China)   | 13:45 - 13:45 |
| <b>Clinical characteristics and prognosis of Super-Refractory Status Epilepticus: Insights from a Single-Centre Observational Study</b><br>Teresa Moncada Cordeiro (Portugal)        | 13:45 - 13:45 |
| <b>Accelerated long-term forgetting - are we missing it? Evidence from the Crimes and Four Doors Tests</b>   | 13:45 - 13:45 |



Gus Baker (United Kingdom)

*In-Person Posters*

14:00 - 14:30

In-Person Poster Presentations

**ILAE YES Poster Tour (T1)**

|   |               |
|---|---------------|
| <b>In vivo transcriptomics and proteomics analysis of SEEG electrodes from human epileptic brain</b>  | 14:00 - 14:00 |
| Ninja Ehrnrooth (Finland)   |               |
| <b>A clinicopathological study of factors associated with microvacuolar changes in the cerebral white matter of patients with epilepsy</b>    | 14:00 - 14:00 |
| Hajime Miyata (Japan)   |               |
| <b>Gut-based interventions improve neurological consequences of acute brain injury in mice</b>  | 14:00 - 14:00 |
| Rossella Di Sapia (Italy)   |               |
| <b>Biophysical characterization of pathological GAT1 (SLC6A1) A288V and S295L mutants associated with SLC6A1-neurodevelopmental disorders</b> | 14:00 - 14:00 |
| Tiziana Romanazzi (Italy)   |               |
| <b>Rescue of neuronal activity in iPSC-derived STXBP1 in vitro disease models using viral vectors</b>   | 14:00 - 14:00 |
| Ana Rita Gomes (Belgium)  |               |
| <b>Impact of Intracerebroventricular Orexin-B on Absence Seizures in GAERS: Dose-Dependent Suppression of Spike-and-Wave Discharges</b>       | 14:00 - 14:00 |
| Aylin Toplu (Turkey)  |               |
| <b>Chemogenetic inhibition of ventrobasal thalamus exacerbates absence seizures in a genetic absence epilepsy rat model</b>                   | 14:00 - 14:00 |
| Nihan Carcak (Turkey)   |               |
| <b>iEEG Epileptogenic Networks: Analyzing Preictal Inflow and Outflow Connectivity Dynamics</b>   | 14:00 - 14:00 |
| Amirhossein Jahani (Canada)   |               |
| <b>Microglial Bmal1 downregulation leads to higher seizure susceptibility and altered hippocampal cytokine and chemokine signaling</b>        | 14:00 - 14:00 |
| Tammy Strickland (Ireland)  |               |

*In-Person Posters*

14:00 - 14:30

In-Person Poster Presentations

**ILAE YES Poster Tour (T2)**

|   |               |
|---|---------------|
| <b>Impact of epilepsy type on delivery and neonatal outcomes in pregnant women with epilepsy</b>  | 14:00 - 14:00 |
| Shahla Malikova (Azerbaijan)  |               |
| <b>Patient perspectives on antiseizure medication discontinuation: a mixed-methods exploration of risk perception, tolerance, and counseling</b>  | 14:00 - 14:00 |
| Samuel Terman (United States)   |               |
| <b>Real-World Efficacy and Tolerability of Cenobamate in Drug-Resistant Epilepsy: A Single-Centre Retrospective Study from the United Kingdom</b> | 14:00 - 14:00 |
| Alex Huang (United Kingdom)   |               |

|  |               |
|--|---------------|
| <b>Healthcare Resource Utilization among Adult Patients with Focal-Onset Seizures using Cenobamate: a US Database Analysis</b>   | 14:00 - 14:00 |
| John Paul Leach (Italy)  |               |
| <b>Improving quality of life in patients with intellectual disability and epilepsy through comprehensive inpatient treatment</b>   | 14:00 - 14:00 |
| David Steinbart (Germany)  |               |
| <b>Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): A Novel, Prospective, Large-scale, Observational Study Designed to Better Understand the Patient Journey</b> | 14:00 - 14:00 |
| Jacqueline French (United States)  |               |
| <b>Evaluating the Impact of Vagus Nerve Stimulation (VNS) on seizure frequency, intensity, quality of life and mood</b>  | 14:00 - 14:00 |
| Donald Adjorlolo (United Kingdom)  |               |
| <b>Introducing needs-based epilepsy follow-up - patient satisfaction compared to traditional follow-up</b>   | 14:00 - 14:00 |
| Eline Dahl-Hansen (Norway)   |               |
| <b>Acoustic dynamics of music: a potential mechanism for neuromodulation in epilepsy</b>   | 14:00 - 14:00 |
| Ondřej Strýček (Czech Republic)  |               |
| <b>Evaluating the Utility of Routine Outpatient Electroencephalography: Insights from 18 months</b>  | 14:00 - 14:00 |
| Gonçalo Videira (Portugal)   |               |

*ILAE Pharmacy*  
14:00 - 15:00

**ILAE Pharmacy Section Session - Basics of Therapeutic Drug Monitoring**

|  |               |
|--|---------------|
| <b>Introduction</b>                          | 14:00 - 14:05 |
| <b>Basics of Therapeutic Drug Monitoring</b> | 14:05 - 14:55 |
| Cecilie Johannessen-Landmark (Norway)        |               |
| <b>Conclusion and Q&amp;A</b>                | 14:55 - 15:00 |

*In-Person Posters*  
14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (T4)**

|   |               |
|---|---------------|
| <b>Point of care Lamotrigine monitoring in epilepsy: A Pilot Study Using a Carbon Screen-Printed Electrode</b>                            | 14:30 - 14:30 |
| Albert Kelly (Ireland)  |               |
| <b>Global Seizure Rescue Medication Landscape: Availability &amp; Reimbursement</b>   | 14:30 - 14:30 |
| Patricia Shafer (United States)   |               |
| <b>Hyponatremia in patients on therapy with Carbamazepine, Oxcarbazepine or Eslicarbazepine</b>   | 14:30 - 14:30 |
| Petar Vasilev (Bulgaria)  |               |
| <b>How much difference does depression make to the outcome of neuropsychological assessment of patients with epilepsy</b>                 | 14:30 - 14:30 |
| Christoph Helmstaedter (Germany)  |               |
| <b>Correlation between subclinical seizures and cognitive impairment in adult epilepsy patients - a retrospective observational study</b> | 14:30 - 14:30 |

Pedro Viana (United Kingdom)

**Executive Functioning Improvement with Behavioral Psychotherapy, but not with Sertraline, in Persons with Mesial Temporal Lobe Epilepsy due to Hippocampal Sclerosis and Major Depressive Disorder: a pilot, randomized and controlled study**

14:30 - 14:30

Kette Valente (Brazil)

**Emotion recognition across visual and auditory modalities in temporal lobe epilepsy**

14:30 - 14:30

Maja Milovanović (Serbia)

**Epilepsy beyond seizures: Exploring psychosocial determinants of treatment adherence in patients with epilepsy**

14:30 - 14:30

Saher Ayub (India)

**Influence of epilepsy on neuropsychiatric symptoms and cognitive profile in patients with tuberous sclerosis complex**

14:30 - 14:30

Victoria Ros Castelló (Spain)

**Neurocognitive Characterization and Clinical Aspects of Glioma-Related Epilepsy: Insights from a Surgical Cohort**

14:30 - 14:30

Chiara Falamesca (Italy)

#### *In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

#### **ILAE YES Poster Tour (T5)**

**Brivaracetam Adjunctive Therapy in Paediatric and Adult Patients With Focal-Onset Seizures in Mid-European Countries: 12-Month, Real-World Outcomes from the BRIVA-REG Study**

14:30 - 14:30

Vasilios K. Kimiskidis (Greece)

**Efficacy of Stiripentol Beyond Generalized Tonic-Clonic Seizures: A Retrospective Analysis of Dravet and Non-Dravet Patient Records**

14:30 - 14:30

Nuria Lamagrande Casanova (Spain)

**Impact of Fenfluramine on Convulsive Seizure Frequency in Dose-Capped Patients With Dravet Syndrome**

14:30 - 14:30

Rima Nabbout (France)

**The Bright Side of Drug Load: How Third-Generation Antiseizure Medications Reshape Treatment Strategies in People with Epilepsy**

14:30 - 14:30

Roberta Roberti (Italy)

**Real life experience with cenobamate as monotherapy or part of dual therapy: a Spanish cohort**

14:30 - 14:30

Álvaro Sánchez-Guijo Benavente (Spain)

**Is earlier better? One year cenobamate outcome in a large real world population**

14:30 - 14:30

Federica Ranzato (Italy)

**Re-analysis of trials of brivaracetam using Epilepsy DOOR to holistically account for benefits and harms of anti-seizure medications for people with epilepsy**

14:30 - 14:30

Lucy Vivash (Australia)

**Cenobamate in Pediatric Patients with Drug Resistant Epilepsy: Real-World Data from a European Multicenter Retrospective Study**

14:30 - 14:30

Konstantin L. Makridis (Germany)

**Beyond Seizures: Deep Phenotyping of GABA<sub>A</sub> Receptor Variants Reveals Functional Segregation and Predicts Risk of Gross Motor Dysfunction**

14:30 - 14:30

Sebastian Ortiz De la Rosa (Denmark)

**Genetic and Clinical Characterization of Adult Patients with GABAA-receptor related disorders**

14:30 - 14:30

Anna Gretel Pinzon-Acevedo (Denmark)

*In-Person Posters*

14:30 - 15:00

In-Person Poster Presentations

**ILAE YES Poster Tour (T3)**

**Tau Deposition: A Potential Marker of Sleep and Memory Impairment in Focal Drug-Resistant Epilepsy**

14:30 - 14:30

Thaera Arafat (Canada)

**Neurodegeneration in Mesial Temporal Lobe Epilepsy (MTLE): Absence of Alpha-Synuclein and TDP-43 Pathology**

14:30 - 14:30

Eva Zatloukalova (Czech Republic)

**Temporal lobe epilepsy with amygdala enlargement: long-term outcome and memory**

14:30 - 14:30

Yuyu Yang (China)

**EPISTAR: Educational Patient Information Sheet To Achieve Retention of Information**

14:30 - 14:30

Olga Tanda (United Kingdom)

**Blood melatonin content in patients with sleep-related epileptic seizures**

14:30 - 14:30

Sevara Kalandarova (Uzbekistan)

**Neuro-ophthalmological changes in temporal lobe epilepsy and its surgical treatment**

14:30 - 14:30

Maksim Rusnak (Russian Federation)

**SISCOM Hyper and Hypoperfused Regions: Signal Processing Insights and Correlation with Stereo-EEG**

14:30 - 14:30

Maryam Alherz (Saudi Arabia)

**Epileptic activity in localized RDA - findings from simultaneous scalp and intracranial EEG recordings**

14:30 - 14:30

Hiroshi Shigeto (Japan)

**Comparison of EEG after sleep deprivation and melatonin induction in children of different ages: a randomized controlled trial**

14:30 - 14:30

Greta Gustafsson (Sweden)

*Epilepsy Surgery*

15:15 - 16:15

Aud 1

**Platform Session - Epilepsy Surgery**

Georgia Ramantani (Switzerland)

**Introduction**

15:15 - 15:17

**Good versus severely impaired memory functioning more than 10 years after temporal lobe epilepsy surgery. How did the patients get there?**

15:17 - 15:25

Eli B. Kyte (Norway)

**Hemispherotomy in the first year of life: safety, feasibility, complications and seizure outcome - A single-center experience**

15:25 - 15:33

Mikolaj Pielas (Poland)

**Association between radiofrequency thermocoagulation volume in the epileptogenic zone and surgical outcomes in drug-resistant**

15:33 - 15:41

|   |               |
|---|---------------|
| <b>epilepsy</b>   |               |
| Thanomporn Wittayacharoenpong (Australia)   |               |
| <b>The impact of implanting sentinel or electrodes contralateral to the hypothesized epileptogenic zone in stereoelectroencephalography</b> | 15:41 - 15:49 |
| Ana Suller Marti (Canada)   |               |
| <b>Dynamic brain functional networks to investigate protective mechanisms against epileptic seizures</b>                                    | 15:49 - 15:57 |
| Alessandra Burini (Italy)   |               |
| <b>First-in-human long-term ictal recording with multiple implanted endovascular EEG devices, EP-01</b>                                     | 15:57 - 16:05 |
| Yosuke Masuda (Japan)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:05 - 16:15 |
| <i>Basic science</i>  |               |
| 15:15 - 16:15   |               |
| Aud V (Pav 1)   |               |
| <b>Platform Session - Basic Science</b>   |               |
| Zeinab Koné (Mali)  |               |
| <b>Introduction</b>   | 15:15 - 15:17 |
| <b>ELFN1 deficiency: Mechanistic basis of the neurodevelopmental disorder with expanding phenotypic spectrum</b>                            | 15:17 - 15:27 |
| Amber Declève (Belgium)   |               |
| <b>TBC1D24 and vATPase interplay in the brain: physiopathology of TBC1D24-related epilepsies</b>  | 15:27 - 15:37 |
| Antonio Falace (Italy)  |               |
| <b>Shaping the future of epilepsy research in Europe: The ERN EpiCARE priorities</b>  | 15:37 - 15:47 |
| Sébile Tchaicha (Spain)   |               |
| <b>Unravelling Neurodevelopmental Disruptions in Dravet Syndrome using a Patient-Derived Organoid Model</b>                                 | 15:47 - 15:57 |
| Snezana Maljevic (Australia)  |               |
| <b>Transcriptome analysis revealed <i>Bmal1</i> as a key regulator of circadian-driven neuroinflammation and epileptogenesis</b>            | 15:57 - 16:07 |
| Danielle Carmo Ferreira Bruno (Ireland)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:07 - 16:15 |
| <i>Adult Epileptology</i>   |               |
| 15:15 - 16:15   |               |
| Aud VI+VII  |               |
| <b>Platform Session - Adult Epileptology 2</b>  |               |
| Eugen Trinká (Austria)  |               |
| Cristine Cukiért (Brazil)   |               |
| <b>Introduction</b>   | 15:15 - 15:17 |
| <b>Clinical subtypes and characteristics of sleep-related epilepsy – A real-world study</b>   | 15:17 - 15:25 |
| Jinqi Zhou (China)  |               |
| <b>Neuroimaging correlates of epilepsy in neurodegenerative disorders</b>   | 15:25 - 15:33 |
| Ifrah Zawar (United States)   |               |
| <b>Risk of epilepsy in people with and without dementia - A nationwide cohort study</b>   | 15:33 - 15:41 |

Theresa Wimberley (Denmark)

**Redefining Acute Symptomatic Seizures: The Role of Timing in Predicting Recurrence After Stroke**

15:41 - 15:49

Kai Michael Schubert (Switzerland)

**Long-Term Outcomes in Idiopathic Generalized Epilepsies: A Decade of Follow-Up in a Tertiary Adult Care Population**

15:49 - 15:57

Rui Lopes (Portugal)

**Suicidality at epilepsy diagnosis predicts treatment resistance in newly diagnosed focal epilepsy**

15:57 - 16:05

Sarah Barnard (Australia)

**Conclusion and Q&A**

16:05 - 16:15

*Epilepsy and Reproductive Health*

15:15 - 16:15

AUD VIII

**Platform Session - Epilepsy and Reproductive Health**

Page Pennell (United States)

Torbjorn Tomson (Sweden)

**Introduction**

15:15 - 15:17

**Infertility outcomes in valproate exposed and unexposed men with epilepsy or bipolar disorder: an international cohort study of real-world healthcare data**

15:17 - 15:27

Gashirai K Mbizvo (United Kingdom)

**Pregnancy outcomes after in vitro fertilization in women with epilepsy on antiseizure medications: Prospective data from EURAP**

15:27 - 15:37

Torbjorn Tomson (Sweden)

**Periconceptional Low-Dose vs. High-Dose Folic Acid Supplementation and Neurodevelopmental Outcomes in Children Exposed to Antiseizure Medications: Preliminary Findings from the Prospective Observational Norwegian Mother, father and Child cohort study (MoBa)**

15:37 - 15:47

Marte-Helene Bjørk (Norway)

**Antiseizure medication dose changes in pregnancy and postpartum: findings from MONEAD**

15:47 - 15:57

Denise Li (United States)

**Blood concentrations vs. dose effects of fetal antiseizure medications on cognition and behavior in children of mothers with epilepsy**

15:57 - 16:07

Kimford Meador (United States)

**Conclusion and Q&A**

16:07 - 16:15

*Epidemiology*

15:15 - 16:15

AUD II

**Platform Session - Epidemiology**

Nathalie Jette (Canada)

Angelina Kakooza (Uganda)

**Introduction**

15:15 - 15:23

**Genetic testing practices across EpiCARE Centers: Insights from a multicenter survey**

15:23 - 15:31

Rima Nabbout (France)

**Ultra-refractory epilepsy: The newly-described entity**

15:31 - 15:39

|   |               |
|---|---------------|
| Irena Dolezalova (Czech Republic)   |               |
| <b>Emulating target trials of periconceptional supplementation of high-dose folic acid in women taking antiseizure medication on risk of major congenital anomalies using Nordic Registry data - A SCAN-AED study</b> | 15:39 - 15:47 |
| Yuelian Sun (Denmark)   |               |
| <b>New-onset epilepsy among children with status epilepticus as their first seizure: interim report from the SEED study</b>   | 15:47 - 15:55 |
| Umar Abba Sabo (Nigeria)  |               |
| <b>Conclusion and Q&amp;A</b>   | 15:55 - 16:03 |
| <i>Other</i>  |               |
| 15:15 - 16:15   | AUD III + IV  |
| <b>Platform Session - Mixed Topics</b>  |               |
| Andreas Schulze-Bonhage (Germany)   |               |
| Bertil Rydenhag (Sweden)  |               |
| <b>Introduction</b>   | 15:15 - 15:17 |
| <b>Machine learning models applied to independent cortical folding variables distinguish TLE subgroups</b>  | 15:17 - 15:25 |
| Thais Maria Santos Bezerra (Brazil)   |               |
| <b>Causal relationship between air pollution and epilepsy: A Mendelian randomization study</b>  | 15:25 - 15:33 |
| Hui Zhang (China)   |               |
| <b>The burden of cumulative comorbidities in epilepsy</b>   | 15:33 - 15:41 |
| Ameliagh Terrins-Hutchinson (United Kingdom)  |               |
| <b>Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling</b>   | 15:41 - 15:49 |
| Aurelie Hanin (France)  |               |
| <b>Progressive cortical and hippocampal atrophy after status epilepticus: a prospective longitudinal MRI study</b>  | 15:49 - 15:57 |
| Bernardo Crespo Pimentel (Austria)  |               |
| <b>Real-World Use of Fenfluramine for Dravet Syndrome: a Retrospective Cohort Study Using a National Pharmacy Database</b>  | 15:57 - 16:05 |
| Elaine C. Wirrell (United States)   |               |
| <b>Conclusion and Q&amp;A</b>   | 16:05 - 16:15 |
| <i>Other</i>  |               |
| 15:15 - 16:45   | Room 1.09     |
| <b>ILAE Wikipedia Workshop and Publishing</b>   |               |
| Michael Sperling (United States)  |               |
| Nandan Yardi (India)  |               |
| <b>Introduction</b>   | 15:15 - 15:20 |
| Michael Sperling (United States)  |               |
| Nandan Yardi (India)  |               |
| <b>How to publish and review in Epilepsia and Epilepsia Open - Publishing</b>   | 15:20 - 15:20 |
| Fernando Cendes (Brazil)  |               |
| <b>How to publish and review in Epilepsia and Epilepsia Open - Reviewing</b>  | 15:20 - 15:20 |
| Merab Kokaia (Sweden)   |               |

|   |               |
|---|---------------|
| <b>The importance of Wikipedia as repository for AI</b>   | 15:20 - 15:20 |
| Samuel Wiebe (Canada)   |               |
| <b>Our experience with improving articles on Wikipedia and Expert communities</b>                                 | 15:20 - 15:20 |
| Nandan Yardi (India)  |               |
| <b>Let's learn to edit on Wikipedia</b>   | 15:20 - 15:20 |
| Amin Azzam (United States)  |               |
| <b>Contributing to Wikipedia</b>  | 15:20 - 15:20 |
| Jonah Fox (United States)   |               |
| <b>How you can generate stub articles</b>   | 15:20 - 15:20 |
| John Byrne (United Kingdom)   |               |
| <b>Conclusion and Q&amp;A</b>   | 15:20 - 15:20 |
| <br><i>ILAE YES</i><br>16:00 - 17:00  |               |
| <b>ILAE YES Brainstorming Session - Astrocytes and epilepsy</b>   |               |
| <b>Introduction</b>   | 16:00 - 16:05 |
| <b>Astrocytes and epilepsy</b>  | 16:05 - 16:50 |
| Peter Bedner (Germany)  |               |
| <b>Conclusion and Q&amp;A</b>   | 16:50 - 17:00 |
| <br><i>ILAE Neurotechnology</i><br>16:00 - 17:00  |               |
| <b>ILAE Neurotechnology Section - EEG Debate: Is the routine EEG losing relevance?</b>                            |               |
| <b>Introduction</b>   | 16:00 - 16:05 |
| <b>Shark Tank Past Winner: Neuronostics, modeling the EEG</b>   | 16:05 - 16:25 |
| John Terry (United Kingdom)   |               |
| <b>Shark Tank 2025 Winner</b>   | 16:25 - 16:45 |
| <b>Conclusion and Q&amp;A</b>   | 16:45 - 17:00 |
| <br><i>Paediatric Epileptology</i><br>16:45 - 18:15   |               |
|   | Aud 1         |
| <b>Updates in the treatment of neonatal seizures: exploring controversies on definition and targeted approach</b> |               |
| Magda Nunes (Brazil)  |               |
| Sofia Quintas (Portugal)  |               |
| <b>Introduction</b>   | 16:45 - 16:50 |
| <b>Neonatal EEG Monitoring: Indications, Approach, and Management Indications</b>                                 | 16:50 - 17:06 |
| Nicholas Abend (United States)  |               |
| <b>Do we still have controversies regarding Neonatal Seizures? An introduction to the topic</b>                   | 17:06 - 17:22 |
| Ronit Pressler (United Kingdom)   |               |
| <b>What is neonatal status epilepticus?</b>   | 17:22 - 17:38 |
| Magda Nunes (Brazil)  |               |



|                         |  |               |
|-------------------------|--|---------------|
|                         | <b>What are clues to determine etiology of acute provoked seizures?</b>  | 17:38 - 17:54 |
|                         | Elissa Yozawitz (United States)  |               |
|                         | <b>How we can use etiologically targeted approaches in the treatment of neonatal seizures?</b>   | 17:54 - 18:10 |
|                         | Hans Hartmann (Germany)  |               |
|                         | <b>Conclusion and Q&amp;A</b>  | 18:10 - 18:15 |
| <i>Social Issues</i>    |  |               |
| 16:45 - 18:15           |  | Aud V (Pav 1) |
|                         | <b>Family planning in drug-resistant epilepsies</b>  |               |
|                         | Manuel Toledo (Spain)  |               |
|                         | Ching Soong Khoo (Malaysia)  |               |
|                         | <b>Introduction</b>  | 16:45 - 16:50 |
|                         | <b>Defeating the stigmas in women of childbearing potential with drug-resistant epilepsy.</b>  | 16:50 - 17:06 |
|                         | Elvira Vacas Montero (Ireland)   |               |
|                         | <b>Contraception and things to do before the pregnancy in drug-resistant epilepsy</b>  | 17:06 - 17:22 |
|                         | Page Pennell (United States)   |               |
|                         | <b>Best therapeutic medical options for women of childbearing potential with drug-resistant epilepsy.</b>                                    | 17:22 - 17:38 |
|                         | Torbjorn Tomson (Sweden)   |               |
|                         | <b>Precision medicine and relevance of genetics for family planning in epilepsy</b>  | 17:38 - 17:54 |
|                         | Estefania Conde (Spain)  |               |
|                         | <b>TBC</b>   | 17:54 - 18:10 |
|                         | Emma Lovise Larsen (Norway)  |               |
|                         | <b>Conclusion and Q&amp;A</b>  | 18:10 - 18:15 |
| <i>Epilepsy Surgery</i> |  |               |
| 16:45 - 18:15           |  | Aud VI+VII    |
|                         | <b>Have less invasive surgical techniques and improved mapping of eloquent functions reduced the risks associated with epilepsy surgery?</b> |               |
|                         | Meneka Kaur Sidhu (United Kingdom)   |               |
|                         | Takamichi Yamamoto (Japan)   |               |
|                         | <b>Introduction</b>  | 16:45 - 16:50 |
|                         | <b>Risks associated with resective vs minimally invasive techniques for treating refractory focal epilepsy</b>                               | 16:50 - 17:05 |
|                         | Michele Rizzi (Italy)  |               |
|                         | <b>Advances in functional imaging in the mapping of presurgical eloquent functions</b>   | 17:05 - 17:20 |
|                         | Meneka Kaur Sidhu (United Kingdom)   |               |
|                         | <b>White matter matters: Advances in the mapping of white matter tracts to reduce the risk of cognitive decline</b>                          | 17:20 - 17:35 |
|                         | Davide Giampiccolo (Italy)   |               |
|                         | <b>Incorporating advanced imaging sequences to mitigate the risks of epilepsy surgery- worked examples</b>                                   | 17:35 - 17:50 |
|                         | Jorge Gonzalez-Martinez (United States)  |               |
|                         | <b>PPIE: Lived Example- Right temporal DNET</b>  | 17:50 - 18:05 |

Christopher Hallatt Wells (United Kingdom)

**Conclusion and Q&A**

18:05 - 18:15

*AI and Computational Medicine*

16:45 - 18:15

AUD II

**Equitable, ethical, and effective global AI solutions in epilepsy**

Colin Josephson (Canada)

**Introduction**

16:45 - 16:50

**AI in epilepsy - the putative benefits and risks**

16:50 - 17:00

Lara Jehi (United States)

**AI to advance care in LMIC regions**

17:00 - 17:10

Gabriel Jones (United Kingdom)

**Epilepsy Diagnostic Companion**

17:10 - 17:15

Arjune Sen (United Kingdom)

**SCORE-AI**

17:15 - 17:20

Sándor Beniczky (Denmark)

**EPISAVE seizure detection**

17:20 - 17:25

Philippe Ryvlin (Switzerland)

**A roadmap for global implementation of AI-based solutions in epilepsy**

17:25 - 17:45

Colin Josephson (Canada)

**Panel discussion**

17:45 - 18:10

**Conclusion and Q&A**

18:10 - 18:15

*IGAP Implementation*

16:45 - 18:15

Pavilion 3A

**Strengthening the capacity of the non-specialist workforce to improve epilepsy care**

Martin Kirkpatrick (United Kingdom)

**Introduction**

16:45 - 16:50

**Non-Specialist Workforce Training and the IGAP**

16:50 - 17:01

J Helen Cross (United States)

**20 years of PET - what has been achieved around the world?**

17:01 - 17:12

Jo Wilmshurst (South Africa)

**PET in Brazil - successes and challenges**

17:12 - 17:23

Ana Coan (Brazil)

**Taking a coordinated approach to training across the paediatric and adult workforces**

17:23 - 17:34

MV Gule (South Africa)

**Conclusion and Q&A**

17:34 - 18:04

*SUDEP & Mortality*

16:45 - 18:15

Pavilion 3B

**Mortality in DEEs across the lifespan: Timing, causes and prevention**

Danielle Andrade (Canada)

**Introduction**

16:45 - 16:50

|   |               |
|---|---------------|
| <b>Epidemiology and risk factors for mortality in DEEs</b>  | 16:50 - 17:01 |
| Jose Angel Aibar (Spain)<br>Rima Nabbout (France)   |               |
| <b>Genetic mutations in shaping mortality risk</b>  | 17:01 - 17:12 |
| Ingrid Scheffer (Australia)   |               |
| <b>Mechanisms and predictors of death in children and adults with DEEs</b>                                  | 17:12 - 17:23 |
| Danielle Andrade (Canada)   |               |
| <b>Discussing mortality with families</b>   | 17:23 - 17:34 |
| Kette Valente (Brazil)  |               |
| <b>How should we handle mortality in children and adults with DEE: is there a role for palliative care?</b> | 17:34 - 17:45 |
| Victor Lira (Canada)  |               |
| <b>Conclusion and Q&amp;A</b>   | 17:45 - 18:15 |
| <br><i>Epilepsy in Older People</i>   |               |
| 16:45 - 18:15   | Pavilion 3C   |
| <b>The dual relationship between dementia and seizures: Clinical and epidemiological perspectives</b>       |               |
| Francesco Brigo (Italy)   |               |
| <b>Introduction</b>   | 16:45 - 16:50 |
| <b>Deciphering the Complex Interplay Between Dementia and Seizures</b>                                      | 16:50 - 16:55 |
| Francesco Brigo (Italy)   |               |
| <b>From dementia to seizures: epidemiological and clinical challenges</b>                                   | 16:55 - 17:25 |
| Laura Abraira (Spain)   |               |
| <b>From seizures to dementia: epidemiological and clinical challenges</b>                                   | 17:25 - 17:55 |
| Johan Zelano (Sweden)   |               |
| <b>Case Studies</b>   | 17:55 - 18:10 |
| Laura Abraira (Spain)<br>Johan Zelano (Sweden)<br>Francesco Brigo (Italy)                                   |               |
| <b>Conclusion and Q&amp;A</b>   | 18:10 - 18:15 |

Wednesday, September 3, 2025

*Epilepsy in Resource-restricted Settings*

08:00 - 09:30

Aud 1

**Mitigating the global treatment gap in pediatric epilepsy**

Jitendra Kumar Sahu (India)

Alberto Espeche (Argentina)

**Introduction**

08:00 - 08:05

**Treatment gaps in pediatric epilepsies- Global unmet needs**

08:05 - 08:21

Francesca Sofia (Italy)

**Mitigating treatment lag for infantile epilepsy in LMICs: IESS Model**

08:21 - 08:37

Priyanka Madaan (India)

**Real life examples of missed and delayed diagnosis with patient experience videos**

08:37 - 08:53

Sameer Zuberi (United Kingdom)

**Telehealth Epilepsy Smart School Model in India: An innovative model**

08:53 - 09:09

Sulena Singh (India)

**How can we minimize mortality in developmental and epileptic encephalopathies?**

09:09 - 09:25

Jo Wilmshurst (South Africa)

**Conclusion and Q&A**

09:25 - 09:30

*Paediatric Epileptology*

08:00 - 09:30

Aud V (Pav 1)

**VIREPA Paediatric EEG & VIREPA MRI**

**Introduction**

08:00 - 08:05

**VIREPA Paediatric EEG**

08:05 - 08:45

Monika Eisermann (France)

**VIREPA MRI**

08:45 - 09:25

Stefan Rampp (Germany)

**Conclusion and Q&A**

09:25 - 09:30

*Status Epilepticus*

08:00 - 09:30

Aud VI+VII

**Recent advances and future directions in NORSE/FIRES research.**

Aurelie Hanin (France)

Sara Parreira (Portugal)

**Introduction**

08:00 - 08:05

**Diagnosis, clinical features, and outcomes in NORSE/FIRES.**

08:05 - 08:25

Francesca Bisulli (Italy)

**Pathophysiological mechanisms underlying NORSE and its consequences: cytokine and single-cell transcriptomic analyses.**

08:25 - 08:45

Aurelie Hanin (France)

**Treatment strategies for NORSE/FIRES: available medications and future possible clinical trials.**

08:45 - 09:05

Lawrence Hirsch (United States)

**Supporting families affected by NORSE**

09:05 - 09:25

Nora Wong (United States)

**Conclusion and Q&A**

09:25 - 09:30

*Genetics*

08:00 - 09:40

AUD VIII

**Reconceptualising mesial temporal lobe epilepsy with hippocampal sclerosis - Understanding genetic and acquired contributions**

Michael S. Hildebrand (Australia)

Norman Delanty (Ireland)

**Introduction**

08:00 - 08:05

**Interactive Introduction to MTLE+HS including Audience Live QR Code Survey**

08:05 - 08:22

Ingmar Blümcke (Germany)

**Living with MTLE+HS: A journey through drug-resistance and epilepsy surgery**

08:22 - 08:42

Petra Naydenov (Portugal)

**Clinical phenotypes and risk factors of MTLE+HS**

08:42 - 08:59

Sam Gooley (Australia)

**Role of acquired factors in MTLE+HS over the lifespan**

08:59 - 09:16

Aristea Galanopoulou (United States)

**Role of genetic factors in MTLE+HS**

09:16 - 09:33

Sattar Khoshkhoo (United States)

**Conclusion and Q&A**

09:33 - 09:40

*Social Issues*

08:00 - 09:30

AUD II

**Turning challenges into solutions: Advancing epilepsy care together**

Katharina Moser (Austria)

Alison Kukla (United States)

**Introduction**

08:00 - 08:04

**Challenges and Priorities in Epilepsy Care: Setting the Stage**

08:04 - 08:18

Katharina Moser (Austria)

**From Challenges to Solutions: Global Perspectives from Young Voices**

08:18 - 08:32

Alison Kukla (United States)

**Overcoming Global Implementation Challenges: A Collaborative Exchange**

08:32 - 08:46

Members of the ILAE-YES Advocacy Task Force and IBE staff  
Members of the ILAE-YES Advocacy Task Force and IBE staff**From Vision to Reality: Turning Strategies into Practice**

08:46 - 09:00

ILAE-YES Advocacy Task Force and IBE staff  
ILAE-YES Advocacy Task Force and IBE staff**Conclusion and Q&A**

09:00 - 09:30

*IGAP Implementation*

08:00 - 09:30

AUD III + IV

**Epilepsy primary care debates: Second edition!**

Gagandeep Singh (India)

**Introduction**

08:00 - 08:05

**Is medicine access in high income countries ideal and can it be replicated in LMICs?**

08:05 - 08:16

Ley Sander (United Kingdom)

**Medicine access in LMICs - what it really is and what can be done?**

08:16 - 08:27

Arjune Sen (United Kingdom)

**One-time epilepsy care camps - Incredibly useful**

08:27 - 08:38

Mamta Singh (India)

**Community health worker engagement in primary care -**

08:38 - 08:49

Jane von Gaudecker (United States)

**Community health worker engagement in primary care - impractical**

08:49 - 09:00

Faith Mosha (Tanzania)

**Conclusion and Q&A**

09:00 - 09:30

*Epilepsy Surgery*

09:45 - 11:45

Aud V (Pav 1)

**Understanding and using neuromodulation for refractory epilepsy**

Arthur Cukiert (Brazil)

Antonio Valentin (United Kingdom)

**Introduction**

09:45 - 09:55

**Mechanisms of action of neuromodulation**

09:55 - 10:15

Kristl Vonck (Belgium)

**Biomarkers in neuromodulation**

10:15 - 10:35

Lawrence Hirsch (United States)

**Neuromodulation for treatment of focal epilepsy**

10:35 - 10:55

Arthur Cukiert (Brazil)

**Neuromodulation for treatment of generalized epilepsy**

10:55 - 11:15

Mark Richardson (United States)

**Moving forward: Do we need thalamic recordings to guide neuromodulation?**

11:15 - 11:35

Linda Dalic (Australia)

**Conclusion and Q&A**

11:35 - 11:45

*Clinical Neurophysiology*

09:45 - 11:45

Aud VI+VII

**The evolving landscape of epilepsy diagnosis and management**

Melody Asukile (Zambia)

Ley Sander (United Kingdom)

**Introduction**

09:45 - 09:55

**Lived experiences (video) - patient and provider experiences relating to climate change, disease outbreaks and conflict**

09:55 - 10:15

Melody Asukile (Zambia)

|   |               |
|---|---------------|
| <b>Epilepsy and the Environment - A reflection on the challenges that environmental factors pose on epilepsy management, including the effects of disease outbreaks, conflict, and climate change</b> | 10:15 - 10:35 |
| Medine Gulcebi Idriz Oglu (Turkey)  |               |
| <b>Precision Medicine: The changing face of epilepsy diagnosis and management through genetics</b>  | 10:35 - 10:55 |
| Rikke Møller (Denmark)  |               |
| <b>The role of artificial intelligence in the diagnosis and management of epilepsy</b>  | 10:55 - 11:15 |
| Arjune Sen (United Kingdom)   |               |
| <b>Specialised epilepsy care at different settings and resource levels</b>  | 11:15 - 11:35 |
| Patricia Braga (Uruguay)  |               |
| <b>Conclusion and Q&amp;A</b>   | 11:35 - 11:45 |
| <i>Paediatric Epileptology</i>  |               |
| 12:15 - 13:15   | Aud 1         |
| <b>Platform Session - Paediatric Epileptology 2</b>   |               |
| Jithangi Wanagasinghe (Sri Lanka)   |               |
| Kees Braun (Netherlands)  |               |
| <b>Introduction</b>   | 12:15 - 12:17 |
| <b>Evolution of ictal epileptogenic foci over time in children with tuberous sclerosis complex</b>  | 12:17 - 12:25 |
| Carmen Stevering (Netherlands)  |               |
| <b>Better Breathing, Better Seizure Control: Sleep Apnea in Children with Drug Resistant Epilepsy</b>   | 12:25 - 12:33 |
| Nuria Lamagrande Casanova (Spain)   |               |
| <b>Decreased interictal heart rate variability in children and adolescents aged 6-14 years with epilepsy</b>  | 12:33 - 12:41 |
| Jinping Zhou (Germany)  |               |
| <b>Ictal emotional features in pediatric and young adult patients with frontal lobe epilepsy: insights from developing brain</b>  | 12:41 - 12:49 |
| Ming-Chen Tsai (United States)  |               |
| <b>Cortical oscillatory activity evoked by chirp: a biomarker of gabaergic interneuron dysfunction in Dravet syndrome</b>   | 12:49 - 12:57 |
| Nadia Irazabal (Spain)  |               |
| <b>Potential role for microRNAs as biomarkers in epilepsy: a prospective paediatric study</b>   | 12:57 - 13:05 |
| Licia Salimbene (Italy)   |               |
| <b>Conclusion and Q&amp;A</b>   | 13:05 - 13:15 |
| <i>Genetics</i>   |               |
| 12:15 - 13:15   | Aud V (Pav 1) |
| <b>Platform Session - Genetics</b>  |               |
| Chahnez Triki (Tunisia)   |               |
| Raidah Al-Baradie (Saudi Arabia)  |               |
| <b>Introduction</b>   | 12:15 - 12:17 |
| <b>Genetic testing of DNA obtained from stereoEEG electrodes - successes and pitfalls</b>   | 12:17 - 12:25 |
| Barbora Straka (Czech Republic)   |               |

|   |  |               |
|---|--|---------------|
|   | <b>Clinical and genetic insights from a large cohort of individuals with SCN2A-related disorders</b>   | 12:25 - 12:33 |
|   | Sopio Gverdtiteli (Denmark)  |               |
|   | <b>Phenotypic spectrum of loss-of-function variants in the KCNA2 gene and genotype-phenotype correlation</b>   | 12:33 - 12:41 |
|   | Leonardo Affronte (Italy)  |               |
|   | <b>Regional somatic mosaicism in focal pediatric epilepsy</b>  | 12:41 - 12:49 |
|   | H. Westley Phillips (United States)  |               |
|   | <b>Involvement of CACNA2D2 in developmental and epileptic encephalopathy through disruption of calcium channel functionality and synaptic function</b> | 12:49 - 12:57 |
|   | Miriam Essid (France)  |               |
|   | <b>Long-term Safety and Efficacy of Deoxycytidine/Deoxythymidine Combination Therapy in POLG-related Disorders</b>                                     | 12:57 - 13:05 |
|   | Kenneth A. Myers (Canada)  |               |
|   | <b>Conclusion and Q&amp;A</b>  | 13:05 - 13:15 |
| <i>Other</i>  |  |               |
| 12:15 - 13:15   |  | Aud VI+VII    |
| <b>Quiz - Final</b>   |  |               |
| <i>Neuroimaging</i>   |  |               |
| 12:15 - 13:15   |  | AUD VIII      |
| <b>Platform Session - Neuroimaging</b>                          |  |               |
| John Duncan (United Kingdom)                                    |  |               |
|   | <b>Introduction</b>  | 12:15 - 12:17 |
|   | <b>Multimodal investigation of the thalamus in children with temporal lobe epilepsy</b>  | 12:17 - 12:25 |
|   | Xiyu Feng (United Kingdom)   |               |
|   | <b>Premature structural brain ageing and domain-specific cognitive changes in epilepsy</b>   | 12:25 - 12:33 |
|   | Heath Pardoe (Australia)   |               |
|   | <b>Refining the radiological spectrum of GATOR1-related epilepsy</b>   | 12:33 - 12:41 |
|   | Chiara Pepi (Italy)  |               |
|   | <b>Expanding language assessment in epilepsy patients through the individual functional connectome</b>   | 12:41 - 12:49 |
|   | Radheshyam Stepponat (Austria)   |               |
|   | <b>Peri-ictal MRI abnormalities in Status Epilepticus, cluster of seizures and single seizures: a prospective neuroimaging study</b>                   | 12:49 - 12:57 |
|   | Angelo Pascarella (Italy)  |               |
|   | <b>Advanced Diffusion MRI Reveals Microstructural Alterations in Focal Cortical Dysplasia: Insights Beyond Conventional Imaging</b>                    | 12:57 - 13:05 |
|   | Jakub Otáhal (Czech Republic)  |               |
|   | <b>Conclusion and Q&amp;A</b>  | 13:05 - 13:15 |
| <i>Paediatric Epileptology</i>                                  |  |               |
| 12:15 - 13:45   |  | AUD III + IV  |
| <b>SEEG in young children. "Build your implantation scheme"</b> |  |               |
| Mathilde Chipaux-Raffo (France)                                 |  |               |



|  |               |
|--|---------------|
| <b>Introduction</b>  | 12:15 - 12:33 |
| <b>SEEG in children with spasms- epileptologist perspective</b><br>Emmanuel Raffo (France)                               | 12:33 - 12:47 |
| <b>SEEG in young children with Tuberous Sclerosis Complex-<br/>Epileptologist Perspective</b><br>Andrea Andrade (Canada) | 12:47 - 13:01 |
| <b>SEEG when eloquent cortex is involved</b><br>Manjari Tripathi (India)   | 13:01 - 13:15 |
| <b>Conclusion and Q&amp;A</b>  | 13:15 - 13:45 |
| <i>Clinical Neurophysiology</i><br>12:15 - 13:45   | Room 1.09     |
| <b>Teaching Session: MEG</b><br>Sándor Beniczky (Denmark)<br>Stefan Rampp (Germany)                                      |               |
| <b>Introduction</b>  | 12:15 - 12:20 |
| <b>Basic principles of MSI: flux-maps, source-space and averaging</b><br>Sándor Beniczky (Denmark)                       | 12:20 - 12:40 |
| <b>Inverse solutions and reporting</b><br>Stefan Rampp (Germany)   | 12:40 - 13:00 |
| <b>Cases and examples of MSI</b><br>Sándor Beniczky (Denmark)<br>Stefan Rampp (Germany)                                  | 13:00 - 13:40 |
| <b>Conclusion and Q&amp;A</b>  | 13:40 - 13:45 |
| <i>Other</i><br>14:45 - 15:45  | Aud 1         |
| <b>Congress Highlights Session</b><br>J Helen Cross (United States)<br>Francesca Sofia (Italy)                           |               |
| <b>Introduction</b>  | 14:45 - 14:50 |
| <b>ILAE President</b>  | 14:50 - 14:55 |
| <b>IBE President</b>   | 14:55 - 15:00 |
| <b>Epilepsy Surgery Highlights</b><br><br>Arthur Cukiert (Brazil)  | 15:00 - 15:05 |
| <b>Basic Science Highlights</b><br>Aristea Galanopoulou (United States)  | 15:05 - 15:10 |
| <b>Psychology Highlights</b><br>Genevieve Rayner (Australia)   | 15:10 - 15:15 |
| <b>Paediatrics Highlights</b><br>Elaine C. Wirrell (United States)   | 15:15 - 15:20 |
| <b>Clinical Highlights</b><br>Melody Asukile (Zambia)  | 15:20 - 15:25 |
| <b>Social Issues Highlights</b>  | 15:25 - 15:30 |

Graeme Shears (Australia)

**Conclusion**

15:30 - 15:45